










I,$ Luke$ Aidan$ Massey,$ conﬁrm$ that$ the$ work$ presented$ in$ this$ thesis$ is$ my$ own.$Where$












































































































































































































































































This$ thesis$ examines$ clinical$ and$ radiological$ aspects$ of$ Progressive$ Supranuclear$ Palsy$
(PSP)$and$related$conditions.$
• Signiﬁcant$milestones$occur$sooner$in$pathologically$conﬁrmed$PSP$than$multiple$system$
atrophy$ (MSA);$older$age$ of$onset$and$shorter$duration$to$ﬁrst$milestone$are$ associated$
with$worse$ prognosis$ in$both;$ in$ PSP,$ the$ Richardson’s$ syndrome$ phenotype$ and$male$
gender$and$in$MSA,$early$autonomic$failure$ and$the$ female$gender$are$also$predictive$ of$
poorer$prognosis.$
• Using$ objective$ measurements$ of$ bradykinesia$ we$ found$ progressive$ bradykinesia$ and$
hypokinesia$ in$Parkinson’s$disease$ (PD)$which$correlates$with$disability$ and$ responds$to$
levodopa$but$hypokinesia$without$decrement$in$PSP.$





when$ compared$ to$ histology$ in$ post$ mortem$ material.$The$ anteromedial$ portion$ was$
hypointense$in$correlation$with$Perls$stain$and$there$was$ variability$ in$the$volume,$shape$
and$ location$of$its$ borders.$The$ nigrosomes$within$ the$ substantia$ nigra$ were$ visibile$ as$
high$intensity$bands$which$correlated$with$calbindin$poor$zones$on$immunohistochemical$
stains.$The$volume$and$anatomy$were$preserved$in$PD$but$not$PSP.
• Multimodal$3$Telsla$MRI$during$life$ revealed$distinct$patterns$ of $atrophy$ in$PSP$and$MSA$
using$ voxelXbased$morphometry.$TractXbased$spatial$ statistics$ revealed$ abnormalities$ in$
the$frontal$and$parietoXoccipital$white$matter$changes$in$PSP$more$ than$MSA.$$Midbrain$














This$ study$was$ conceived,$ planned,$ participants$ were$ recruited$ from$ the$QSBB$and$data$
collected$ with$ input$ from$ Dr$ Dominic$ Paviour,$ Dr$ Caroline$ Micallef,$ Dr$ Rolf$ Jager$ and$




This$ study$was$ conceived,$ planned,$ participants$ were$ recruited$ from$ the$QSBB$and$data$
were$collected$with$input$from$Dr$Dominic$Paviour,$Dr$Caroline$Micallef,$Dr$Rolf$Jager$and$













from$ clinics$ at$ the$ National$ hospital$ for$ Neurology$ (Professor$ Andrew$ Lees,$ Professor$
Kailash$Bhatia,$Professor$Christopher$Matthias,$Professor$Claire$ Fowler,$Dr$Pras$Korlipara,$
Dr$Michael$Lunn)$and$through$adverts$ in$the$PSP$(Europe)$association$and$Sara$Matheson$
Trust$publications.$Pilot$ studies$ and$data$ analysis$ were$ devised$with$ input$ from$ all$of$the$
above$ but$particularly$Dr$Enrico$Devita$with$regards$ to$ volumetric$ analysis$ including$VBM$
and$TBSS.$
This$ thesis$ was$ performed$ under$ the$ supervision$ of$ Professor$ Andrew$ Lees$ (clinical$


































































































(NPV)$ Likelihood$ ratio$ for$a$ positive$ result$(LR+)$ and$ likelihood$ratio$for$ a$negative$ result$
(LRX)$in$pathologically$conﬁrmed$PSP
Table$4.7:$ $Sensitivity,$Speciﬁcity,$Positive$Predictive$Value$(PPV),$Negative$Predictive$Value$




































































































































































































































The$ aim$was$ to$ study$ clinical$ and$ radiological$aspects$ in$ progressive$ supranuclear$palsy$
(PSP)$and$related$conditions.$
This$thesis$has$four$sections.




2. In$ the$ second$ section$ the$ accuracy$ of$ conventional$MRI$ (cMRI)$ is$ studied$ in$
pathologically$ conﬁrmed$ disease$ X$ both$ subjective$ assessment$ and$ the$
development$ of $ a$ simple$ linear$ measurement$ based$ on$ the$ pathological$
topography$of$disease.$
3. In$the$third$section$the$importance$of$anatomical$accuracy$using$MRI$is$studied$
after$ a$ literature$ review$ focusing$ on$ the$ subthalamic$ nucleus$ (STN)$ and$













in$ the$ brainstem,$ basal$ ganglia$ and$ cerebellum$ and$ presenting$ clinically$ with$ a$ vertical$




Epidemiological$ studies$ give$ an$ estimated$ prevalence$ of$ 5.0$ –$ 6.4$ /$ 100$ 000$ in$ the$ UK$
(Schrag,$BenXShlomo$et$al.$1999;$Nath,$BenXShlomo$et$al.$2001).
& & b)&Clinical&presentation
Classically$ PSP$ presents$ in$ the$ seventh$ and$ eighth$ decades$ and$ no$ cases$ have$ been$




The$ classical$PSP$presentation$ has$ been$referred$to$as$ ‘Richardson’s$ syndrome’$ (PSPXRS):$
these$ patients$ present$with$postural$instability$ and$ early$ falls$ ,$dysarthria,$ a$ supranuclear$
downgaze$palsy,$hypokinesia$which$does$not$respond$well$to$levodopa,$and$a$dysexecutive$
syndrome$ with$ bradyphrenia,$ apathy,$ reduced$ verbal$ ﬂuency,$ utilization$ or$ imitation$
behaviour$and$frontal$release$signs$(Steele,$Richardson$et$al.$1964;$Litvan,$Agid$et$al.$1996).$
Although$not$described$until$the$Steele$et$al$paper,$Charles$Dickens$and$Wilkie$Collins$may$
have$ been$describing$PSP$when$ they$ wrote$ ‘The% Lazy%Tour %of% Two% Idle% Apprentices‘$ $ and$
described$meeting
“.....A$chilled,$slow,$earthy,$ﬁxed$old$man.$A$cadaverous$man$of$measured$speech.$An$








The$ gait$ is$ wide$ based,$erect$with$a$ characteristic$tendency$ to$ fall$backwards.$They$ may$
exhibit$motor$recklessness,$the$ ‘rocket$sign’$on$ standing$up$and$ sit$‘en$bloc’.$NonXspeciﬁc$
visual$complaints$ including$diplopia,$diﬃculty$reading,$and$photophobia$are$ superceded$by$
the$development$of$a$supranuclear$gaze$palsy$with$particular$diﬃculty$looking$down$which$
may$be$manifest$as$ messy$eating$and$the$ ‘messy$ tie$ sign’$ (Steele,$Richardson$et$al.$1964;$
Litvan,$Agid$et$al.$ 1996;$Burn$and$Lees$2002).$ $The$ﬁrst$eye$ sign$may$be$ reduced$speed$of$
vertical$saccadic$movements$ and$there$may$be$diﬃculties$ suppressing$blinking$to$a$bright$
light$ stimulus$ (Litvan,$ Agid$ et$ al.$ 1996).$There$ is$ a$ severely$ reduced$blink$ frequency$ and$
eyelid$opening$dyspraxia$with$associated$overactivity$of$the$frontalis$muscle$giving$rise$ to$
the$ impression$of$a$constantly$surprised$or$worried$expression.$Symmetrical$parkinsonism$
with$ axial$ rigidity,$ and$ bulbar$ features$ characteristed$ by$ a$ distinctive$ growling$ dysarthria$
and$dysphagia$with$risk$of$aspiration$pneumonia$(Litvan,$Agid$et$al.$1996;$Williams$and$Lees$
2009)$and$cognitive$and$behavioural$features$are$seen$early$in$the$disease$progression$when$
compared$ to$ Parkinson’s$ disease.$ The$ ‘subcortical$ dementia’$ of$ PSP$ includes$ cognitive$
slowing$(bradyphrenia),$dysexecutive$ function$as$demonstrated$ in$reduced$verbal$ﬂuency,$
and$in$tests$of$initiation$and$set$shifting,$and$impaired$memory$characterised$by$recall$but$
not$ recognition$ deﬁcits,$ grasping$ and$ utilization$ behaviour,$ perseveration,$ apathy$ and$
depression$and$irritability$(Albert,$Feldman$et$al.$1974;$Magherini$and$Litvan$2005).$$
In$the$ original$description$of$PSP$the$authors$felt$that$clinical$confusion$with$PD$would$be$
unlikely.$ However,$ subsequently$ most$ neurologists$ now$ class$ PSP$ in$ the$ category$ of$
‘Parkinson’s$plus’$syndromes$due$to$prominent$akineticXrigid$features,$although$response$to$




asymmetric$syndrome$ with$ a$ typical$pill$rolling$ tremor$which$ is$ moderately$ responsive$ to$
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levodopa$ and$ diﬃcult$ to$ distinguish$ from$ PD$ and$ multiple$ system$ atrophy$ with$
predominant$ parkinsonism$ (MSAXP),$which$ is$ now$ termed$PSPXParkinsonism$(PSPXP),$ are$
associated$with$PSP$pathology$at$post$mortem,$with$PSPXP$accounting$for$around$a$third$of$
pathologically$conﬁrmed$cases$ (Morris,$Gibb$et$al.$2002;$Williams,$de$Silva$ et$al.$2005).$The$
absence$ of$ postural$ instability,$ cognitive$ impairment$ and$ eye$ movement$ abnormalities$
mean$ a$ diagnosis$ of$ PSP$ is$ diﬃcult$ particularly$ early$ in$ the$ disease,$ however,$ visual$
hallucinations,$drugXinduced$dyskinesias$and$autonomic$dysfunction$are$very$uncommon$in$
PSPXP$and$support$a$diagnosis$of$PD$(Williams$and$Lees$2010).







PSP$ presenting$ with$ a$ corticobasal$ syndrome$ (PSPXCBS)$ X$ with$ markedly$ asymmetric$
levodopaXunresponsive$parkinsonism,$dystonia,$myoclonus,$dyspraxia,$cortical$sensory$loss$
and$the$alien$limb$phenomenon$$without$early$postural$instability$and$falls,$bulbar$failure$or$





PSP$ can$ also$ present$ with$ progressive$ apraxia$ of$ speech$ evolving$ into$ progressive$ nonX
ﬂuent$ aphasia$ with$ eﬀortful,$ nonXﬂuent,$agrammatic$ speech$with$phonemic$ paraphasias$
(PSPXPNFA)$ (Josephs,$ Boeve$ et$ al.$ 2005)(Boeve,$ Dickson$ et$ al.$ 2003),$ late$ onset$








In$addition$to$the$ variable$ clinical$presentation$of$PSP,$there$ is$ a$ diﬀerential$diagnosis$ for$
patients$ presenting$with$a$ PSP$ syndrome$ including$ parkinsonism,$postural$instability$ and$
falls,$ and$ eye$ movement$ abnormalities.$ This$ includes$ the$ other$ neurodegenerative$
parkinsonian$ syndromes$ (PD,$ MSA$ and$ CBD),$ but$ also$ prion$ disease$ (Petrovic,$ MartinX
Bastida$et$al.$2012)$ and$dementia$with$Lewy$bodies$ (Fearnley,$Revesz$et$al.$1991;$Josephs$
and$Dickson$2003;$Haug,$Boyer$et$al.$2013).$There$ is$an$association$of$atypical$parkinsonism$
in$ Guadeloupe$ including$ a$ PSPXlike$ syndrome$ with$ soursop$ consumption$ (Lannuzel,$
Hoglinger$ et$ al.$ 2007).$ A$ PSP$ phenotype$ has$ also$ been$ reported$ in$ vascular$ disease$
(Winikates$and$Jankovic$1994),$infectious$diseases$ (Whipple’s$disease$(Amarenco,$Roullet$et$
al.$ 1991;$ Magherini,$ Pentore$ et$ al.$ 2007),$ HIV$ (Jang,$ Kim$ et$ al.$ 2012),$ Neurosyphilis$
(Murialdo,$ Marchese$ et$ al.$ 2000)),$ lead$ toxicity$ (Sanz,$ Nogue$ et$ al.$ 2007),$ as$ a$
paraneoplastic$ syndrome$ with$ BXcell$ lymphoma$ (Tan,$ Goh$ et$ al.$ 2005)$ and$ in$
antiphospholipid$antibody$syndrome$(Reitblat,$Polishchuk$et$al.$2003).$Metabolic$conditions$
associated$with$a$supranuclear$gaze$palsy$include$adult$onset$Nieman$Pick$type$C$(GodeiroX
Junior,$ Inaoka$ et$ al.$ 2006)$ and$Gaucher’s$ disease$ with$ mutations$ in$ glucocerebrosidase$
(AlonsoXCanovas,$ Katschnig$ et$ al.$ 2010).$ PSP$ phenotypes$ have$ been$ described$ in$
association$with$mutations$of$Microtubule$associated$protein$tau$(MAPT)$ (Borroni,$Agosti$
et$ al.$ 2011),$ progranulin$ (PRGN)$ (Tremolizzo,$ Bertola$ et$ al.$ 2011),$ chromosome$ 9$ open$




PSP$ along$ with$ CBD$ is$ associated$ with$ the$ deposition$ of$ insoluble$ ﬁbrillary$ deposits$
containing$ the$microtubuleXassociated$protein,$tau$(Williams$ 2006).$There$ are$ six$ isoforms$
of$tau:$ $ in$normal$brain$3$ repeat$and$4$repeat$tau$are$ approximately$ equally$ abundant;$ in$
Alzheimer’s$ disease$ there$ is$ preponderance$ of$ 3$ repeat$ tau$ whereas$ PSP$ and$ CBD$ are$
associated$with$predominantly$ four$microtubule$ binding$domains$ (Arai,$Ikeda$ et$al.$2001).$
Tau$is$ involved$ in$stabilisation$of$the$cell$cytoskeleton:$in$PSP$ insoluble$and$resistant$tau$is$
deposited$in$tangles$and$threads$ in$speciﬁc$brain$regions.$PSP$and$CBD$are$associated$with$




Atrophy$of$the$globus$ pallidus,$subthalamic$nucleus$ and$brainstem,$dilatation$of$the$ third$
and$fourth$ventricles$and$cerebral$aqueduct,$hypopigmentation$of$the$substantia$nigra$and$
locus$ coeruleus$ and$ mild$ atrophy$ of$ Brodman’s$ area$ 4$ may$ be$ seen$ on$ macroscopic$
examination$(Hauw,$Daniel$et$al.$1994).
Tau$immunoreactive$ neuroﬁbrillary$ tangles,$neuropil$ threads$ and$ tufted$astrocytes$ in$ the$
brainstem$and$basal$ganglia$associated$with$variable$neuronal$loss$and$astrogliosis$with$tau$
positive$ glial$ inclusions$ called$ coiled$ bodies$ are$ the$ histological$hallmarks$ of$PSP$ (Hauw,$
Daniel$et$ al.$ 1994).$ Particulary$ aﬀected$ regions$ include$ the$ globus$ pallidus,$ subthalamic$
nucleus,$ substantia$nigra$ and$pontine$ nuclei$and$other$regions$usually$ aﬀected$include$ the$
striatum,$oculomotor$compex,$medulla$and$dentate$nucleus$(Hauw,$Daniel$et$al.$1994).$






































PD$ occurs$ in$ all$ ethnic$ groups$ and$ aﬀects$ male$ and$ female$ in$ equal$ proportion.$ The$






It$ is$ important$ to$ exclude$ secondary$ causes$ of$ parkinsonism$ including$ iatrogenic$ drugX
induced$parkinsonism$associated$with$dopaminergic$antagonists$ including$antiemetics$and$
major$tranquilizers,$post$encephalitic$parkinsonism,$head$injury$ (including$boxing),$normal$
pressure$ hydrocephalus$ and$ structural$ lesions$ such$ as$ stroke$ and$ other$ space$ occupying$


























Table& 1.2:& Queen$ Square$ Brain$ Bank$ Clinical$ Diagnostic$ Criteria$ for$ the$ Diagnosis$ of$
Parkinson’s$Disease$(Gibb$and$Lees$1991).
Post$Mortem$series$have$shown$that$around$a$quarter$of $those$clinically$diagnosed$with$PD$
during$ life$ will$ turn$ out$ to$ have$ an$ alternative$ diagnosis$ (Hughes,$ Daniel$ et$ al.$ 1992),$
although$ more$ recently$ this$ ﬁgure$ was$ found$ to$ be$ less$ than$ 10%$ in$ specialist$ hands$










symptoms$ by$ some$ time,$ neuropsychiatric$ features$ including$ depression$ and$ dementia,$
sleep$disorders$such$as$REM$sleep$behaviour$disorder$which$may$also$preXdate$ the$motor$
features,$ autonomic$ features$ including$ urinary$ incontinence,$ disorders$ of$ sweating,$
orthostatic$ hypotension$ and$ erectile$ impotence,$ disorders$ of$ the$ gastrointestinal$ tract$
(constipation)$and$$sensory$disturbances$amongst$other$symptoms$(Chaudhuri,$Healy$et$al.$
2006).$
Typically$ medical$ treatment$ is$ required$within$the$ﬁrst$few$years$ of$disease$ and$currently$
there$ are$ many$ symptomatic$ treatments$ available$ which$ act$ to$ replace$ the$ dopamine$
deﬁcit$found$in$PD.$Despite$being$the$ﬁrst$medical$treatment$for$PD$levodopa$ remains$the$
most$ eﬃcacious$ although$ it$ is$ associated$ with$ motor$ complications$ in$ the$ longer$ term$
including$a$reduction$in$the$duration$of$action$leading$to$a$ ‘wearing$oﬀ’$eﬀect,$choreiform$
dyskinesias$ and$ unpredictable$ oﬀ$ periods.$ Other$ medications$ which$ stimulate$
dopaminergic$ receptors$ (dopamine$ agonists)$ or$ act$ to$ reduce$ the$ rate$ of$ dopaminergic$
breakdown$ (COMT$ inhibitors,$ MAOB$ inhibitors)$ and$ others$ (amantadine)$ are$ used$ to$
control$ these$ complications$ and$ it$ is$ often$ possible$ to$ control$ symptoms$ adequately$




However$ as$ the$ disease$ progresses$ axial$ and$ levodopa$ unresponsive$ features$ including$
abnormalities$of$postural$stability,$speech$and$cognitive$decline$become$more$evident$and$
form$ the$ most$ disabling$ symptoms$ after$ around$ 15$ years$ of$ disease$ (Hely,$ Morris$ et$ al.$




Degeneration$ of$ the$ dopaminergic$ neurons$ in$ the$ SNc$ leads$ to$ a$ reduction$ in$ striatal$
dopamine.$Through$the$ basal$ganglia$ thalamocortical$circuitry$ this$ ultimately$results$ in$an$
increased$activity$ in$the$subthalamic$nucleus$ (STN)$and$an$ensuing$increase$ in$GABAergic$
activity$ in$the$output$nuclei$of$the$ basal$ganglia$(the$ substantia$ nigra$pars$ reticulata$(SNr)$
and$ internal$ segment$ of$ the$ globus$ pallidus$ (GPi))$ and$ inhibition$ of$ the$ thalamus$ and$
brainstem$ outﬂow$nuclei.$This$ in$turn$ causes$ inhibition$ of $cortical$motor$areas.$Although$
there$are$inconsistencies$ in$this$ simpliﬁed$theory$of$the$pathophysiology$of$parkinsonism$it$
has$enabled$the$development$of$targeted$surgical$interventions$including$stimulation$of$the$
subthalamic$nucleus$ which$ is$ an$ eﬀective$ symptomatic$ therapy$ for$ PD$ in$ some$ patients$
(Limousin,$Pollak$et$al.$1995;$Limousin,$Pollak$et$al.$1995).
& & d)&Molecular&Biology
Although$ the$ vast$ majority$ of$ Parkinson’s$ disease$ is$ sporadic$ there$ are$ now$ wellX
characterised$ genetic$ forms$ of$ the$ disease$ (PARK1X12).$ The$ autosomal$ dominant$ forms$
include$ mutations$ of$ alphaXsynuclein$ SNCA$ (PARK1/4)$ and$ dardarin$ LRRK2$ (PARK8)$
although$ this$ condition$ has$ a$ variable$ penetrance.$ Autosomal$ recessive$ forms$ include$
parkin$PRKN$(PARK2),$PINK1$(PARK6)$and$DJX1$(PARK7)$(Hardy,$Cai$et$al.$2006).$
& & e)&Macroscopic&pathology&and&Histopathology
The$ pathological$hallmark$ of$PD$ is$ the$ round$eosinophilic$ intracytoplasmic$ inclusion$ (the$
Lewy$ body)$ and$ dystrophic$ neurite$ (Lewy$ neurite)$ (Forno$ 1996).$ The$ Lewy$ body$ has$ a$
distinctive$ dense$ core$ from$ which$ can$ be$ seen$ radiating$ microﬁlaments$ on$ electron$





of$the$ ubiquitin$proteasomal$system$ all$of$which$interact$ at$several$levels.$ In$ sporadic$PD$









is$ greatest$ in$ the$ lateral$ ventral$ tier$ (Fearnley$ and$ Lees$ 1991;$ Gibb$ 1992).$This$ leads$ to$
selective$ loss$ of$ dopaminergic$ innervation$ of$ the$ striatum$ and$ explains$ the$ pattern$ of$
reduced$presynaptic$nigrostriatal$loss$ seen$ in$PET$ and$SPECT$ studies.$The$ progression$of$
pathology$ in$ PD$ progresses$ from$ the$ caudal$ ventrolateral$ SNpc$ rostrally,$ medially$ and$
dorsally$(Damier,$Hirsch$et$al.$1999).
Not$only$ the$ SN$ is$ aﬀected$ and$ the$ recent$pathological$ staging$ of$PD$ suggests$ that$ the$
disease$ starts$ in$the$ dorsal$motor$nucleus$of$the$vagus$and$olfactory$areas$ and$progresses$

































cerebellar$ atrophy$ (OPCA),$ striatonigral$ degeneration$ (SND)$ and$ Shy$ Drager$ syndrome$
(SDS).$
& & a)&Epidemiology
The$ageXadjusted$prevalence$ of $MSA$is$4.4$/$100$000$(Schrag,$BenXShlomo$et$al.$1999).$It$ is$
equally$prevalent$in$men$and$women.
& & b)&Clinical&Presentation
MSA$ presents$ in$ the$ 6th$ decade$ and$ lasts$ up$ to$9$years$ from$ ﬁrst$ symptom.$The$ clinical$




Autonomic$ features$ include$ erectile$ impotence,$ urinary$ incontinence,$ constipation$ and$
orthostatic$ hypotension.$Some$patients$ present$with$ syncope.$Parkinsonism$may$ initially$
respond$ to$ levodopa$ to$ some$ degree$ but$ classically$ this$ wanes;$ patients$ may$ develop$
characteristic$ orofacial$dyskinesias$ and$ dystonia.$There$ is$ also$axial$dystonia$ manifest$ as$
antecollis,$ a$ ‘Pisa$ syndrome’$ or$camptocormia.$Tremor,$ if$ present,$ is$ jerky.$Gait$ and$ limb$
ataxia$ and$oculomotor$abnormalities$ indicate$ cerebellar$ involvement$(Litvan,$Bhatia$ et$al.$
2003;$Wenning,$Colosimo$et$al.$2004).$
Depending$ on$ the$ mode$ of$ presentation$ and$ relative$ distribution$ of$ pathology$ in$ the$
nigrostriatal$or$olivoXpontoXcerebellar$pathways$MSA$can$be$clinically$confused$with$PD,$or$
other$cerebellar$degenerations.$MSAXC$accounts$up$for$a$around$1/4$of$sporadic$$cerebellar$
ataxia$ (Gilman,$ Little$ et$ al.$ 2000);$ MSAXP$ accounts$ for$ 8%$ of $ those$ presenting$ with$
parkinsonism$(Schwarz$et$al.,$1998).
Clinical$ red$ ﬂags$ for$ a$ diagnosis$ of$MSA$ include$ early$ postural$ instability,$ early$ use$ of$ a$












Clinical Domain Features Criterion
Autonomic and urinary 
dysfunction
Orthostatic hypotension
Urinary incontinence incomplete 
bladder emptying
Orthostatic fall in blood 


















Extensor plantar responses with hyper-
reflexia Not a requirement
Table&1.5:&Clinical$Consensus$Criteria$for$diagnosis$of$MSA$(Gilman,$Low$et$al.$1999)
Diagnostic Category Inclusion Criteria Excluson Criteria
Possible MSA
One criterion plus two other features 
or poor response to levodopa if 
criterion is parkinsonism
1. Symptom onset < 30 yrs
2. Family history
3. Systemic features or other causes 
for features present
4. Hallucinations off medication
5. Dementia
6. Prominent slowing of vertical 
saccades or supranuclear gaze 
palsy
7. Evidence of focal cortical 
dysfunction
8. Metabolic, genetic or imaging 
evidence of alterative cause for 
features
Probable MSA
One criterion for autonomic 
dysfunction plus poorly levodopa 
responsive parkinsonism or 
cerebellar dysfunction
Definite MSA
Pathologically confirmed with glial 
cytoplasmic inclusions in 






PD$ and$ dementia$ with$ Lewy$ bodies$ forms$ the$ group$ of$ proteinopathies$ called$ the$




There$ is$ putaminal$atrophy$with$greyXgreen$ discolouration$particularly$ in$ the$ dorsolateral$
and$posterior$two$thirds$(Fearnley$and$Lees$1990;$Kume,$Takahashi$et$al.$1993)$and$atrophy$
of$ the$ pons$ and$pontocerebellar$ ﬁbres,$ the$ middle$ cerebellar$ peduncle,$ and$ cerebellum.$
There$is$pallor$of$the$SN$and$LC$(Lantos$1998).
Glial$Cytoplasmic$inclusions$ (GCI)$with$astrogliosis$neuronal$loss$and$demyelination$are$the$
hallmarks$ of$ MSA$ and$ occur$ in$ a$ characteristic$ distribution$ in$ the$ striatonigral$ and$
olivopontocerebellar$pathways$(Papp,$Kahn$et$al.$1989;$Ozawa,$Paviour$et$al.$2004).$GCI$are$
halfXmoon/oval/sickle$shaped$oligodendroglial$argyrophilic$inclusions$which$are$made$up$of$
tubular$ﬁlaments$ (Lantos$ 1998).$The$ most$severe$ lesions$ in$MSA$are$ found$ in$the$SN,$LC,$
putamen,$ inferior$olives,$ the$ pontine$ nuclei,$ the$ Purkinje$ cells$ and$ the$ intermediolateral$
columns$(Lantos$1998).$Neuronal$cytoplasmic$inclusions$also$occur.$Pathologically$both$the$
nigrostriatal$ and$ olivopontocerebellar$ pathways$ may$ be$ aﬀected$ although$ the$
pontocerebellar$ pathway$ is$more$ aﬀected$ in$MSAXC$ and$nigrostriatal$ pathway$ in$MSAXP$
(Ozawa,$ Paviour$ et$ al.$ 2004).$The$ topography$ of$ disease$ is$ typically$ in$ the$ dorsolateral$
posterior$2/3$of$the$putamen$in$MSAXP,$and$ the$ lateral$SNc.$Loss$ of$neurons$ in$the$SNc$is$





Corticobasal$ degeneration$ (CBD)$ was$ ﬁrst$ described$ in$ 1968$ by$ Rebeiz$ et$ al$ as$
‘corticodentatonigral$degeneration$with$neuronal$achromasia’$(Rebeiz,$Kolodny$et$al.$1968).$
CBD$ has$ gone$ by$ a$ variety$ of$ other$ names$ including$ corticonigral$ degeneration$ with$
neuronal$ achromasia$ (1993),$ cortical$ degeneration$ with$ swollen$ chromatolytic$ neurons$




CBD$ is$ onset$ in$ the$ 7th$ decade$ (61X66$yrs$ (Rinne,$Lee$ et$ al.$1994)(Wenning,$Litvan$et$al.$
1998)(Ling,$O'Sullivan$et$al.$2010))$with$no$cases$identiﬁed$under$45$yrs$(Wenning,$Litvan$et$
al.$1998).$ $There$ is$ no$gender$predisposition$(Rinne,$Lee$et$al.$1994;$Ling,$O'Sullivan$et$al.$
2010).
True$ incidence$ is$ unknown$and$in$a$ UK$ community$ based$study$ no$cases$ were$ identiﬁed$
(Schrag,$ BenXShlomo$ et$ al.$ 2000).$ At$ the$ Queen$ Square$ Brain$ Bank$ for$ Neurological$
disorders$ 19/1440$cases$in$the$archive$had$a$pathological$diagnosis$of$CBD$which$was$much$
less$common$than$PD$(608),$PSP$(179)$and$MSA$(117)$(Ling,$O'Sullivan$et$al.$2010).$However,$




The$ features$ found$in$CBD’s$ classic$presentation$are$ known$as$ the$ corticobasal $syndrome$





































does$ not$ response$ to$ levodopa$ therapy$ (Gibb,$Luthert$et$al.$ 1989;$Wenning,$ Litvan$et$al.$
1998;$ Ling,$ O'Sullivan$ et$ al.$ 2010).$ This$ can$ start$ in$ the$ arm$ or$ leg$ with$ associated$
manifestations.$There$may$be$ a$mild$nonXsustained$levodopa$ response$which$ is$unusual$to$
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be$ signiﬁcant$ enough$ to$lead$ to$confusion$with$levodopa$ responsive$ idiopathic$ PD$ (Lang$
2005),$although$this$has$been$described$(Ling,$O'Sullivan$et$al.$2010).$Parkinsonism$was$an$
early$ prominent$ feature$ seen$ in$9/19$ (47%)$ pathologically$ conﬁrmed$CBD$ patients$ (Ling,$
O'Sullivan$ et$ al.$ 2010).$ Myoclonus$ is$ also$ found$ in$ approximately$ 50%$ of$ corticobasal$
presentations$of$CBD,$and$in$approximately$37%$of$all$pathologicallyXconﬁrmed$CBD$cases$
(Stamelou,$ AlonsoXCanovas$ et$ al.$ 2012).$ Often$ there$ is$ a$ jerky$ tremor$ but$ this$ is$ not$
characteristic$of$PD$and$likely$related$to$myoclonus$with$action$and$postural$components.
Apraxia$ commonly$ coXexists$ with$ the$ parkinsonian$ features$ and$ is$ found$ in$ 80X90%$ of$
corticobasal$ syndromes$ (Leiguarda,$ Lees$ et$ al.$ 1994)$ and$ 72%$ of$ patients$ with$




reaching$for$objects$ in$the$ immediate$environment$and$ interXmanual$conﬂict$are$reported$
(Boeve,$Lang$et$al.$2003).$
The$presence$of$delayed$saccadic$latency$supports$the$diagnosis$of$CBD$(Gibb,$Luthert$et$al.$
1989;$Rinne,$Lee$ et$al.$ 1994)$whereas$ abnormalities$ of$saccadic$ speed$and$in$the$ vertical$
plane$are$more$predictive$of$PSP$although$abnormalities$ in$the$ vertical $plane$may$be$ seen$
later$in$the$disease$but$are$ likely$ to$be$milder$than$in$PSP$(RivaudXPechoux,$Vidailhet$et$al.$
2000).$Oculomotor$apraxia$ and$ a$ late$ supranuclear$ gaze$ palsy$ have$ also$ been$ described$
(Boeve,$Lang$et$al.$2003).$ $Axial$signs$ including$bulbar$ (dysarthria$and$dysphagia)$and$gait$






this$ clinical$conundrum$can$be$ approached.$Determining$the$ pathology$associated$with$ a$



























Neurological$Disorders,$of$19$cases$with$a$ pathological$diagnosis$ of $CBD,$only$5$had$a$CBS$
diagnosis$ at$ time$ of$death$ i.e.$ approximately$ a$ quarter$ of$cases$ of$CBD$were$ accurately$
diagnosed$during$ life$ (sensitivity$26.3%).$On$the$ other$hand,$of$21$corticobasal$ syndrome$
presentations$only$5$were$associated$with$CBD$pathology$i.e.$approximately$one$quarter$of$
cases$of$corticobasal$syndrome$turn$out$to$have$corticobasal$degeneration$at$post$mortem$


















In$ another$ series$ from$ a$ primarily$ cognitive$ centre$ 18$ cases$ with$ CBD$ pathology$ were$
associated$ with$ an$ executive$ motor$ presentation$ (containing$ both$ features$ of$CBS$ and$
being$PSPXlike$ but$not$fulﬁlling$clinical $research$criteria$ for$the$ diagnosis)$ in$7/18$.$At$post$
mortem$ examination$ of$ 40$ patients$ with$ corticobasal$ syndrome,$ 14$ had$ a$ pathological$
diagnoses$of$CBD$(35%)$(Lee,$Rabinovici$et$al.$2011).
This$has$ led$to$ the$ development$of$more$ complicated$clinical$research$diagnostic$criteria$
(Armstrong,$Litvan$et$al.$2013).$
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Lang 1994 Boeve 2003 Armstrong 2013
Inclusion criteria:
Rigidity and one cortical 
sign:
1. apraxia
2. cortical sensory loss
3. alien limb
Asymmetric rigidity, 











supportive of another 
diagnosis
Core features:
Insidious onset and progressive 
course
no identifiable cause
cortical dysfunction with at least 
one of:
• focal or asymmetric idiomotor 
apraxia
• alien limb phenomenon
• cortical sensory loss
• visual or sensory neglect
• constructional apraxia
• focal or asymmetric 
myoclonus
• apraxia or speech or non 
fluent aphasia
Extrapyramidal dysfunction:
• focal or asymmetric 
appendicular rigidty lacking 
sustained or prominent 
levodopa respnonse
• focal or asymmetric dystonia
Supportive features:
•cognitive dysfunction with 
relative preservation of learning 
and memory
•focal or asymmetric perifrontal 
cortex atrophy on structural 








plus 2 of: 
•orobuccal or limb 






•behavioural or personality 
change
•visuospatial deficit
Nonfluent variant of 
primary progressive 
aphasia:
•impaired grammar with 










•supranuclear gaze palsy 
or slowing of  vertical 
saccades
Table) 1.8:$ diagnostic$ criteria$ for$ CBD.$ Lang$ 1994,$ Boeve$ 2003$ (Boeve,$ Lang$ et$ al.$ 2003)$ and$
Armstrong$ 2003$(Armstrong,$Litvan$et$ al.$2013).$Using$ the$Armstong$criteria$ for$ possible$CBS$only$
one$feature$from$ the$extrapyramidal$and$ cortical$ domains$are$needed;$for$ probable$CBD$the$onset$
must$ be$ insidious$ with$ gradual$ progression,$ duration$ greater$ than$ one$ year,$ age$ greater$ than$ 50$






uncertainties$ surrounding$ CBS$ and$ CBD$ it$ was$ not$ until$ 2002$ that$ standardised$
neuropathological$criteria$were$agreed$ for$the$diagnosis$ of$CBD$ (Dickson,$ Bergeron$et$al.$
2002).$Although$there$ is$ general$ consensus$ that$CBD$ is$ a$ distinct$entity,$there$ is$ ongoing$
nosological$ debate$ about$ whether$ PSP$ and$CBD$ form$ part$ of $ a$ spectrum$ of$ the$ same$
disease$ given$ (1)$ their$ clinical$and$pathological$overlap,$ (2)$ that$ they$ both$ are$ associated$
with$ 4$microtubule$ binding$ repeat$ tau$deposition$ and$ a$ H1$ haplotype$ and$ (3)$ that$both$





Typically$ there$ is$ cortical$atrophy$ in$ frontal$lobes$ with$ lateral$ventricle$ dilatation$(Massey,$
Micallef$et$al.$ 2012)$ and$ characteristically$parasagittal$cortical$gyri$narrowing$ is$ seen$ in$ a$
periXRolandic$distribution$with$the$ posterior$ superior$frontal$gyrus$more$ aﬀected$than$the$
middle$or$inferior$frontal$gyri$(Dickson,$Bergeron$et$al.$2002).$Atrophy$may$be$asymmetric$
and$ in$cases$with$aphasia$ inferior$frontal$and$temporal$lobe$ involvement$is$ seen.$ $Loss$ of$
associated$white$matter$ is$ seen$ (Massey,$Micallef$et$ al.$2012)$with$ thinning$of$the$ corpus$
callosum.$The$ thalamus$ may$ be$ atrophic$and$ the$ caudate$ head$ﬂattened.$The$ substantia$
nigra$ is$ pale$ (Massey,$Micallef$et$ al.$ 2012)$ but$ the$ locus$ coeruleus$ is$ preserved$ (Dickson,$
Bergeron$et$al.$2002)$or$pale$(Massey,$Micallef$et$al.$2012).
Neuronal$ loss$ and$ astrogliosis$ are$ found$ in$ aﬀected$ areas$ with$ spongiosis$ and$




if $ in$ characteristic$ cortical$ areas$ are$ relatively$ speciﬁc$ for$CBD$ (Dickson,$ Bergeron$ et$ al.$
2002).$Tau$immunohistochemistry$reveals$pretangles,$or$small $neuroﬁbrillary$tangles$in$the$
cortex$ and$ substantia$ nigra$ and$ locus$ coeruleus.$ The$ neuropil$ also$ contains$ tauX
immunoreactive$ cell$processes$ and$ the$ location$in$ cell$processes$ is$ characteristic$of$CBD.$
TauXimmunoreactive$ alphasynuclein$ negative$ coiled$ bodies$ are$ found$ in$ oligodendroglia$
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(Dickson,$Bergeron$et$al.$2002).$In$the$neocortex$tauXimmunoreactive$astrocytic$lesions$are$



























As$ can$ be$ seen$ accurate$ clinical$ diagnosis$ of$ these$ parkinsonian$ conditions,$ even$ in$




consistent$ with$ pathologically$ conﬁrmed$ disease,$ 6$ had$ PSP$ pathology,$ 5$ MSA,$ 3$
Alzheimer’s$ disease,$ 3$ AlzheimerXtype$ pathology,$ 3$ vascular$ disease,$ 2$ nigral$ pathology$
without$Lewy$bodies,$1$postXencephalitic$parkinsonsim$and$1$was$normal$(Hughes,$Daniel$et$
al.$1992).$Likely$ due$ to$ improved$awareness$ in$the$ neurological$community$ 10$years$ later$
the$ diagnostic$ accuracy$ was$ approximately$ 90%$ for$ PD$ with$ PSP$ and$ MSA$ the$ most$
commonly$identiﬁed$pathologies$masquerading$as$PD$clinically$(Hughes,$Daniel$et$al.$2001).$
The$positive$predictive$value$of$a$clinical$diagnosis$by$a$movement$disorder$neurologist$of$
MSA$ is$ 85.7%$ and$PSP$80%$with$sensitivity$of$88.2%$ in$MSA$ and$84.2%$ in$PSP$ (Hughes,$
Daniel$et$al.$2002),$which$is$greater$than$the$accuracy$of$the$clinical$research$criteria$ for$in$
PSP$ (probable$ PSP$ sensitivity$ 50%,$ PPV$ 100%;$ possible$ PSP$ sensitivity$ 83%,$ PPV$ 83%$













Table&1.12:&Diagnostic$acumen$in$parkinsonian$syndromes$ from$1440$cases$ at$ the$
Queen$Square$Brain$Bank$(Ling,$O'Sullivan$et$al.$2010).
Thus,$although$ improvements$ in$clinical$diagnosis$ have$ certainly$ been$made$ over$ the$ last$
20$years,$the$heterogeneity$of$clinical$features$of$these$diseases$and$in$CBD$particularly$the$
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Progressive$ Supranuclear$ Palsy$ (PSP)$ and$Multiple$ System$ Atrophy$ (MSA)$ are$ the$ most$
common$ causes$ of$ neurodegenerativeXparkinsonism$ after$ Parkinson’s$ disease,$ with$ an$
estimated$prevalence$ for$PSP$ of$6~4$per$100$000$and$for$MSA$of$4~4$per$100$000$ (Schrag,$
BenXShlomo$et$al.$1999).$MSA$may$be$divided$ into$clinical$subtypes,$according$to$whether$
cerebellar$ (MSAXC)$ or$parkinsonian$ (MSAXP)$ symptoms$ predominate$ (Gilman,$Low$ et$ al.$
1999)$and$a$ recent$study$has$demonstrated$that$early$autonomic$dysfunction$may$also$be$a$
prognostic$indicator$in$MSA$(Tada,$Onodera$et$al.$2007).$PSP$may$also$be$classiﬁed$into$two$
clinical$ subtypes,$ ‘Richardson’s$ syndrome’$ (PSPXRS)$ and$ ‘PSPXparkinsonism’$ (PSPXP)$
(Williams,$de$Silva$et$al.$2005).
Currently,$ there$ is$ little$ data$ available$ comparing$ the$ clinical$ progression$ of$ the$ clinical$
subtypes$ of$MSA$and$PSP.$There$ have$been$two$published$studies$ of$the$natural$history$ of$
PSP$ with$over$100$cases$but$with$only$ a$minority$of$cases$ with$ pathological$ conﬁrmation$
(Nath,$ BenXShlomo$ et$ al.$ 2001;$ Golbe$ and$ OhmanXStrickland$ 2007).$ Similarly,$ with$ the$
exception$ of $a$ metaXanalysis$ $ (Wenning,$Tison$et$ al.$ 1997)$ the$ few$ large$ natural$history$
studies$in$MSA$lack$pathological$conﬁrmation,$with$only$22$of$the$230$patients$described$by$
Watanabe$undergoing$autopsy$(Watanabe,$Saito$et$al.$2002).
Accurate$ natural$history$ data$ is$ essential$ for$ clinicians$ to$ be$ able$ to$ provide$ prognostic$
information$to$patients$ and$their$families.$ $Furthermore$ this$ information$could$serve$as$ a$
source$ of$ historical$ controls$ for$ use$ in$ future$ interventional$ studies.$ However,$ because$
clinical$ diagnosis$ is$ diﬃcult$ in$ these$ conditions$ (Hughes,$ Daniel$ et$ al.$ 2002)$ prospective$










Patients$ with$a$ pathologically$proven$diagnosis$ of$PSP$and$MSA$were$ identiﬁed$ from$ the$
records$ of$donors$ to$ the$Queen$ Square$ Brain$Bank$ for$Neurological$Disorders$ that$were$
autopsied$between$1987$and$2007$where$tissue$ is$donated$according$to$ethically$approved$
protocols$and$is$stored$under$a$licence$from$the$Human$Tissue$Authority.$
The$ diagnosis$ of$ PSP$ was$ made$ according$ to$ the$ National$ Institute$ for$ Neurological$
Diseases$ and$ StrokeXSociety$ for$ PSP$ (NINDSXSPSP)$ neuropathological$ criteria$ (Hauw,$
Daniel$et$al.$1994;$Litvan,$Hauw$et$al.$1996)$and$the$diagnosis$of$MSA$was$made$according$




of$ the$ family$ doctor$ and$ all$ of$ the$ correspondence$ between$ the$ family$ doctor$ and$ the$
medical$ specialist.$All $patients$ had$ been$ assessed$ by$ hospital $specialists$ (neurologists$ or$
geriatricians)$ who$were$ blinded$ to$the$ pathological$diagnosis. 'Cases$were$ excluded$ if$the$
medical$ records$ did$ not$ contain$ regular$ and$ wellXdocumented$ reports$ of $ clinical$
developments.$
A$ clinical$data$ sheet$was$ designed$ to$ record$ the$ presence$ or$ absence$ of $clinical$ features$
either$ early$ in$ the$ disease$ course$ (within$ 2$years$ of$ ﬁrst$ symptom$onset)$ or$ at$ any$ time$
during$the$disease,$as$described$previously$(Williams,$de$Silva$et$al.$2005).$ $Symptoms$were$
recorded$ as$ being$ absent$ if $not$ reported$ and$ clinical$ signs$ were$ recorded$ separately$ as$









and$ the$ right,$ asymmetry$ was$ recorded$ as$ being$ present.$ This$ included$





(vii)$ Impaired$ postural$ reﬂexes:$ the$ presence$ of$ this$ sign$ was$ recorded$ only$ if$
speciﬁcally$mentioned$in$the$clinical$notes.$
(viii)$ Supranuclear$ gaze$ palsy:$ the$ speciﬁc$ recording$ of$ restricted$ range$ of$ eye$
movement$in$the$vertical$plane.$




(xi)$ Pyramidal$ signs:$ pathologically$ brisk$ reﬂexes$ and/or$ extensor$ plantar$
response(s).$
(xii)$ Autonomic$ dysfunction:$ either$ abnormal$ autonomic$ function$ testing$ or$
documentation$ of$any$ two$of$ urinary$ urgency,$ frequency$ and$ nocturia$ without$
hesitancy;$chronic$constipation;$postural$hypotension;$sweating$abnormalities;$or$
erectile$dysfunction.$
(xiii)$ Response$ to$ levodopa:$ the$ patient’s$ and$ clinician’s$ interpretation$ of$





nil,$ or$ slight$ response$ (<30%$ improvement);$ 2$ =$moderate$ response$ (30–50%$




Seven$ milestones$ of$ disease$ advancement$ were$ selected$ on$ the$ basis$ that$ each$ was$
clinically$ important$ and$ therefore$ likely$ to$ require$ additional$medical$attention$ and$ to$ be$
well$recorded$in$the$case$notes.$These$were:$









The$year$of$onset$or$occurrence$ of$each$was$ recorded.$When$the$onset$of$a$ symptom$was$
not$ documented,$ we$ recorded$ the$ time$ that$ the$ symptom$ was$ ﬁrst$ documented.$
Judgments$about$onset$of $cognitive$disability$were$ the$most$diﬃcult$to$make$as$ confusion$
was$ often$ initially$ episodic$ (Kempster,$Williams$ et$ al.$ 2007).$ $ Substantial$ and$ apparently$
permanent$ impairment$ of$ ability$ to$ perform$ tasks$ of$ daily$ living$ because$ of$ cognitive$




The$ conﬁrmed$cases$ of$PSP$were$ subdivided$when$possible$ according$ to$the$ two$clinical$
phenotypes:$ ‘Richardson’s$ syndrome’$ (PSPXRS)$ and$ ‘PSPXparkinsonism’$ (PSPXP)$ (Williams,$
de$ Silva$ et$ al.$ 2005).$ These$ groups$ were$ assigned$ according$ to$ the$ number$ of$ clinical$
features$ present$ in$ the$ ﬁrst$ two$ years$ of$ disease.$ When$ falls,$ cognitive$ dysfunction,$
supranuclear$gaze$palsy,$abnormalities$of$saccadic$eye$movements$and$postural$instability$
were$the$predominant$clinical$features,$patients$were$grouped$as$PSPXRS.$$However,$PSPXP$
was$ designated$ if$ these$ features$ were$ absent$ in$ the$ ﬁrst$ two$ years$ of$ disease$ in$ the$




In$ MSA,$ we$ compared$ patients$ presenting$ with$ symptoms$ and$ signs$ of$ autonomic$
dysfunction$within$ the$ ﬁrst$ two$years$ from$disease$ onset$ (early$ autonomic$ dysfunction$ X$
EAD).$ Because$ of$ referral$ bias$ to$ the$ Queen$ Square$ Brain$ Bank,$ which$ specialises$ in$
parkinsonian$ disorders,$ the$ vast$ majority$ of $ MSA$ cases$ were$ of$ the$ MSAXP$ subtype.$
Therefore$comparisons$between$MSAXP$and$MSAXC$were$not$possible.$
& 4.&Statistical&Analysis
Clinical$ details$ including$ age$ at$ disease$ onset,$ age$ at$ death,$ disease$ duration$ were$
compared$ between$patient$ groups.$ Mean$ results$ and$ comparisons$ for$each$milestone$ of$
advanced$ disease$ refer$ only$ to$ those$ patients$ in$ whom$ one$ of$ these$ event$ occurred.$
Univariable$ analyses$using$χ2$ for$categorical$and$twoXtailed$tXtest$or$the$Mann–Whitney$UX
test,$as$ appropriate,$ for$continuous$ variables$were$applied.$The$ interval$in$years$ from$ﬁrst$
symptom$ onset$ to$ each$ key$ motor$ impairment$or$ death$was$ graphically$ assessed$ using$
KaplanXMeier$curves,$and$curves$ from$each$patient$subgroup$were$ compared$with$ the$ log$
rank$ test.$Cox$multiple$ stepwise$ regression$ analysis$ was$ performed$ in$MSA$ and$PSP$ for$
disease$ duration,$ using$ clinical$ factors$ present$around$disease$ onset$ (within$ the$ ﬁrst$ two$




A$ total$ of$ 123$ cases$ of$ pathologically$ conﬁrmed$ PSP$ were$ identiﬁed,$ of$ which$ 13$ were$










A$ higher$proportion$of$ those$ patients$ with$ RS$ (86%)$ than$PSPXP$ (41%)$ were$ diagnosed$
during$ life$ with$ PSP$ (χ2,$ p<0.001).$ Patients$ with$MSA$ and$ EAD$ were$ more$ likely$ to$ be$
diagnosed$ during$ life$ with$ MSA$ (χ2,$ p=0.001).$ A$ higher$ proportion$ of$ males$ had$ EAD$
(male:female$1.5:1.0)$than$in$the$group$of$patients$without$EAD$(0.4:1.0,$χ2,$p=0.0012).$
Clinical$ features$ were$ compared$ between$ cases$ with$ MSA$ or$ PSP$ in$ addition$ to$
comparisons$between$clinical$subgroups$of$MSA$and$PSP$[Table$2.1].$
PSP&vs&MSA PSP&subtypes MSA&subtypes










































































































































































than$those$ patients$without$ EAD.$Figures$ 2.1D$ –$ 2.1E$ describe$ survival$ curves$ in$PSP$ and$
MSA$according$to$the$age$of$disease$onset.









of$ symptom$ onset.$ Log$ Rank$ (MantelXCox),$ df=2,$ P=0.011$ <$60$ yrs$ old,$ blue;$
60X69.9$yrs$old,$green;$>70$yrs$old$yellow.
(E) $ Interval$ from$disease$ onset$ to$death$ in$MSA$ subtype$ (years)$ according$to$ the$






clinical$ features,$ age,$ and$ gender$ identiﬁed$ several$ clinical$ factors$ which$ independently$
inﬂuence$disease$duration.$
In$PSP,$a$ PSPXRS$ phenotype,$male$ gender,$older$ age$ of$onset,$and$ a$ short$ interval $from$
disease$ onset$ to$ reaching$ the$ ﬁrst$ clinical$ milestone$ were$ all$ independent$ predictors$ of$
shorter$ disease$ duration$ until$death.$ In$MSA,$EAD,$ female$ gender,$older$ age$ of$onset,$ a$
short$ interval$ from$ disease$ onset$ to$ reaching$ the$ ﬁrst$ clinical$milestone,$ and$ not$ being$
admitted$to$residential$care$were$ independent$factors$ predicting$shorter$disease$duration$
until$death$[Table$2.2].
Independent&Predictors HR 95%&CI p
PSP
RS&phenotype 2.37 1.21R4.64 0.01
Age&of&onset 1.05 1.02'R1.1 0.005





Not&admitted&to&residential&care 2.8 1.45'–'5.46 0.002
Early&Autonomic&dysfunction& 6.0 3.1'R11.7 <0.001
Age&of&onset 1.05 1.02'–'1.1 0.003












Frequent$ falling$was$ the$ most$common$ﬁrst$milestone$ reached$ in$PSP$ (63.6%)$ and$MSA$
(39.3%).$The$next$most$frequent$ﬁrst$milestone$in$PSP$was$cognitive$impairment$(15.4%);$in$
MSA$the$ next$most$frequent$ﬁrst$milestone$ reached$was$requiring$urinary$ catheterization$
(29.4%).$ Approximately$ 10%$ of$ patients$ in$ both$ groups$ reached$ more$ than$ one$ ‘ﬁrst$
milestone’$ simultaneously.$Patients$with$PSP$reached$their$ﬁrst$clinical$milestone$earlier$in$
the$disease$course,$after$a$mean$of$3.9$±$2.7$years$from$disease$onset,$compared$to$patients$
with$ MSA$ at$5.3$ ±$2.2$ years$ (tXtest,$ p$ <$0.001,$ Log$Rank$ (MantelXCox),$ p=0.004)$ [Figure$
2.3A].$ Of$ the$ patients$ documented$ as$ having$ frequent$ falls,$ 53%$ of$ patients$ with$ PSP$
became$ wheelchair$ dependent$ (χ2,$ p=0.001),$ and$ 50%$ of$ those$ with$ MSA$ became$
wheelchair$dependent$(χ2,$p=0.6).$See$table$2.3$for$the$proportion$of$patients$in$each$clinical$
subgroup$reaching$individual$clinical$milestones,$ the$mean$intervals$ from$disease$ onset$ to$
developing$clinical $milestones,$and$the$mean$intervals$from$developing$a$clinical$milestone$
to$death.
Comparing$those$ patients$ reaching$particular$ clinical$milestones$ with$either$PSP$ or$MSA,$
the$ following$occurred$after$a$shorter$mean$interval$in$the$PSP$group:$regular$falls$ (tXtest,$










































n&(%) 84'(82%) 47'(59%) 0.001* 60'(92%) 15'(60%) 0.001* 22'(55%) 23'(64%) ns
Time&from&onset
(mean&±&SD)
3.9'±'2.5 5.5'±'2.2 <'0.001'** 2.9'±'1.5 6.0'±'3.0 0.002** 5.7'±'2.2 5.4'±'2.4 ns
Time&to&death
(mean&±&SD)





n&(%) 48'(46%) 43'(54%) ns 32'(47%) 13'(50%) ns 23'(55%) 19'(56%) ns
Time&from&onset
(mean&±&SD)











n&(%) 39'(38%) 34'(41%) ns 28'(44%) 6'(23%) ns 14'(33%) 19'(53%) ns
Time&from&onset
(mean&±&SD)
6.0'±'2.5 7.2'±'2.0 0.04** 5.7'±'2.3 7.0'±'3.9 ns 6.7'±'2.0 7.6'±'2.0 ns
Time&to&death
(mean&±&SD)
1.5'±'1.5 1.7'±'1.6 ns 0.5±'0.9 0.7'±'1.7 ns 1.7'±'1.4 1.8'±'1.7 ns
Severe&
dysphagia
n&(%) 35'(33%) 26'(32%) ns 28'(42%) 4'(15%) 0.02* 13'(32%) 12'(33%) ns
Time&from&onset
(mean&±&SD)
6.4'±'2.4 7.2'±'2.3 ns 5.9'±'1.9 9.4'±'3.8 ns 7.1'±'2.4 7.6'±'2.3 ns
Time&to&death
(mean&±&SD)





n&(%) 27'(26%) 49'(60%) 0.000* 18'(27%) 6'(23%) ns 29'(71%) 18'(50%) ns
Time&from&onset
(mean&±&SD)
6.3'±'3.1 6.1'±'2.6 ns 5.4'±'2.7 8.3'±'3.2 ns 5.8'±'2.7 6.9'±'2.3 ns
Time&to&death
(mean&±&SD)
1.2'±'1.1 1.9'±'1.7 0.02** 0.3'±'0.8 0.2'±'0.6 ns 1.9'±'1.5 2.1'±'2.0 ns
Cognitive&
impairment
n&(%) 54'(52%) 11'(14%) <0.001* 41'(62%) 7'(28%) 0.005* 5'(13%) 5'(14%) ns
Time&from&onset
(mean&±&SD) 4.2'±'2.9 6.2'±'2.4 0.03** 3.7'±'2.4 6.5'±'4.7' ns 6.6'±'2.5 6.6'±'2.0 ns
Time&to&death
(mean&±&SD)
2.4'±'1.8 1.1'±'1.1 0.005** 1.4'±'1.9 0.5'±'1.0 0.001** 0.9'±'0.5 0.8'±'1.2 ns
Residential&
care
n&(%) 27'(26%) 14'(18%) ns 19'(28%) 5'(19%) ns 5'(12%) 9'(25%) ns
Time&from&onset
(mean&±&SD)
6.1'±'3.0 7.9'±'3.3 ns 4.8'±'2.0 9.9'±'2.2 0.003** 9.0'±'2.0 7.3'±'3.8 ns
Time&to&death
(mean&±&SD)





n&(%) 100'(91%) 79'(95%) ns 68'(99%) 20'(69%) <0.001* 40'(95%) 35'(95%) ns
Time&from&onset
(mean&±&SD)






3.7'±'2.2 2.6'±'1.9 0.001** 3.5'±'2.1 4.4'±'2.8 ns 2.0'±'1.5 3.4'±'2.2
0.002
**
Table& 2.3:$ Milestones$ of$ disease$ advancement$ according$ to$ disease$ (MSA$ or$ PSP)$ and$
disease$ subXcategories$ (RS$v$PSPXP,$ and$MSA$with$v$without$early$ autonomic$symptoms).$
*Chi$squared$test.$**$Student’s$tXtest.
See$ ﬁgures$ 2.3AX2.3H$ for$ KaplanXMeier$ curves$ of$ the$ intervals$ to$ reaching$ clinical$
milestones.
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Fig.2.3)APD:$Comparison$between$PSP$and$MSA$ of$ interval$ from$ disease$onset$ to$reaching$ clinical$
milestones.$PSP,$green;$MSA,$blue.




(C) Interval$ in$years$from$disease$onset$ to$developing$signiﬁcant$cognitive$impairment.$Log$
Rank$(MantelXCox),$df$=$1,$P$=$0.07.
(D) $ Interval$ in$ years$ from$ disease$ onset$ to$ developing$ signiﬁcant$ dysphagia.$ Log$ Rank$
(MantelXCox),$df$=$1,$P$=$0.29.$$
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Fig.2.3)EPH:$Comparison$ between$ PSP$and$MSA$of$ interval$ from$disease$onset$ to$reaching$ clinical$
milestones.$PSP,$green;$MSA,$blue.
(E) Interval$ in$ years$ from$ disease$ onset$ to$ developing$ wheelchair$ dependence.$Log$ Rank$
(MantelXCox),$df$=$1,$P$=$0.95.$$
(F) Interval$ in$ years$ from$ disease$ onset$ to$ developing$ unintelligible$ speech.$ Log$ Rank$
(MantelXCox),$df$=$1,$P$=$0.28.$






until$death$at$3.7$±$ 2.2$ years,$ than$those$ with$MSA$ at$ 2.6$ ±$1.9$years$ (tXtest,$p$ =$0.001).$
Patients$ with$PSP$who$ develop$ regular$ falls$ (Log$ Rank$ (MantelXCox),$df$ =$1,$ p=0.016)$ or$
signiﬁcant$ cognitive$ impairment$ (Log$ Rank$ (MantelXCox),$df$ =$ 1,$ p=0.015)$ have$ a$ longer$
disease$ duration$ from$developing$these$milestones$ than$patients$ with$MSA$who$ develop$
these$milestones.$Patients$ with$MSA$who$require$ urinary$ catheterization$live$ longer$from$
reaching$this$milestone$than$patients$with$PSP$(Log$Rank$(MantelXCox),$df$=$1,$p=0.049).$No$
other$ diﬀerences$ were$ seen$ between$ the$ PSP$ and$ MSA$ groups$ when$ comparing$ the$
intervals$from$reaching$clinical$milestones$to$death.$
& 5.&Clinical&milestones&reached:&PSPWRS&vs&PSPWP
Patients$ with$ PSPXRS$ reached$ their$ ﬁrst$ clinical$milestone$ after$ a$ shorter$ interval$ from$
disease$ onset$ compared$to$ patients$ with$PSPXP$ (tXtest,$ p<$0.001$Log$Rank$ (MantelXCox),$
p<0.001).$ A$ higher$ proportion$ of$ patients$ with$ PSPXRS$ developed$ frequent$ falls$ (χ2,$
p=0.001),$signiﬁcant$cognitive$ impairment$ (χ2,$p=0.005)$and$ severe$dysphagia$ (χ2,$ p=0.02)$
than$ patients$ with$ PSPXP.$A$ similar$ proportion$ of$patients$ with$PSPXRS$ and$ PSPXP$ were$
documented$ as$ having$ the$ other$ clinical$ milestones,$ however$ these$ occur$ earlier$ in$ the$








according$ to$ the$ presence$ of$ early$ autonomic$ dysfunction.$ However,$ the$ interval$ from$
developing$the$ﬁrst$clinical$milestone$and$the$following$milestones,$to$the$patients’$deaths$
was$ shorter$in$those$with$EAD:$frequent$ falls$ (tXtest,$p=$0.002),$wheelchair$dependence$ (tX




We$have$described$the$natural $history$of$disease$ in$pathologically$ conﬁrmed$PSP$and$MSA$
and$ compared$ the$ disease$ course$ according$ to$ subXgroups$ based$ on$ early$ presenting$
features.$ Progression$ of$ disease$ was$ measured$ using$ clinically$ signiﬁcant$ milestones$
relevant$to$independence.$We$have$ identiﬁed$early$clinical$features$in$PSP$and$MSA$that$are$






Patients$ with$ PSP$ were$ older$ at$ disease$ onset$ than$ those$ with$ MSA,$ consistent$ with$
previous$ studies$ describing$ the$ onset$ of$PSP$ in$ the$ 7th$ decade$ (Nath,$BenXShlomo$ et$ al.$
2003;$Papapetropoulos,$Gonzalez$et$al.$2005;$Golbe$and$OhmanXStrickland$2007)$and$MSA$
in$ the$ 6th$ decade$ (Wenning,$ Ben$ Shlomo$ et$ al.$ 1994).$ In$ both$ conditions$ the$ interval$
between$disease$ onset$ to$ﬁnal$clinical$diagnosis$ was$ around$3.5X4.0$years,$consistent$with$
results$seen$in$a$comparison$of$nonXpathologically$conﬁrmed$cases$of$PSP$and$MSA$(Testa,$
Monza$et$al.$2001).$
The$mean$PSP$ disease$ duration$of$ 8.0$±$ 4.1$ years$ in$ our$ study$ is$ similar$ to$ other$clinical$
studies,$showing$a$duration$of$between$6$and$10$years$(Maher$and$Lees$1986;$Golbe,$Davis$
et$al.$1988;$Golbe$and$OhmanXStrickland$2007).$The$mean$survival$of$patients$with$MSA$of$
7.9$±$2.8$years$ in$our$study$is$consistent$with$previous$ data$ showing$a$survival$duration$of$
between$ 6$ and$ 9$ years$ (BenXShlomo,$Wenning$ et$ al.$ 1997;$ Testa,$ Monza$ et$ al.$ 2001;$
Watanabe,$ Saito$ et$ al.$ 2002).$ We$ observed$ a$ predominance$ of$ males$ in$ PSP,$ when$
compared$to$MSA.$
& & b)&Diagnostic&accuracy
Similar$ rates$of$diagnostic$accuracy$were$ seen$between$groups$ (70X72%),$which$are$ lower$
than$ those$ in$ a$ similar$ study$ which$ found$a$ diagnostic$ sensitivity$ of$84X88%$for$ PSP$ and$








from$disease$ onset,$with$only$ the$ requirement$for$urinary$catheterization$tending$to$occur$
later$ than$ in$ the$ course$ of$MSA.$This$ suggests$ that$ although$survival$ﬁgures$ in$these$ two$
conditions$ are$similar,$ the$ clinical$burden$of$PSP$which$occurs$ in$an$older$patient$group$is$





ﬁrst$ clinical$ milestone,$ and$ older$ age$ of$ onset$ were$ associated$ with$ shorter$ disease$
duration.$Previous$studies$on$smaller$numbers$of$pathologicallyXconﬁrmed$PSP$cases$have$
suggested$ early$ falls$ and$ dementia$ (Papapetropoulos,$ Gonzalez$ et$ al.$ 2005)$ and$ early$
dysphagia$and$incontinence$(Litvan,$Mangone$et$al.$1996)$as$poor$prognostic$indicators$for$
disease$ progression$ and$ survival.$ In$ nonXpathologically$ conﬁrmed$ PSP,$ Nath$ and$Golbe$







PSPXRS$patients$ had$a$ similar$age$ at$disease$ onset$ but$ a$more$ rapid$disease$ progression$
than$ those$ patients$ with$PSPXP$ as$ shown$by$ the$ shorter$ disease$ course$ in$ RS$ and$ in$ the$
increased$frequency$ of$clinical$milestones$ reached,$ and$the$development$of$frequent$ falls$
and$wheelchair$dependence$at$an$earlier$stage.$Although$it$ is$ important$to$note$ that$early$
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falling$ in$ PSPXRS$ may$ inﬂuence$ these$ ‘ambulatory$ milestones’,$ there$ is$ also$ a$ trend$ for$
patients$with$RS$to$reach$other$milestones$not$always$associated$with$mobility$at$an$earlier$
stage$ including$ severe$ dysphagia,$ unintelligible$ speech,$ signiﬁcant$ cognitive$ impairment,$
requirement$for$urinary$catheterization,$and$admission$to$residential$care.$
& 4.&Clinical&factors&predicting&disease&progression&in&MSA
Female$ gender,$ an$ older$ age$ of$ onset,$ a$ short$ interval$ from$ disease$ onset$ to$ the$
development$of$the$ﬁrst$clinical$milestone,$and$not$being$admitted$to$residential$care$were$
independent$ factors$ predicting$shorter$ disease$ duration$until$death$in$MSA.$Older$age$of$
MSA$ onset$ was$ seen$ to$ be$ associated$ with$ increased$ risk$ of$ death$ and$ wheelchair$
dependence$ in$a$ study$by$Watanabe$ and$colleagues,$although$gender$was$not$found$to$be$
associated$ with$ diﬀerence$ in$ prognosis$ (Watanabe,$ Saito$ et$ al.$ 2002).$ Klockgether$ and$
colleagues$ found$older$age$ of$disease$ onset$to$be$ associated$with$decreased$survival,$and$
also$ $demonstrated$an$increased$risk$ of$wheelchair$dependence$ in$females,$but$no$gender$
diﬀerences$regarding$survival$(Klockgether,$Ludtke$et$al.$1998).
Our$ﬁnding$of$a$potential $beneﬁcial$eﬀect$on$survival$associated$with$admission$to$nursing$











those$ with$EAD$had$shorter$disease$duration.$The$ higher$proportion$of$males$ in$the$EAD$
group$may$reﬂect$the$frequency$of$documentation$of$erectile$failure$as$an$early$symptom$of$
autonomic$ failure$ in$ men,$ in$ comparison$ to$ the$ lack$ of$ documentation$ of$ secondary$
anorgasmia$ as$ a$ symptom$ of$ sexual$dysfunction$ in$women,$ a$ ﬁnding$ noted$ in$ previous$
studies$ (Wenning,$Ben$Shlomo$et$al.$ 1994).$Although$we$ did$not$ﬁnd$diﬀerences$between$
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MSA$ subXgroups$ when$ analyzing$ the$ interval$from$ disease$ onset$ to$ the$ development$ of$
other$clinical$milestones,$we$show$that$when$patients$with$EAD$reach$the$following$clinical$
milestones,$there$is$a$shorter$interval$from$this$point$to$death$–$ frequent$falling,$wheelchair$
dependence,$ severe$ dysphagia$ and$ requirement$ for$ residential$ care.$These$ ﬁndings$ may$
also$ suggest$ an$ accelerated$ later$ stage$ of $disease$ progression$ in$ this$ patient$ subgroup$
[Figure$2.4].$
Figure& 2.4:$ Milestones$ of$ disease$ advancement$ and$ total$ disease$ course.$ The$ grey$
rectangles$represent$disease$duration,$commencing$with$the$ time$point$of$ﬁrst$symptoms.$
The$ vertical$ lines$ denote$ time$ of$ clinical$ diagnosis$ (Dx)$ and$ time$ of$ documentation$ of$
milestones$ (Residential$ care,$R;$Cognitive$ disability,$C;$Dysarthria/dysphagia,$D;$ Frequent$
falls,$F;$Wheelchair$dependent,$W;$Urinary$ catheter,$U).$Error$bars$ for$standard$error$of $the$
mean.
& 5.&Limitations
The$ retrospective$data$collection$methodology$and$the$ selection$bias$ that$is$ expected$ in$a$
brain$ bank$ post$ mortem$ series$ may$ account$ for$ the$ diﬀerences$ with$ previous$ studies$
(Maraganore,$ Anderson$ et$ al.$ 1999).$ As$ our$ data$ was$ obtained$ from$ diﬀerent$ sources,$
without$using$a$systematic$historyXtaking$method,$ it$is$ likely$ that$ there$ is$ variability$ in$the$




The$ fact$ that$the$milestones$ often$were$ reached$some$ time$before$a$ clinic$ visit$may$have$
reduced$the$accuracy$of $the$timing$of $these$determinations,$particularly$if $patients$were$not$
reviewed$on$a$ frequent$basis.$The$ large$ number$of$patients,$and$the$ inclusion$of$patients$
who$otherwise$ might$ not$ have$ been$ included$ in$a$ prospective$ clinical$ study$ are$ relative$
strengths$of$this$study.$$
F.&Conclusions
We$ describe$ the$ natural $ history$ of$ pathologicallyXproven$ cases$ of$ PSP$ and$ MSA,$ and$









Bradykinesia$is$ key$for$the$diagnosis$of$Parkinson’s$disease$ (PD)$[Figure$ 1.2]$(Gibb$and$Lees$
1988).$The$ term$ bradykinesia$ is$ often$ used$ interchangeably$ with$ the$ terms$ akinesia$ and$
hypokinesia.$ However,$ bradykinesia$ literally$ describes$ slowness$ in$ movements,$ akinesia$
means$absence$of$expected$spontaneous$voluntary$movement$including$slow$reaction$time$
(Hallett$ 2011),$ and$ hypokinesia$ refers$ to$ small$ amplitude$ movements.$ Bradykinesia,$
akinesia$ and$ hypokinesia$ are$ closely$ related$ but$ not$ necessarily$ correlated$ in$ individual$
patients.$ Each$ component$ of$ motor$ abnormality$ probably$ has$ a$ diﬀerent$ underlying$
mechanism$(Berardelli,$Rothwell$et$al.$2001).$
& 2.&Bradykinesia&in&PD
Bradykinesia$ is$ explicitly$ deﬁned$ in$ the$Queen$Square$ Brain$Bank$ (QSBB)$ criteria$ for$ the$
diagnosis$ of$ Parkinson’s$ disease$ as$ ‘slowness$ of$ initiation$ of$ voluntary$ movement$ with$
progressive$ reduction$ in$ speed$and$amplitude$ of$ repetitive$ action’$ (Gibb$ and$ Lees$ 1988).$
Both$bradykinesia$and$hypokinesia$ in$PD$ improve$with$levodopa$ therapy$whereas$ reaction$
time$ is$ thought$ to$ be$ related$ to$ nonXdopaminergic$ deﬁcit$ (Velasco$ and$ Velasco,$ 1973,$
Berardelli% et% al.% ,$ 1986,$ Jahanshahi % et% al.% ,$ 1992).$ The$ term$ ‘sequence$ eﬀect’$ is$ used$ to$
describe$ progressive$ reduction$in$amplitude$ and$speed$in$sequential$movements$ and$is$ a$
key$ feature$ of$ PD$ (Berardelli,$ Rothwell$ et$ al.$ 2001;$ Iansek,$ Huxham$ et$ al.$ 2006).$ If$ the$





PSP$ is$ characterized$ by$ vertical$ supranuclear$ gaze$ palsy,$ early$ gait$ instability$ with$ falls$
characteristically$ in$ a$ backwards$ direction,$ axial$ rigidity$ and$ bulbar$ dysfunction.$ In$ the$
original$description,$elements$ of$bradykinesia$were$ seen$ in$only$ two$ cases,$ one$ of$whom$





neurological% picture% which% has% been% considered% as% parkinsonism% by% any% of% the% numerous%
neurologists%who%have%examined%them.%In%earlier %stages% there%have%been%features% leading%one%
to% wonder% if% the% case%would% progress% to% parkinsonism,% but% in% all% cases% the% fully% developed%
clinical%picture%has%diﬀered%widely%from%any%acceptable%deﬁnition%of%“parkinsonism”.%Aside%from%
the% absence% of% tremor% there% has% not% been% any% ﬂexion%of% attitude,% not% has% there% been%any%
parkinsonian%posturing% of% hands.%The%gait%has% diﬀered%and%there% has% been%a%preservation%of%
associated% movements% unlike% paralysis% agitans.% Of% course% the% ophthalmolplegia% has% been%
much%greater%and%diﬀerent%from%the%pseudoIophthalmoplegia%occurring% in%some%cases....%The%
immobile% facies% of% these% cases% is% superﬁcially% similar %to% that% of% parkinsonism,% but% there% are%
deeper% lining% and%more% frequent% blinking...% In% later% stages% the% rigidity% of% limbs% and% trunk% in%
these%cases% does% not%present% features% similar%to% advanced%stages% of% parkinsonism%and%other%
basal%ganglion%diseases...’%(Steele,%Richardson%et%al.%1964)




with$a$clinical$diagnosis$of$Parkinson’s$disease$ $turn$out$to$have$ tau$pathology$ compatible$
with$ PSP$ at$ postXmortem$ examination$ (Hughes,$ Daniel $ et$ al.$ 2002).$ $ These$ and$ other$
ﬁndings$ have$ led$ to$ the$ delineation$ of$ two$ common$ clinical$ phenotypes:$ classical$ PSP,$
termed$Richardson’s$syndrome$(PSPXRS)$and$PSPXParkinsonism$(PSPXP)$(Morris,$Gibb$et$al.$
2002;$Williams,$de$Silva$et$al.$2005).$In$accordance$with$the$original$description$of$Steele$et$
al,$our$clinical$observations$over$the$ last$ ten$years$ suggest$that$most$PSP$patients$do$not$
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and$ Lees$ 1994;$ Derkinderen,$ Dupont$ et$ al.$ 2002;$ Kim,$ Lee$ et$ al.$ 2005;$ Kuoppamaki,$
Rothwell$ et$ al.$ 2005),$ postXencephalitic$ parkinsonism$ (Froment,$ 1921),$ PD$ (McLennan,$
Nakano$ et$ al.$ 1972)$ and$ Huntington’s$ disease$ (Iwasaki,$ Ikeda$ et$ al.$ 1999).$ Micrographia$
characterised$ by$ small$ handwriting$ with$ further$ progressive$ reduction$ in$ size$ can$ be$
observed$ in$ 15%$ of$patients$ with$ PD$ (McLennan,$ Nakano$ et$ al.$ 1972).$The$ relationship$
between$micrographia$ and$ bradykinesia$ remains$ controversial$ (McLennan,$Nakano$ et$ al.$
1972).$It$is$also$not$known$if$handwriting$in$PD$diﬀers$from$that$in$PSP.
B.&Aims
Using$ objective$ measurements$ we$ assessed$ performance$ of$ repetitive$ ﬁnger$ tapping$
movements$ and$ handwriting$ in$ PD$ and$ PSP$ to$ determine$ whether$ there$ are$ any$
quantitative$diﬀerences$that$may$be$of$clinical$utility.$Repetitive$ﬁnger$tapping$was$selected$







participated$ in$this$ study.$Patients$ fulﬁlled$the$United$Kingdom$Queen$Square$Brain$Bank$
diagnostic$ criteria$ for$ PD$ (Gibb$ and$ Lees$ 1988),$ the$ Neurological$ Disorders$ and$ Stroke$
(NINDS)$Society$ for$PSP$ diagnostic$ criteria$ (Litvan,$ Agid$ et$ al.$ 1996)$ and$were$ recruited$
from$ the$ movement$ disorder$ clinics$ in$ the$ National$ Hospital$ for$ Neurology$ and$
Neurosurgery,$Queen$Square,$London,$United$Kingdom.$PD$patients$were$ included$if$they$
were$ taking$levodopa$ treatment$with$predictable$ motor$ﬂuctuations$ but$were$ excluded$if$
they$had$hand$dystonia$or$if$their$tremor$or$dyskinesia$were$severe$enough$to$interfere$with$
their$motor$performance$in$the$experiments.
Exclusion$ criteria$ included$ signiﬁcant$ medical$ coXmorbidity,$ cognitive$ impairment$ (Mini$
Mental $State$ Examination$ score$ <$ 28)$ (Folstein,$ Folstein$ et$ al.$ 1975),$ depression$ (Beck$
depression$score$ ≥$21)$ (Beck,$Ward$ et$ al.$ 1961)$ and$disabilities$ that$ might$ restrict$ﬁnger$




of$ antiXparkinsonian$ medications$ including$ levodopa,$ dopamine$ agonist,$ monoamine$
oxidase$ type$ B$ inhibitor,$ catecholXOXmethyl$ transferase$ inhibitor$ and$ amantadine$ was$
recorded.$ Total$ daily$ levodopa$ equivalent$ dose$ (LED)$ was$ calculated$ for$ each$ patient$
according$to$published$conversion$formulae$(Tomlinson,$Stowe$et$al.$2010).$The$study$was$
conducted$with$the$understanding$and$written$consent$of$all$participants$and$was$approved$
by$ the$ Camden$ and$ Islington$ Community$ Research$ Ethics$ Committee$ of$ the$ National$
Research$Ethics$Service.$
& 2.&Experimental&Method
Participants$were$ instructed$to$repeatedly$ tap$their$index$ﬁnger$and$thumb$as$ rapidly$and$
as$widely$as$possible$for$15$seconds.$The$participants$were$instructed$to$relax$the$3rd,$4th$and$
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5th$ digits$ in$ a$ semiXextended$position$ so$ that$the$ index$ ﬁngerXthumb$movements$ are$ not$
restricted.$ The$ beginning$ and$ the$ end$ of$ the$ 15Xsecond$ each$ ﬁnger$ tapping$ trial$ were$
signalled$by$a$buzzer.$InfraredXemitting$diodes$were$ﬁxed$to$8$designated$regions$on$digits$
and$the$back$of$the$hand,$and$motion$was$recorded$in$3D$(Coda$Cx1,$Charnwood$Dynamics,$
Rothley,$UK)$ [Figure$ 3.1].$Three$ 15Xsecond$ trials$ were$ performed$ consecutively$ by$ each$








was$ repeated$during$‘ON’$ by$ PD$patients.$The$participant$was$asked$to$copy$three$times$ a$
standardised$ print$ of$ an$ elevenXword$ sentence$ in$ Times$ New$ Roman,$ 34$ font$ size,$ on$
unlined$paper.$No$instructions$were$provided$to$the$participants$regarding$the$required$size$




were$plotted$separately$ against$successive$ sentence$ trials$(1$to$3).$Progressive$reduction$in$
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3.2].$Mean$speed,$designed$to$be$ sensitive$ to$both$amplitude$ and$cycle$ duration,$was$ the$
mean$rate$of$change$ in$aperture$regardless$of$whether$the$aperture$was$opening$or$closing.$
Thus,$ mean$ speed$ decreased$ when$ the$ cycle$ duration$ increased$ independently$ of$
amplitude,$when$amplitude$decreased$independently$of$duration,$and$when$both$occurred$
simultaneously.$ If$amplitude$ increased$at$the$ expense$ of$cycle$ duration,$ or$vice$ versa,$the$
mean$ speed$ tended$ to$ stay$ constant.$Close$ and$ open$ velocities$ (mm/s)$ were$ the$ peak$
velocities$ of$ aperture$ closure$ and$ opening$ within$ a$ cycle.$ To$ eliminate$ potential$
confounding$factors$ of$diﬀerent$hand$ size$ and$ﬁnger$length$ across$ participants,$ distance$
(mm)$ measured$was$ converted$ into$ the$ degree$ (deg)$ of$ angle$ separation$ between$ index$
ﬁnger$ and$ thumb.$The$ conversion$was$ obtained$by$ the$ product$ of$distance$ (mm)$ and$kX
value$ (deg/mm),$ calculated$ by$ the$ linear$ regression$ slope$ of$ maximum$ ﬁngerXthumb$




Progressive$ changes$ in$ amplitude,$ duration$and$ speed$ across$ a$ 15Xsecond$ ﬁnger$tap$ trial$
were$ represented$by$the$slope$of$the$ ﬁtted$linear$regression$line$across$ the$ scatterXplot$of$
the$kinematic$parameter$against$the$ tap$cycle.$The$slope$of$change$ in$amplitude$was$used$
to$ assess$ progressive$ hypokinesia$ or$ ‘decrement’.$ The$ slope$ of$ change$ in$ speed$ which$
encompassed$ both$ amplitude$ and$ duration$ was$ used$ to$ assess$ progressive$ slowing$ of$
movement$ or$ ‘fatigue’$ [Figure$ 3.3].$ Measurement$ of$ regularity$ of$ amplitude$ and$ speed$
across$a$ tap$trial$was$ represented$by$the$coeﬃcient$of$variation$(CV),$which$was$ computed$
by$ the$ residual$ standard$ deviation$ about$ the$ linear$ regression$ line$ divided$by$ the$ mean$
value.$ High$ amplitude$ or$ speed$ CV$ values$ represent$ irregularities$ of$ these$ kinematic$
parameters.
Figure&3.3:&Kinematic$parameters$ during$ the$ ﬁrst$15s$ right$ﬁnger$tap$trial$ in$a$Parkinson’s$
disease$patient$when$OFF$(left)$and$PSP$patient$(right).$Slopes$for$amplitude,$duration$and$
speed,$and$ coeﬃcient$of$variation$ for$speed$are$ shown.$Lack$of$decrement$and$fatigue$ in$




open$ velocity,$ mean$ speed,$ slopes$ and$ CVs$ were$ summarized$ by$ computing$ the$ mean$
parameter$value$for$all$tap$cycles$across$three$ﬁnger$tap$trials$of$both$hands$for$all$subjects.$
& 4.&Statistical&analysis
Comparisons$ of$ continuous$ variables$ were$ carried$ out$ by$ univariate$ Analysis$ of$Variance$
(ANOVA)$with$gender,$age$and$disease$ duration$as$covariates$ to$ensure$ comparisons$were$
adjusted$for$any$gender,$age$and$disease$ duration$diﬀerences$across$ subjects.$Student’s$ tX
test$ was$ used$ to$ compare$ disease$ duration$ and$ total$ daily$ levodopa$ equivalent$ dose$
between$ two$ patient$ groups.$ Tukey$ HSD$ postXhoc$ analysis$ was$ used$ to$ determine$
diﬀerences$ between$ groups$ (controls,$ PDXOFF$ and$ PSP).$ Paired$ tXtests$ were$ used$ to$














Age)(years) 68.9$±$4.5 70.9$±$8.3 65.0$±$9.2 0.14**
Gender) 9M$:$7F 5M$:$4F 9M$:$6F 0.97#















NA 255.6$±$194.4 874.8$±$323.9 <0.001*
UPDRS
I NA NA 3.1$±$2.5
IIPON NA NA 7.7$±$3.9
IIPOFF NA NA 17.2$±$8.7
IIIPON NA NA 24.4$±$9.3
IIIPOFF NA 41.6$±$14.1$ 36.3$±$9.7
IV NA NA 6.7$±$4.3
H&Y
ON NA NA 2.1$±$0.4
OFF NA NA 2.8$±$0.6
PSP)Rating)Scale NA 39.4$±$2.4$ NA
FAB) NA 14.4$±$2.4$ NA
Table& 3.1:$ Demographic$ and$ Clinical$ data.$ Mean$ ±SD.$ *$ Student’s$ tXtest.$ **$ ANOVA.$#$
Pearson$Chi$square$test.$NA$not$applicable.
The$ demographic$ features$ and$ clinimetric$ scores$ are$ listed$ in$ table$ 3.1.$ Age$ was$ closely$






The$mean$total$daily$ levodopa$equivalent$dose$ in$PD$was$ greater$than$that$of$PSP$(tXtest,$
p<0.001).$Eight$PSP$patients$were$taking$amantadine$but$only$two$were$receiving$levodopa$
therapy.$ The$ PSP$ patients$ who$ were$ not$ receiving$ levodopa$ had$ failed$ to$ respond$ to$
levodopa$and$had$a$negative$ therapeutic$response$ to$an$acute$levodopa$challenge$(Steiger$
and$ Quinn$ 1992).$ The$ mean$ bradykinesia$ subscore,$ which$ included$ the$ sum$ of$UPDRS$







Amplitude,$duration,$ peak$ velocities,$ and$mean$speed$ were$ measured$for$each$tap$ cycle$
and$ used$ to$ calculate$ mean$ performance,$ progressive$ changes$ in$ performance$ (slope$ of$
linear$ regression$ line$ of $ variable$ against$ cycle$ number),$ and$ regularity$ of$ performance$
(coeﬃcient$of$variation;$CV)$achieved$over$a$15Xs$trial.$OneXway$ANOVA$revealed$signiﬁcant$

















45.91$(8.7) 18.65$(6.3) 37.82$(16.0) 18.53$ <0.001*
Duration)
(ms)












788.91$(167.9) 327.72$(106.1) 584.40$(297.0) 10.34 0.005*
Speed))))))
(deg/s)





0.09$(0.03) 0.27$(0.13) 0.14$(0.08) 9.69 0.006*
Duration)CV) 0.09$(0.03) 0.28$(0.18) 0.17$(0.10) 4.26 <0.001*











0.77$(0.75) 1.86$(2.58) 1.49$(2.39) 0.16$ 0.70
Speed)slope)
(deg/s/cycle)





gender.$ Mean$ cycle$ duration$ was$ longer$ for$ the$ nonXdominant$ hand$ (dominant$ hand:$
289.38±64.6ms;$ nonXdominant$ hand:$ 302.23±67.5ms;$p=0.003)$ but$ no$ other$performance$
parameters$diﬀered$between$the$two$hands.$
The$slope$of$the$ dominant$hand’s$mean$speed$was$ signiﬁcantly$more$negative$ in$the$third$







The$ small $mean$ amplitude$ in$ PSP$ (mean=18.65deg)$ was$ less$ than$ half$ that$ of$ healthy$
subjects$(mean=45.91deg)$and$PDXOFF$(mean=37.82deg)$(p<0.001$in$both$cases)$[Table$ 3.2$
&$Figure$ 3.4a].$The$amplitude$ slope$ in$PSP$had$a$positive$ value$ of $0.01,$indicating$a$lack$ of$
amplitude$ decrement.$This$ value$ diﬀered$signiﬁcantly$ from$ the$ negative$ slope$ in$PDXOFF$
(p=0.002)$[table$3.2$&$ﬁgure$3.4b].$After$adjusting$for$the$ low$mean$amplitude$in$PSP,$there$
was$ no$ diﬀerence$ in$ mean$ amplitude$ slope$ between$ PSP$ and$ controls,$ indicating$ an$
absence$of$decrement$in$PSP$[p=0.36,$table$3.3].$
A$ greater$ number$of$ tap$ cycles$ were$ achieved$ by$ PSP$ patients$ (mean=52.22$ cycles/15s)$
when$ compared$ to$ PDXOFF$ (mean=41.54$ cycles/15s;$ p=0.046),$ but$ not$ controls$ (50.03$
cycles/15s)$[table$3.2].
Although$the$ cycle$duration$was$ normal$in$PSP,$the$markedly$reduced$amplitude$ led$to$an$
overall$reduction$ in$close$ and$open$ velocities$ and$mean$ speed$ in$PSP$when$ compared$to$














0.47 0.501 3.75 0.067# 3.20 0.09#
Speed)slope)(adjusted)
for)mean)speed)
2.89 0.070# 1.70 0.208 3.33 0.085#
Table&3.3:& p$ values$for$ the$comparisons$ of$ slope$ values$between$PDXOFF,$PSP$and$ controls$after$
adjusting$ for$ mean$ amplitude,$ duration$ and$ speed$ respectively. $General$ linear$ model$ univariate$
analysis$ (*signiﬁcant,$ p<0.05,$ #$ borderline$ signiﬁcant,$ p=0.05X0.10).$ Covariates$ appearing$ in$ the$
model$PDXOFF$vs.$controls$are$evaluated$at$ the$following$values:$gender$=$0.58,$age$=$66.99,$mean$
amplitude$ for$ amplitude$ slope$ model$ =$ 42.34,$ mean$ duration$ for$ duration$ slope$ model$ =$ 325.18,$
mean$speed$ for$speed$ slope$model$=$278.81.$Covariates$appearing$ in$ the$model$PSP$vs$controls$are$
evaluated$ at$ the$ following$ values:$gender$=$ 0.56,$age$ =$ 69.6,$mean$ amplitude$for$ amplitude$slope$
model$=$36.09,$mean$duration$for$duration$slope$model$=$293.12,$mean$speed$for$speed$slope$model$
=$262.73.$Covariates$appearing$ in$ the$model$ PSP$vs.$PDXOFF$ are$evaluated$at$ the$following$ values:$
gender$ =$ 0.58,$age$=$67.19,$disease$ duration$ =$ 8.43,$mean$ amplitude$ for$ amplitude$ slope$model$ =$
31.08,$mean$duration$for$duration$slope$model$=$330.95,$mean$speed$for$speed$slope$model$=$193.64;$
F(degrees$of$freedom)$=$f$value$from$univariate$analysis$of$variance




Among$ the$ PSP$ group,$ there$ was$ no$ correlation$ between$mean$ amplitude$ and$ clinical$
markers$of$disease$severity$including$disease$duration,$total $daily$levodopa$equivalent$dose,$
















greater$ variability$ of$ speed$ between$ tap$ cycles.$ When$ compared$ with$ PSP,$ PDXOFF$
exhibited$ larger$ amplitude$ movements,$ a$ smaller$ number$ of$ tap$ cycles,$ and$ greater$
decrement$of$performance$during$a$trial.
PDXOFF$amplitude$ tended$to$be$smaller$than$that$in$healthy$ subjects$(p=0.10)$while$ cycle$
duration$ tended$ to$ be$ more$ prolonged$ (p=0.06),$ but$ only$ with$ borderline$ signiﬁcance.$
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However,$the$combination$of$both$these$trends$led$to$a$highly$signiﬁcant$lower$mean$speed$
of$PDXOFF$compared$with$ controls$ (p=0.001)$ [ﬁgure$ 3.4].$Similarly,$ peak$ open$ velocity$ of$
PDXOFF$was$ less$ than$controls$ (p=0.033),$ although$there$ was$ no$ diﬀerence$ in$peak$ close$
velocity$between$the$two$groups.$In$addition,$CV$of$mean$speed$in$PDXOFF$was$signiﬁcantly$
greater$ than$ that$ of$ controls$ (p=0.004),$ suggesting$ proportionally$ greater$ irregularities$
between$cycles.$
Both$ amplitude$ and$ speed$ slopes$ in$ PDXOFF,$ reﬂecting$ the$ progressive$ decrement$ in$
performance,$were$ more$ strongly$ negative$ when$ compared$ to$ those$ of$ PSP$ (amplitude:$
p=0.002;$mean$speed:$p=0.028).$However,$the$negative$amplitude$and$speed$slopes$of$PDX
OFF,$were$numerically,$but$not$signiﬁcantly,$greater$than$in$healthy$subjects.$In$PD$patients$
with$ severe$ parkinsonism,$ slope$ measurements$ may$ be$ underestimated$ due$ to$ poor$
performance$during$the$tap$trial,$which$would$render$their$slope$values$ lower$than$patients$
with$ milder$ disease$ severity$ who$ do$ not$ exhibit$ a$ ‘ﬂoor’$ eﬀect.$ After$ adjusting$ for$
diﬀerences$ in$mean$amplitude,$the$ amplitude$ slope$ in$PDXOFF$became$ signiﬁcantly$more$
strongly$ negative$ than$PSP$ and$ healthy$ controls$ (PDXOFF$ vs$ PSP,$ p$ =$ 0.048;$ PDXOFF$vs$
controls,$p=0.046)$[table$3.3].$There$was$a$ trend$for$a$more$negative$ speed$slope$in$PDXOFF$
when$ compared$ to$ controls$ after$ adjusting$ for$ mean$ speed$ (p=0.07)$ [table$ 3.3].$ These$
ﬁndings$ demonstrate$ progressive$ decrement$ in$ performance$ in$ PDXOFF$ and$ represents$
sequence$eﬀect$in$PD.
The$ UPDRSIIIXOFF$ score$ was$ correlated$ with$ small$ amplitude$ (Spearman’s$ coeﬃcient:$
X0.79,$ p<0.001),$ slow$ mean$ speed$ (Spearman’s$ coeﬃcient:$ X0.68,$ p=0.005)$ and$ high$
irregularities$ in$ speed$ (Spearman’s$ coeﬃcient:$ 0.75,$ p=0.001).$There$ was$ no$ correlation$
between$ performance$ decrement,$ i.e.$ slopes$ for$ amplitude$ and$ speed,$ and$ disease$
duration,$total$daily$ levodopa$equivalent$dose,$UPDRS$motor$scores$or$H&Y$(p>0.05$ in$ all$
cases).
Levodopa$ therapy$ improved$the$ total$number$of$tap$cycles$ (OFF:$41.5±9.7;$ON:$45.9±9.5,$
p=0.04),$ peak$ open$ velocity$ (OFF:$ 584.4±297.0;$ ON:$ 639.9±269.0;$ p=0.04),$ mean$ speed$
(OFF:$ 224.1±93.1;$ ON:$ 255.6±86.4;$ p=0.006)$ and$ speed$ CV$ (OFF:$ 0.167±0.07;$ ON:$
0.150±0.08;$ p=0.014).$ However,$ levodopa$ therapy$ did$ not$ signiﬁcantly$ improve$
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performance$ decrement$ (amplitude$ slope:$ OFF=X0.20±2.1;$ ON=X0.17±2.1;$ speed$ slope:$
OFF=X1.71±1.6;$ON=X1.78±1.4).$
When$analysis$of$the$eﬀect$of$levodopa$was$limited$to$the$PD$patients’$more$aﬀected$hand,$
more$ robust$ ON$ vs$ OFF$ diﬀerences$ were$ observed.$ In$ addition$ to$ the$ improvements$
described$ above,$ improvement$ was$ also$ observed$ in$ mean$ cycle$ duration$ (OFF:$
370.8±103.6;$ ON:$ 321.1±93.2;$ p=0.005)$ and$ there$ was$ a$ trend$ towards$ improvement$ in$
performance$decrement$(amplitude$slope:$OFF:$X0.20;$ON:$X0.15;$p=0.07).$
& 5.&Hypokinesia&without&decrement
Hypokinesia$ was$ deﬁned$ as$ a$ mean$amplitude$ of$ less$ than$23deg,$ i.e.$ 50%$ of$the$ mean$
amplitude$in$the$control$group.$$Hypokinesia$was$observed$in$70%$of$the$ﬁnger$tap$trials$in$
the$PSP$group,$24%$of$the$PDXOFF$group$and$2%$of$the$control$group.$The$ remaining$30%$
of$ $ ﬁnger$tap$ trials$ in$the$ PSP$ group$had$a$ small$mean$ amplitude$of$27.8$ ±3.7$deg$and$ a$
positive$ mean$ amplitude$ slope$ of$ 0.05deg/cycle.$ The$ 24%$ of$ the$ PDXOFF$ group$ with$
hypokinesia$ were$ performed$ by$ 4$ patients$ who$ had$ severe$ parkinsonism$ with$ a$ mean$
UPDRSIIIXOFF$score$ of$46.4$and$a$ long$mean$disease$ duration$of$17.5$ years.$All$4$patients$
had$good$levodopa$response$and$an$average$improvement$in$UPDRS$motors$ score$by$ 14.3$
one$ hour$ after$ intake$ of$ levodopa$ therapy.$ Despite$ severe$ hypokinesia$ with$ a$ mean$
amplitude$ of$11.4$±5.6$deg,$ decrement$was$ still$evident$with$a$ negative$ mean$ amplitude$








The$ scripts$ by$ 1$ PSP$ and$ 2$ PD$ patients$ were$ discarded$ from$ the$ analysis$ as$ they$ were$
written$in$capital$ letters.$The$mean$script$ size$ of$PSP$(0.50cm2±0.42)$was$ numerically,$but$
not$statistically,$ smaller$ than$PDXOFF$(0.76cm2±0.37)$ and$ controls$ (0.75cm2±0.19)(p=0.25)$
[Figure$3.5].$ In$all $groups,$there$was$ less$ progressive$ reduction$ in$the$ letter$ ‘a’$of$the$third$
word$(script$slope$1)$than$the$tenth$word$(script$slope$2)$ in$successive$sentences.$The$mean$
script$slope$2$was$signiﬁcantly$diﬀerent$between$PSP$(2.33±3.22)$and$PDXOFF$(X3.24±11.15)$




was$ represented$by$ a$ positive$mean$script$slope.$Micrographia$was$more$ frequent$in$PSP$
(N=6,$ 75%)$ than$in$PDXOFF$(N=2,$15.4%)$and$control$(N=1,$6.3%)$ (p=0.003).$Micrographia$
persisted$ in$ the$ same$ PD$ patients$ after$ levodopa$ therapy;$ their$mean$ script$ size$ slightly$
improved$but$did$not$make$the$cutXoﬀ$of$0.40cm2.$Positive$script$slope$2$was$more$frequent$
in$PSP$ (N=5,$ 62.5%)$ than$ in$control$(N=1,$6.3%)$and$PDXOFF$(N=2,$15.4%)(χ2,$p=0.005).$A$
similar$trend$was$noted$in$script$slope$1$(PSP:$N=6,$75%,$PDXOFF:$N=3,$23.1%,$Control:$N=8,$
50%;$χ2,$p=0.06).$The$ smallest$script$ size$ (mean=0.14cm2)$was$ observed$in$a$ patient$with$
advanced$PSP.$
A$positive$script$slope$1$was$more$frequent$in$PSP$(n$=$6,$75%)$than$in$PDXOFF$patients$(n$=$
3,$ 23.1%;$P$ =$0.03),$but$ it$did$not$diﬀer$ from$ control$subjects$ (n$ =$8,$50%;$P$ =$ 0.23).$The$
patients$with$the$smallest$script$size$in$the$PSP$and$PDXOFF$groups$were$also$noted$to$have$
the$ most$ severe$UPDRSIII$ score$ in$ their$ group$ (minimum$ script$ size$ in$ PSP$ =$0.14$ cm2,$
UPDRSIII$=$69;$minimum$script$size$in$PDXOFF$=$0.11$cm2,$UPDRSII$I$=$50).
There$were$more$ patients$with$PSP$(n$=$5,$62.5%)$who$had$both$hypokinesia$ (<23deg)$and$
micrographia$ (50.40cm2)$ than$the$control$ (0;$P$ =$0.001)$ and$the$ PDXOFF$(n$=$1,$7.7%;$ P$=$









ﬁnger$ tap$ pattern$ in$ PD$ consists$ of$ slowness$ with$ variability$ in$ speed$ and$ progressive$
decrement$ in$ performance,$ as$ demonstrated$ here$ and$ in$ previous$ studies$ (Agostino,$
Berardelli$et$al.$1994;$Agostino,$Berardelli$et$al.$1998).$Although$levodopa$ improved$most$
tapping$ parameters$ in$ PD,$ it$ did$ not$ improve$ the$ sequence$ eﬀect$ of$ progressive$
deterioration$in$cycle$ duration$and$speed.$$ $However,$there$was$a$borderline$ improvement$





sequence$ eﬀect,$and$ in$another$study,$ reduced$ stride$ length$ (hypokinesia)$ improved$with$
either$levodopa$or$visual$cues,$but$the$progressive$reduction$of$stride$length$(the$sequence$






markedly$ reduced.$The$ average$ amplitude$of$ﬁnger$separation$in$PSP$was$less$ than$half$of$
that$ in$ controls$ and$ PDXOFF.$ PSP$ patients$ also$ had$ a$ greater$number$ of$ tap$cycles$ and$
higher$variability$ in$amplitude$ and$speed$when$compared$to$PDXOFF.$The$ greater$number$




score,$there$was$no$correlation$between$the$amplitude$and$markers$ for$disease$ severity$ in$
the$PSP$group.$Hence,$the$diﬀerences$ in$disease$ duration$between$PD$and$PSP$ could$not$
account$for$the$ reduced$mean$amplitude$ in$PSP.$Also,$ the$ﬁnding$of$severe$hypokinesia$ in$
PSP$ in$relation$to$PDXOFF$was$not$dependent$on$medication$state$because$all$PD$and$PSP$
patients$were$tested$after$12$hourXwithdrawal$of$antiXparkinsonian$medication.




in$PDXOFF.$The$ possibility$ that$ lack$ of$ decrement$ in$ PSP$ might$ be$ due$ to$ a$ ﬂoor$ eﬀect$
caused$ by$ severe$ hypokinesia$ would$ seem$ unlikely,$ as$ even$ among$ the$ subgroup$ of$PD$
patients$with$severe$ hypokinesia$ (amplitude<23deg),$we$ noted$a$mean$amplitude$slope$of$
X0.037deg/cycle$ (vs$ controls,$ p=0.051),$ and$ furthermore$ when$ comparisons$ between$
amplitude$ slopes$of$the$ patient$groups$and$ controls$were$performed$after$adjustment$for$
any$ diﬀerences$ in$mean$amplitudes$ between$groups$ $ the$ amplitude$slope$ in$PDXOFF$was$
more$negative$than$in$PSP$and$controls$[Table$ 3.3],$while$ there$was$no$diﬀerence$between$
PSP$ and$ controls.$These$ ﬁndings$ support$ the$ notion$ of$minimal$ or$ lack$ of$performance$





PSPXParkinsonism$ (PSPXP),$of$which$ the$ clinical$ symptoms$ can$mimic$PD.$The$ remaining$
PSP$ﬁnger$tap$trials$also$had$a$small$mean$amplitude$of$27.8deg,$but$not$quite$making$the$
cutXoﬀ$value$of$23deg$for$hypokinesia.$Small$ﬁnger$tap$amplitudes$can$be$easily$recognized$
by$ careful$bedside$ examination.$Small $degrees$ of$decrement$may$ however$be$ diﬃcult$ to$
detect$ in$patients$with$Parkinson’s$disease$with$ severe$motor$impairment$who$have$ small$
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amplitude$ﬁnger$movements$on$initiation$of $ﬁnger$movements.$These$patients$ are$readily$




(Williams,$ de$ Silva$ et$ al.$ 2005).$ In$addition$ to$decrement,$ delayed$ initiation$of$ voluntary$
movements$ and$motor$ arrests$ during$ repetitive$ ﬁnger$tapping$were$ other$ﬁndings$ in$PD$
which$may$also$have$clinical$usefulness$(Fahn,$Elton$et$al.$1987;$Marsden$1989).$$
The$average$number$of$tap$cycles$performed$in$15$seconds$was$50$in$controls,$52$in$PSP,$42$
in$PDXOFF$and$46$ in$ PDXON.$Therefore,$ to$ detect$ the$ diﬀerences$ reported$ above$ would$
require$a$ tap$trial$of $approximately$50$ﬁngerXthumb$tap$cycles.$The$modiﬁed$MDSXUPDRS$
(Goetz,$ Tilley$ et$ al.$ 2008)$ proposed$ a$ 10Xtap$ trial,$ which$ would$ take$ an$ average$ of$ 3.8$
seconds$ (15s/42taps$x$10taps)$ for$PDXOFF$subjects$to$perform,$as$estimated$by$data$ in$the$
present$study.$We$postulated$that$a$tap$trial$consisting$of$only$10$taps$would$be$too$brief$for$





amplitudes$ of$ less$ than$ half$ the$ expected$ size.$Mean$ speed$ in$ PDXOFF$was$ slower$ than$
controls$ (p=0.007).$ However,$ after$20$taps,$ the$ amplitude$ slope$ (mean=+0.04)$ and$ speed$
slope$(mean=+0.21)$in$PDXOFF$group$were$both$positive,$indicating$the$ lack$of$decrement$
and$fatigue$at$that$time$point$and$the$slope$values$did$not$diﬀer$between$PDXOFF,$PSP$and$
control$groups.$This$ analysis$ indicated$ that$ 20Xtap$ trials$ were$ not$ adequate$ in$detecting$
decrement$or$fatigue$in$PD.$We$propose$ that$repetitive$ ﬁnger$tapping$with$50$tap$cycles$is$
required$ to$ detect$ criteriaXdeﬁned$ bradykinesia$ in$ treated$ and$ untreated$ PD$ patients.$
























Duration)(ms) 279.80$(65.7) 342.13$(82.1) 285.18$(58.2) 4.40 0.05 NA










X0.08$(6.4) 0.04$(0.3) 0.13$(0.3) 0.80 0.38 NA
Duration)
slope)(s/cycle)
X0.37$(1.7) 1.27$(3.8) 1.80$(6.9) 0.54 0.47 NA
Speed)slope)
(deg/s/cycle)
X0.10$(2.1) 0.21$(1.2) 0.45$(2.8) 1.19 0.29 NA
Table&3.6:&Parameter$measurements$ of$the$ initial$20$ taps$ of$ the$ ﬁrst$ trials$ performed$ by$
both$ hands.$ Mean$ (Standard$ Deviation);$ Covariates$ appearing$ in$ the$ model$ above$ are$




Micrographia$ was$ more$ common$ in$ PSP$ (75%)$ than$ in$ PD$ (15%).$ $ There$ was$ also$ less$
progressive$ reduction$ in$script$size$ in$PSP$ than$ in$ PDXOFF.$These$ ﬁndings$ in$handwriting$
were$ equivalent$to$ hypokinesia$with$lack$ of$decrement$in$ repetitive$ﬁnger$ tapping$in$PSP$
and$might$share$common$underlying$mechanisms.$Five$of$the$6$patients$with$PSP$who$had$
micrographia$also$manifested$hypokinesia$on$repetitive$ﬁnger$tapping.$‘Fast$micrographia’$
characterised$ by$ small$ size$ handwriting$ performed$ at$ a$ normal$ or$ slightly$ faster$ than$






Our$ﬁnding$ of$a$ small$ number$of$ PD$ patients$ with$micrographia$ is$ similar$ to$ a$ previous$
study$ (McLennan,$Nakano$et$al.$1972).$A$copying$task,$as$ in$the$ present$study,$writing$on$
parallel$lines$and$with$a$verbal$reminder$to$write$‘big’$can$serve$as$external$clues$to$prevent$
reduction$in$script$size$(Oliveira,$Gurd$et$al.$1997;$Kim,$Lee$et$al.$2005;$Bryant,$Rintala$et$al.$
2010).$Abnormally$ increased$ dependence$ on$ external$ visual$ feedback$ has$ been$ noted$ in$
patients$ with$ PD$ (Demirci,$ Grill$ et$ al.$ 1997).$The$ mechanism$ of$micrographia$ is$ poorly$
understood$but$the$hypothesis$of$a$‘tunedXdown’$sensorimotor$apparatus$might$explain$the$
reduction$ in$ motor$ scaling$ during$ sequential$ motor$ tasks$ such$ as$ ﬁnger$ tapping$ and$
handwriting$(Demirci,$Grill$et$al.$1997).$Levodopa$therapy$does$not$improve$script$size$in$PD$
except$in$a$ small$group$of$patients$(McLennan,$Nakano$et$al.$1972).$In$4$of$our$PD$patients$
script$ size$ was$ numerically$ improved$ but$ such$ improvement$ did$ not$ achieve$ statistical$




The$3Xdimensional$motion$assessment$used$ in$this$ study$ to$objectively$measure$repetitive$
ﬁnger$ tapping$ proved$ particularly$ useful$ in$ tremulous$ patients$ who$ would$ have$ had$
diﬃculties$maintaining$their$ﬁnger$separation$in$a$ 2Xdimensional$plane.$Pilot$studies$were$
conducted$ on$healthy$ volunteers$ and$ it$was$ determined$ that$healthy$ elderly$ participants$
become$ tired$ after$ prolonged$ tap$ sequences$ of$ more$ than$ 15X20$ seconds.$ In$ order$ to$
minimise$ the$ confounding$factor$of$physiological$fatigue,$the$ trial$duration$was,$ therefore,$
limited$ to$ 15$ seconds.$ Not$ all$ of$ these$ measurements$ are$ practical$ at$ the$ bedside$ and$
further$studies$ are$warranted$to$apply$our$ﬁndings$ in$ such$ a$ setting.$However,$very$ small$
ﬁnger$tapping$amplitudes$ should$be$easily$identiﬁed$during$neurological$examination.$The$
relative$ persistence$ of$ the$ sequence$ eﬀect$ despite$ levodopa$ therapy$ in$ PD$ makes$ it$ an$
especially$useful$physical$sign$to$help$distinguish$PD$and$PSP.$Future$prospective$studies$on$





are$ found$ at$ postXmortem$ to$ have$ a$ diﬀerent$ pathology$ (Ling,$O'Sullivan$ et$ al.$ 2010).$




Patients$ with$PSP$have$ small$ﬁnger$separation$amplitude$without$ progressive$decrement$
on$repetitive$ﬁnger$tapping$and$do$not$have$ “true”$ bradykinesia.$The$ severe$hypokinesia$














•PSP$ aﬀects$ the$ midbrain,$ subthalamic$ nucleus,$ globus$ pallidus,$ dentate$ nucleus$ and$
frontal$lobes$(Williams,$Holton$et$al.$2007).
•MSA$aﬀects$ the$ corpus$striatum,$globus$ pallidus,$the$olivopontocerebellar$structures,$the$
intermediolateral $column$of $the$ spinal$cord$and$Onuf’s$ nucleus$ (Wenning,$Colosimo$et$al.$
2004).$
•PD$ aﬀects$ the$ locus$ coeruleus,$dorsal$motor$nucleus$of$the$vagus,$the$pedunculopontine$
nucleus$and$nucleus$basalis$of$Meynert$(Braak,$Del$Tredici$et$al.$2003).
•CBD$ aﬀects$ perirolandic$ cortical$ areas$ which$may$ be$ asymmetric$ and$ some$ subcortical$
regions$(Mahapatra,$Edwards$et$al.$2004).
These$ topographical$ diﬀerences$ should$ be$ amenable$ to$ assessment$ during$ life$ with$
conventional$MRI$(cMRI).






1997;$ Schrag,$ Good$ et$ al.$ 2000;$ Savoiardo$ 2003;$ Paviour,$ Price$ et$ al.$ 2005;$ Slowinski,$
Imamura$ et$al.$ 2008),$midbrain$ signal$ hyperintensity$ on$T2$ (Drayer,$Olanow$ et$ al.$ 1986;$
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Savoiardo,$Strada$ et$ al.$ 1989;$ Savoiardo,$Girotti$ et$ al.$ 1994;$Yagishita$ and$Oda$ 1996)$ or$
proton$density$weighted$images$(Oka,$Katayama$et$al.$2001)$and$ﬂuid$attenuated$inversion$
recovery$ (FLAIR)$ images$ (Kataoka,$ Tonomura$ et$ al.$ 2008).$ A$ concave$ appearance$ of$ the$
superior$ proﬁle$ of$ the$ midbrain$ (Righini,$ Antonini$ et$ al.$ 2004),$ a$ characteristic$
‘hummingbird’$ (the$HB$sign)$ (Kato,$Arai$et$al.$2003)$or$‘giant$penguin’$(Oba,$Yagishita$et$al.$
2005)$ appearance,$or$in$ the$ axial$images$ a$ ‘morning$glory$ ﬂower’$ (the$MGF$sign)$ (Adachi,$
Kawanami$et$ al.$ 2004;$ Mori,$Aoki$ et$ al.$ 2004)$ are$ highly$ suggestive$ in$ the$ context$ of$ a$
Parkinsonian$ syndrome.$An$ ‘eye$ of$the$ tiger$ sign’$ has$ also$ been$ reported$ in$PSP$ (Davie,$
Barker$et$al.$1997).$[Table$4.1;$Figure$4.1]
Figure)4.1:$Hummingbird$ (HB)$and$morning$glory$ﬂower$(MGF)$signs$ in$PSP.$Sagittal$T1$ [AXC]$sand$
axial$T2$[DXF]$ images$ in$ pathologically$conﬁrmed$disease.$[A]$HB$(arrow)$&$ [D]$MGF$in$PSP$1.5$yrs$
after$onset;$[B]$HB$(arrow)$&$[D]$MGF$ in$ PSP$4$yrs$after$ onset;$[C]$&$[F]$normal$appearances$of$ the$
midbrain$ in$ PD.$Axial$ images$ were$ screened$ for$ the$ presence$ of$ the$MGF$ sign$ by$ the$ published$
method$which$detects$a$ concave$proﬁle$ of$the$midbrain$ tegmentum$ in$PSP$(arrow$heads)$(Adachi,$
Kawanami$et$al.$2004).
Putaminal$atrophy$ and$signal$abnormalities$ are$ seen$in$MSA$ (Drayer,$Olanow$et$al.$1986;$
Pastakia,$Polinsky$et$al.$1986;$Drayer$1988;$Savoiardo,$Strada$et$al.$1989;$Stern,$Braﬀman$et$
al.$ 1989;$Savoiardo,$Girotti$et$ al.$ 1994;$Schrag,$Kingsley$ et$al.$ 1998;$ Schrag,$Good$ et$ al.$
2000;$ Bhattacharya,$ Saadia$ et$ al.$ 2002;$Yekhlef,$ Ballan$et$ al.$ 2003;$Seppi,$ Schocke$ et$ al.$
2006),$ and$ a$ hyperintense$ putaminal$ rim$ is$ characteristic$ (Savoiardo,$ Strada$ et$ al.$ 1989;$
Savoiardo,$Strada$ et$al.$ 1990;$Yagishita$ and$Oda$ 1996;$ Bhattacharya,$ Saadia$ et$al.$ 2002;$






1996;$ Schrag,$ Kingsley$ et$ al.$ 1998;$Schrag,$Good$et$ al.$ 2000;$Savoiardo$ 2003;$Seppi$ and$
















































































































































































































































































































































































































patients$ frontal$and$parietal$ atrophy$ were$ the$ most$ common$abnormalities,$ followed$ by$
dilatation$ of$ the$ lateral$ and$ third$ ventricles;$ asymmetric$ frontoparietal$ atrophy$
accompanied$by$ lateral$ventricular$dilatation$was$ the$most$ reliable$ predictor$ of$a$ clinical$
diagnosis$of$CBS$when$compared$to$PD,$PSP$and$MSA$(Yekhlef,$Ballan$et$al.$2003).$In$CBD,$
cortical$ atrophy$ of$ the$ frontal$ and$ parietal$ regions$ on$ the$ side$ contralateral$ to$ the$
symptoms$ has$ been$ reported$ with$ associated$ enlargement$ of$ the$ lateral $ ventricle;$ no$
deﬁnite$ subcortical$abnormalities$are$ seen$despite$ the$ presence$ of$pathology$within$these$
structures$ (Soliveri,$Monza$et$al.$1999;$Savoiardo$2003).$A$more$ recent$study$ reported$that$
all$CBS$ patients$have$ cerebral$atrophy,$ 81%$asymmetry$with$the$side$ contralateral$to$the$
aﬀected$limb$most$aﬀected$and$atrophy$was$most$severe$in$the$anterior$frontal$and$parietal$
lobes;$ 94%$had$corpus$ callosal$atrophy$ (Koyama,$Yagishita$ et$ al.$2007).$Atrophy$was$ also$
seen$ less$ frequently$ in$ the$ cerebral$peduncles,$ pyramids$ and$midbrain$ tegmentum.$ 88%$




with$ parietal$ signs$ (Koyama,$ Yagishita$ et$ al.$ 2007).$ Furthermore,$ cMRI$ may$ show$ no$
signiﬁcant$patterns$of$regional$atrophy$or$signal$change$enabling$accurate$ identiﬁcation$of$
CBD$(Schrag,$Good$et$al.$2000;$Josephs,$TangXWai$et$al.$2004)$[Table$4.1].
Although$ the$ speciﬁcity$ of$ some$ of$ these$ radiological$ signs$ is$ reported$ to$ be$ as$ high$ as$
100%$(Schrag,$Kingsley$et$al.$1998;$Schrag,$Good$et$al.$2000;$Kato,$Arai$et$al.$2003;$Yekhlef,$
Ballan$et$al.$2003;$Adachi,$Kawanami$et$al.$2004;$Mori,$Aoki$et$al.$2004;$Oba,$Yagishita$et$al.$
2005),$ they$ are$ found$ in$only$ a$ proportion$ of$cases$ and$ are$ often$absent$ in$early$ disease$
when$accurate$clinical$diagnosis$is$most$diﬃcult$[Table$4.2].$
An$ important$ weakness$ of$ published$ cMRI$ studies$ is$ that$ they$ use$ operational$ research$
criteria$to$deﬁne$the$disease$under$study;$while$these$criteria$may$have$high$speciﬁcity$for$a$
pathological$diagnosis$ there$ are$ signiﬁcant$misdiagnoses$ (in$over$10%)$ (Hughes,$Daniel$et$
al.$2002)$and$cases$with$atypical$clinical$features$are$ excluded$by$deﬁnition.$ $Only$very$few$
studies$ have$ reported$MR$ﬁndings$ in$pathologically$ conﬁrmed$ cases$ (Yagishita$ and$Oda$
1996;$ Aiba,$ Hashizume$ et$ al.$ 1997;$ Slowinski,$ Imamura$ et$ al.$ 2008).$ This$ is$ particularly$
important$ in$ CBD$ where$ most$ cases$ presenting$ with$ CBS$ turn$ out$ to$ have$ alternative$
pathological$diagnoses$(Ling,$O'Sullivan$et$al.$2010).
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100% 100% 100% (Oba,$Yagishita$et$al.$2005)
HB/GP PSP 8$PSP 100% n/a n/a (Mori,$Aoki$et$al.$2004)
MGF PSP 5$PSP,$23$PD,$14$MSA 80% 97% 80%
(Adachi,$Kawanami$et$al.$
2004)







HCB MSA 54$MSA,$35$PSP 50% 97% 97% (Schrag,$Good$et$al.$2000)
HPR MSA 54$MSA,$35$PSP 30% 91% 84% (Schrag,$Good$et$al.$2000)
MCP)sign MSA 54$MSA,$35$PSP 50% 94% 93% (Schrag,$Good$et$al.$2000)
Midbrain)
atrophy







described$ in$other$ diseases$ e.g.$MCP$ sign$ is$ seen$ in$other$ diseases$with$ pontocerebellar$
degeneration$(Uchino,$Sawada$et$al.$2004).$Furthermore,$not$all$published$studies$ contain$



















Most$ were$ assessed$ during$ life$ at$ either$ the$ National$ Hospital$ for$ Neurology$ and$
Neurosurgery,$ Queen$ Square,$ or$ the$ Regional$Neurosciences$ centre,$ Newcastle$ General$
Hospital$ by$ a$ hospital$ specialist$ (neurologist$ or$ geriatrician).$ The$ ﬁnal$ working$ clinical$
diagnosis$ during$ life$ was$ retrieved$ from$ available$ records.$ Included$ in$ the$ study$ were$
disease$ controls$ (pathologically$ conﬁrmed$ PD$ and$ CBD)$ and$ a$ group$ of$ living$ healthy$
controls$in$whom$no$evidence$of$neurological$disease$was$evident$at$time$of$imaging.$
& 3.&Image&analysis
Conventional$ MR$ images$ were$ independently$ reviewed$ by$ two$ experienced$
neuroradiologists$ (Dr$ Caroline$ Micallef$ and$ Dr$ H$ Rolf$ Jager)$ blinded$ to$ the$ ﬁnal$ clinical$
diagnosis$ although$ age$ at$the$ time$ of$ imaging$was$ taken$ into$consideration$ and$atrophy$




images$ were$ reviewed$ jointly$ and$ a$ consensus$ reached.$One$ rater$ (Dr$ Caroline$ Micallef)$
systematically$screened$MR$images$ for$a$ comprehensive$ list$of$abnormalities$described$in$
the$literature$[Table$4.1].$





hoc$Bonferroni$ correction$ or$ chi$square$ test$ as$ appropriate.$ Cohen’s$ kappa$ was$ used$ to$
assess$ interXrater$ agreement.$ McNemar’s$ chi$ square$ test$ was$ used$ to$ compare$ the$
proportion$correctly$ identiﬁed$using$the$ clinical$and$radiological$diagnosis.$The$ chi$square$
and$exact$tests$were$ used$ to$ compare$ proportions$with$speciﬁc$abnormalities.$Sensitivity,$
speciﬁcity,$ positive$ and$ negative$ predictive$ values$ and$ likelihood$ ratios$ of$ positive$ and$
negative$ results$were$ calculated$ in$ an$Excel$spreadsheet$(Microsoft$Oﬃce$ for$Mac,$2004)$
using$ published$ formulae$ (Altman$and$Bland$ 1994;$Altman$and$Bland$1994)$ and$accuracy$
(true$ positives$+$true$negatives$ /$ total$of$true$ and$false$positives$ and$negatives)$for$clinical$






Control PSP IPD MSA CBD p)value
n 9 22 7 13 6
Gender
(F)




































































*MSA$ versus$ PSP$ p$ =$ 0.001;$ MSA$ versus$CBD$ p$ =$0.008;$MSA$ versus$ control$ p$ =$0.055;$
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**MSA$versus$PSP$p$ =$0.001;$MSA$versus$CBD$p$=$0.004;$ ***MSA$versus$ PSP$ p$<$0.001;$
MSA$versus$CBD$p$=$0.008.
Group$characteristics$are$ summarised$in$Table$ 4.3.$A$total$of $33$MR$images$ were$ acquired$
digitally$at$the$National$Hospital$for$Neurology$and$Neurosurgery$(NHNN),$9$were$digitized$
ﬁlms$and$15$were$ viewed$as$ ‘hard$copy’$ﬁlms.$ 51/57$ (89.5%)$were$ acquired$on$a$ 1.5T$MRI$
system,$5$on$0.5T$and$1$on$a$1T$system$(1.5T$scans$were$available$in$9/9$control,$21/22$PSP,$
5/7$PD,$11/13$MSA$and$5/6$CBD$cases).$In$57/57$axial$images$were$available,$in$54/57$coronal$
and$ in$46/57$sagittal$ images;$T2$images$were$available$ in$57/57,$T1$images$ in$53/57,$proton$
density$images$in$41/47,$ﬂuid$attenuated$inversion$recovery$images$in$24/57.$
& 2.&Clinical&Diagnosis









































Table& 4.4:$ Diagnostic$ accuracy$ of$clinical$diagnosis,$macroscopic$ post$ mortem$ diagnosis$
and$radiological$diagnosis$ in$pathologically$conﬁrmed$disease$(There$was$substantial$interX
rater$reliability$for$the$radiological$diagnosis$(Cohen’s$kappa$0.733,$p$<$0.001).
Combined$sensitivity$for$the$ PSP$and$MSA$cases$was$ 28/35$(80%):$the$ clinical$diagnosis$ of$
PSP$was$ correct$in$20/22$(90.9%)$ pathologically$conﬁrmed$cases:$They$were$ subXclassiﬁed$
as$ Richardson’s$ syndrome$ (PSPXRS)$ (n=14),$ PSPXParkinsonim$ (n=1),$ PSP$ phenotype$ with$
late$or$no$documented$falls$ (n=3),$PSP$with$unclassiﬁed$subtype$ (n=1)$ and$an$encephalitic$
illness$ followed$much$ later$by$a$ PSP$phenotype$ (n=1).$The$ two$ false$negative$ cases$were$
diagnosed$with$atypical$parkinsonism$and$PD;$there$were$6$false$positive$diagnoses$of$PSP$
(MSA$ n=2,$ CBD$ n=2$ and$ PD$ n=2).$ The$ sensitivity,$ speciﬁcity$ and$ accuracy$ of$ clinical$
diagnosis$of$PSP$in$the$entire$study$cohort$were$90.9%,$82.9%$and$86.0%$respectively
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8/13$ (61.5%)$ cases$of$pathologically$conﬁrmed$MSA$cases$were$ correctly$identiﬁed:$7$were$
classiﬁed$as$ MSAXP$ and$one$ MSAXC.$Other$clinical$ diagnoses$ included$a$ cerebellar$ataxia$
with$ autonomic$ features$ (n=1),$ atypical$ parkinsonism$ (n=1),$ PSP/CBS$ (n=2)$ and$ pure$
autonomic$ failure$ (n=1)$ –$ thus$ of$ the$ 13$ cases$ 10$ had$ a$ predominantly$ Parkinsonian$
presentation,$2$a$predominantly$cerebellar$presentation$and$1$purely$autonomic.$There$was$
only$ one$ false$ positive$ MSAXP$ (PD$ histopathologically).$ The$ sensitivity,$ speciﬁcity$ and$
accuracy$ of$ clinical$ diagnosis$ of$ MSA$ in$ the$ entire$ study$ cohort$ were$ 61.5%,$ 97.7%$ and$
89.5%$respectively.
& 3.&Radiological&Diagnosis
In$ 45/48$ (93.8%)$ cases$ images$ were$ reviewed$ by$ both$ raters$ with$ substantial$ interXrater$
agreement$ for$ the$ radiological$ diagnosis$ (Cohen’s$ kappa$ 0.708,$ p$ <$ 0.001).25$ Combined$
sensitivity$for$the$PSP$and$MSA$cases$was$ 26/35$(74.3%).$The$radiological$diagnosis$of$PSP$
was$ correct$in$16/22$(72.7%)$and$of$MSA$in$10/13$ (76.9%)$cases.$ $The$sensitivity,$speciﬁcity$
and$ accuracy$ of$radiological$diagnosis$of$PSP$were$ 72.7%,$94.3%$and$ 86.0%$respectively.$
The$sensitivity,$speciﬁcity$and$accuracy$of$radiological$diagnosis$of$MSA$were$76.9%,$100%$





Although$the$ clinical$diagnosis$ was$more$ sensitive$ in$PSP,$the$ radiological$ diagnosis$ was$
more$ speciﬁc;$ the$ radiological$ diagnosis$ was$ more$ sensitive$ in$ MSA$ and$ slightly$ more$









PPV$for$PSP$ (p$<$0.05);$when$PD$was$ compared$to$MSA$4th$ventricle$ dilatation,$the$MCP$
sign$and$HCB$sign$had$100%$speciﬁcity$and$PPV$for$MSA$(p$<$0.05).$When$compared$to$CBD$
the$HB$sign,$and$ the$MCP$ and$HCB$signs$had$ 100%$speciﬁcity$ and$PPV$for$PSP$and$MSA$
respectively$(p$<$0.05).$
Table&4.5& (overleaf):$ Frequency$of$abnormalities$ seen$on$conventional$MRI$by$group.$The$
abnormalities$ listed$ are$ those$ that$ have$ been$ reported$ in$ the$ literature$ and$ formed$ a$
checklist$ for$the$ blinded$systematic$screen$of$cMRI$images.$ In$agreement$with$ published$





Control PSP PD MSA CBD
Substantia&
Nigra
Atrophy 1/9 11.1% 7/19 36.8% 1/7 14.3% 2/12 16.7% 0/6 0%
Smudging 1/9 11.1% 7/19 36.8% 1/7 14.3% 3/12 25% 0/6 0%
Hyperintensity 0/9 0% 2/19 10.5% 0/7 0% 0/12 0% 0/6 0%
Restoration&of&lateral&
signal
0/9 0% 1/19 5.3% 0/7 0% 0/12 0% 0/5 0%
Putamen
Atrophy 1/9 11.1% 10/18 55.6% 1/5 16.7% 6/12 50% 1/5 20%
Hypointensity 2/9 22.2% 5/19 26.3% 0/7 0% 1/12 8.3% 1/6 16.7%
Hyperintensity 0/9 0% 0/19 0% 0/7 0% 1/11 8.3% 2/4 33.3%
Hyperintense&
putaminal&rim




3/9 33.3% 19/22 86.4% 2/7 28.6% 4/12 33.3% 4/6 66.7%
Periaqueductal&
hyperintensity
3/9 33.3% 6/19 31.6% 1/7 14.3% 5/12 41.7% 3/6 50%
Tectal&hyperintensity 0/9 0% 0/20 0% 0/7 0% 0/12 0% 0/6 0%
Atrophy&of&
quadrigeminal&plate
3/9 33.3% 17/22 77.3% 2/7 28.6% 3/12 25% 4/6 66.7%
Dilatation&of&3rd&
ventricle
3/9 33.3% 17/22 77.3% 4/7 57.1% 4/12 33.3% 5/6 83.3%
Superior&colliculus&
hypointensity
0/9 0% 0/19 0% 1/7 14.3% 0/12 0% 0/6 0%
Hummingbird&/&Giant&
Penguin
0/9 0% 13/19 68.4% 0/5 0% 0/11 0% 0/4 0%
Morning&Glory&
Flower
1/9 11.1% 11/22 50% 0/7 0% 0/12 0% 0/6 0%
Mickey&Mouse 0/9 0% 1/22 4.5% 0/7 0% 0/12 0% 0/6 0%
SCP&hyperintensity 1/9 11.1% 3/20 15.0% 0/7 0% 1/12 8.3% 2/6 33.3%
Dentate&
hypointensity
0/9 0% 1/20 4.8% 0/7 0% 1/12 8.3% 0/6 0%
SCP&atrophy 1/9 11.1% 12/21 57.1% 0/7 0% 2/12 16.7% 2/6 33.3%
DSCP&hyperintensity 0/9 0% 2/20 10% 0/7 0% 0/12 0% 0/6 0%
Pons& &
Cerebellum
Pontine&atrophy 0/9 0% 5/22 22.7% 0/7 0% 4/12 33.3% 1/6 16.7%
Cerebellar&atrophy 2/9 22.2% 9/22 40.9% 1/7 14.3% 7/12 58.3% 1/6 16.7%
MCP&atrophy 0/9 0% 3/22 13.6% 0/7 0% 4/12 33.3% 0/6 0%
Medullary&atrophy 0/9 0% 2/22 9.1 0/7 0% 1/12 8.3% 0/6 0%
Inferior&olivary&
atrophy
0/9 0% 4/22 18.4% 0/7 0% 2/12 16.7% 0/6 0%
Dilatation&of&4th&
ventricle
0/9 0% 12/22 54.5% 0/7 0% 8/12 66.7% 1/6 16.7%
Pontocerebellar&ﬁbre&
hyperintensity 0/9 0% 3/20 15.0% 0/7 0% 4/12 33.3% 1/6 16.7%
MCP&hyperintensity 0/9 0% 0/21 0% 0/7 0% 6/12 50.0% 0/6 0%
Pontine&
hyperintensity
0/9 0% 2/20 10.0% 0/7 0% 1/11 8.3% 1/6 16.7%
Cerebellar&
hyperintensity
0/9 0% 0/21 0% 0/7 0% 0/12 0% 0/6 0%
Inferior&olivary&
hyperintensity
0/9 0% 0/21 0% 0/7 0% 0/12 0% 0/6 0%





Cortical&atrophy 3/9 33.3% 15/21 71.4% 4/7 57.1% 4/12 33.3% 4/6 66.7%
Lateral&ventricle&
dilatation
6/9 66.7% 16/19 84.2% 7/7 100% 8/12 66.7% 6/6 100%
Asymmetric&atrophy 0/9 0% 2/21 9.5% 1/7 14.3% 0/12 0% 0/6 0%
Global&atrophy 1/9 11.1% 10/21 47.6% 1/7 14.3% 2/12 16.7% 3/6 50.0%
Frontal&atrophy 1/9 11.1% 12/21 57.1% 1/7 14.3% 2/12 16.7% 4/6 66.7%
Parietal&atrophy 3/9 33.3% 14/21 66.7% 3/7 42.9% 2/12 16.7% 4/6 66.7%
Temporal&atrophy 1/9 11.1% 11/21 52.4% 1/7 14.3% 2/12 16.7% 3/6 50.0%
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Region Abnormality Sensitivity Speciﬁcity PPV NPV LR+ LRW p
PSP&vs&
Ctrl
Putamen Atrophy 55.6 88.9 90.9 50.0 5.0 0.5 0.042
Midbrain




77.3 66.7 85.0 54.5 2.3 0.3 0.038
Dilatation&of&3rd&
ventricle
77.3 66.7 85.0 54.5 2.3 0.3 0.038
Hummingbird&/&
Giant&Penguin
68.4 100.0 100.0 60.0 ∞ 0.3 0.001





54.5 100.0 100.0 47.4 ∞ 0.5 0.005
Supratentorial
Frontal&atrophy 57.1 88.9 92.3 47.1 5.1 0.5 0.042
Temporal&
atrophy








77.3 71.4 89.5 50.0 2.7 0.3 0.030
Hummingbird&/&
Giant&Penguin
68.4 100.0 100.0 45.5 ∞ 0.3 0.011
MGF 50.0 100.0 100.0 38.9 ∞ 0.5 0.026





67.7 100.0 100.0 41.2 ∞ 0.3 0.023








77.3 75.0 85.0 64.3 3.1 0.3 0.003
Dilatation&of&3rd&
ventricle&
77.3 66.7 81.0 61.5 2.3 0.3 0.025
Hummingbird&/&
Giant&Penguin
68.4 100.0 100.0 64.7 ∞ 0.3 0.000
MGF 50.0 100.0 100.0 52.2 ∞ 0.5 0.003
SCP&atrophy 57.1 83.3 85.7 52.6 3.4 0.5 0.024
Supratentorial
Frontal&atrophy 57.1 83.3 85.7 52.6 3.4 0.5 0.024
Parietal&atrophy 66.7 83.3 87.5 58.8 4.0 0.4 0.006
Temporal&
atrophy






68.4 100.0 100.0 40.0 ∞ 0.3 0.024
MGF 50.0 100.0 100.0 35.3 ∞ 0.5 0.055
Table&4.6:$Sensitivity,$Speciﬁcity,$Positive$Predictive$Value$(PPV),$Negative$Predictive$Value$
(NPV)$ Likelihood$ ratio$ for$a$ positive$ result$(LR+)$ and$ likelihood$ratio$for$ a$negative$ result$
(LRX)$in$pathologically$conﬁrmed$PSP.
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MCP&atrophy 33.3 100.0 100.0 52.9 ∞ 0.7 0.104
Dilatation&of&4th&
ventricle
66.7 100.0 100.0 69.2 ∞ 0.3 0.005
MCP&hyperintensity 50.0 100.0 100.0 60.0 ∞ 0.5 0.019
Pontocerebellar&
ﬁrbre&hyperintensity
33.3 100.0 100.0 52.9 ∞ 0.7 0.104
HCB 58.3 100.0 100.0 64.3 ∞ 0.4 0.007
MSA&vs&PSP
Midbrain
Atrophy&(axial) 33.3 13.6 17.4 27.3 0.4 4.9 0.005
Atrophy&of&
quadrigeminal&plate
25.0 22.7 15.0 35.7 0.3 3.3 0.003
Dilatation&of&3rd&
ventricle&
33.3 22.7 19.0 38.5 0.4 2.9 0.025
SCP&atrophy 16.7 42.9 14.3 47.4 0.3 1.9 0.024
Pons& &
Cerebellum
MCP&hyperintensity 50.0 100.0 100.0 77.8 ∞ 0.5 0.001
HCB 58.3 100.0 100.0 80.0 ∞ 0.4 0.000
Supratentor
ial
Frontal&atrophy 16.7 42.9 14.3 47.4 0.3 1.9 0.024




ventricle 66.7 100.0 100.0 63.6 ∞ 0.3 0.013
MCP&hyperintensity 50.0 100.0 100.0 53.8 ∞ 0.5 0.044




MCP&hyperintensity 50.0 100.0 100.0 50.0 ∞ 0.5 0.054
HCB 58.3 100.0 100.0 54.5 ∞ 0.4 0.038
Table&4.7:$Sensitivity,$Speciﬁcity,$Positive$Predictive$Value$(PPV),$Negative$Predictive$Value$
(NPV)$ Likelihood$ ratio$ for$a$ positive$ result$(LR+)$ and$ likelihood$ratio$for$ a$negative$ result$
(LRX)$in$pathologically$conﬁrmed$MSA.
& 6.&Macroscopic&examination&of&the&brain&at&post&mortem
The$ sensitivity$ of$macroscopic$ examination$ in$ predicting$ the$ histopathological $diagnosis$
was$24/35$(68.6%)$ for$combined$PSP$and$MSA$and$ individually$(15/22$(68.2%)$ for$PSP$and$
9/13$ (69.2$ %)$ for$ MSA.$ External$ examination$ of $ the$ brain$ revealed$ prominent$ cortical$
atrophy$ in$PSP$[Table$4],$dilatation$of $the$ lateral $ventricles$and$atrophy$of$the$deep$cortical$
white$ matter.$ STN$ atrophy$ and$ discolouration,$ atrophy$ of $ the$ midbrain$ and$ pontine$
tegmentum,$SCP$ and$blurring$ of$the$ dentate$ nucleus$ were$ frequent$but$ not$ universal$ in$
PSP.$ In$MSA$ there$was$putaminal$atrophy$ and$discolouration,$and$ atrophy$ of$the$ pontine$
base,$cerebellar$cortex$and$atrophy$ and$discolouration$of$cerebellar$white$matter.$ In$MSA$





Macroscopic&Abnormality PSP MSA PD CBD
External&
appearance
Cortical&Atrophy 16/22 (72.7%) 1/10 (10%) 2/4 (50%) 5/6 (83.3%)
Frontal&atrophy 12/22 (54.5%) 1/10 (10%) 2/4 (50%) 4/6 (66.7%)
Frontoparietal&atrophy 4/22 (18.2%) 0/10 (0%) 0/4 (0%) 1/6 (16.7%)
Brain&slices
Lateral&ventricle&dilatation 19/23 (82.6%) 6/13 (46.2%) 3/7 (42.9%) 5/6 (83.3%)
Focal&cortical&atrophy 3/23 (13.0%) 0/13 (0%) 0/7 (0%) 1/6 (16.7%)
Deep&WM&atrophy 13/22 (59.0%) 1/12 (8.3%) 1/7 (14.3%) 4/6 (66.7%)
Global&WM&atrophy 2/22 (9.1%) 0/12 (0%) 1/7 (14.3%) 1/6 (16.7%)
Frontal&WM&atrophy 11/22 (50.0%) 1/12 (14.3%) 0/7 (0%) 3/6 (50.0%)
Corpus&callosum&atrophy 3/18 (16.7%) 0/13 (0%) 0/6 (0%) 0/3 (0%)
Caudate&atrophy 1/23 (4.3%) 1/13 (7.7%) 0/7 (0%) 1/5 (20.0%)
Putaminal&atrophy 0/22 (0%) 7/13 (53.8%) 0/7 (0%) 0/5 (0%)
Putaminal&discolouration 0/22 (0%) 5/13 (38.5%) 0/7 (0%) 0/5 (0%)
Pallidal&atrophy 5/23 (21.7%) 1/12 (8.3%) 0/7 (0%) 0/6 (0%)
Thalamus&atrophy 5/21 (23.8%) 0/12 (0%) 0/7 (0%) 1/4 (25%)
STN&atrophy 16/20 (80.0%) 0/10 (0%) 0/7 (0%) 0/4 (0%)
STN&discolouration 17/20 (85.0%) 0/10 (0%) 0/7 (0%) 2/4 (50.0%)
Amygdala&atrophy 1/18 (5.6%) 0/12 (0%) 0/7 (0%) 0/6 (0%)
Hippocampal&atrophy 1/18 (5.6%) 1/11 (9.1%) 1/7 (14.3%) 2/6 (33.3%)
SN&pallor 21/21 (100%) 13/13 (100%) 6/6 (100%) 5/5 (100%)
LC&pallor 18/19 (94.7%) 11/11 (100%) 7/7 (100%) 5/6 (83.3%)
Midbrain&tegmental&atrophy 13/17 (76.5%) 2/5 (40.0%) 0/4 (0%) 0/3 (0%)
Pontine&tegmental&atrophy 13/20 (65.0%) 1/8 (12.5%) 0/5 (0%) 1/5 (20.0%)
SCP&atrophy 8/10 (80.0%) 0/2 (0%) 0/5 (0%) 1/4 (25.0%)
Pontine&base&atrophy 0/7 (0.0%) 7/10 (70.0%) 0/5 (0%) 0/4 (0.0%)
Medulla&atrophy 1/20 (5.0%) 0/9 (0%) 0/5 (0%) 0/6 (0%)
Inferior&olive&atrophy 1/10 (10.0%) 3/5 (60.0%) 0/3 (0%) 0/5 (0%)
Cerebellar&cortical&atrophy 0/23 (0%) 4/11 (36.4%) 0/7 (0%) 0/6 (0%)
Cerebellar&vermis&atrophy 0/20 (0%) 4/10 (40.0%) 0/6 (0%) 0/6 (0%)
Cerebellar&white&matter&
atrophy
0/23 (0%) 7/13 (53.8%) 0/7 (0%) 0/6 (0%)
Cerebellar&white&matter&
discolouration
0/20 (0%) 9/13 (69.2%) 0/7 (0%) 0/6 (0%)
Dentate&blurring 13/22 (59.1%) 3/9 (33.3%) 0/7 (0%) 1/5 (20.0%)





This$ is$ the$ ﬁrst$ systematic$ radiologicalXpathological$ study$ in$ the$ neurodegenerative$
parkinsonian$ syndromes$ PSP$ and$ MSA.$We$ report$ the$ sensitivity$ and$ speciﬁcity$ of$ the$
radiological$ diagnosis$ in$ a$ cohort$ including$disease$ controls$ (pathologically$ conﬁrmed$PD$
and$ CBD)$ and$ healthy$ controls,$ the$ accuracy$ of$cMRI$ abnormalities$ for$ the$ pathological$
diagnosis$ and$ directly$ compare$ cMRI$ with$ macroscopic$ ﬁndings$ at$ post$ mortem.$ cMRI$
included$ standard$T1Xweighted,$ T2Xweighted$ and$ FLAIR$ images$ and$ not$ advanced$ MRI$
imaging$ techniques,$ such$as$ diﬀusion$ tensor$ imaging$ or$ susceptibility$ weighted$ imaging$
which$ are$ still$not$ commonly$ available$ in$many$ centres.$Our$pragmatic$ evaluation$ of$the$
routine$ diagnostic$ value$ of$ cMRI$ and$ the$ substantial$ interXrater$ reliability$ for$ diagnosis,$
suggest$that$our$results$may$be$applicable$in$standard$clinical$environments.$
& 1.&Accuracy&of&clinical&and&radiological&diagnosis&using&cMRI
We$ found$ that$ the$ clinical$diagnosis$ was$more$ sensitive$ in$PSP$ (90.9%$ in$PSP$ compared$
with$ 72.7%$ in$MSA)$ and$ the$ radiological$ diagnosis$ more$ sensitive$ in$MSA$ (61.5%$ in$PSP$





The$most$ clinically$ useful$abnormalities$ seen$ in$PSP$ were$ signs$ of$midbrain$ atrophy,$SCP$
atrophy$ and$frontal$and$parietal $cortical$atrophy$ [Tables$ 4.5$ &$4.6].$Midbrain$atrophy$was$
seen$ in$86.4%$ and$ third$ ventricular$enlargement$ in$ 77.3%,$ which$ is$ comparable$ to$other$
reports$ (Schrag,$Good$et$al.$2000;$Yekhlef,$Ballan$et$al.$2003;$Righini,$Antonini$et$al.$2004).$
The$MGF$ sign$was$ very$ speciﬁc$ but$with$a$ sensitivity$ of$only$ 50%.$This$ is$ lower$ than$ the$
original$description$ (80%)$ (Adachi,$Kawanami$ et$ al.$ 2004)$ but$ higher$than$ a$ subsequent$
report$(12.5%)$ (Mori,$Aoki$et$al.$2004).$Although$the$ HB$sign$was$ found$ in$only$ 68.4%$(in$
contrast$ to$ published$ studies$ where$ it$was$ seen$ in$ all$ cases$ (Kato,$Arai$et$al.$ 2003;$Oba,$





assessment$ of$midbrain$ atrophy$ (Mori,$Aoki$et$ al.$2004).$This$ is$ due$ to$ variability$ in$ the$
angle$of$the$axial$plane$both$used$in$routine$practice$and$in$our$heterogenous$group$which$
was$not$optimised$for$assessment$of$axial$midbrain$atrophy$(Oba,$Yagishita$et$al.$2005).
Atrophy$ of $the$STN,$ the$ most$characteristic$pathological$ﬁnding$of$PSP,$was$ seen$in$only$
80%$at$post$mortem$[Table$4.8].$The$fact$that$regional$atrophy$of$structures$reported$to$be$




It$may$ seem$ surprising$that$putaminal$abnormalities$ are$not$more$ frequent$ in$this$ group,$






pathology$ is$ well$ known.$ Work$ in$ pathologically$ conﬁrmed$ cases$ suggests$ that$ SNDX
predominant$cases$have$more$ severe$parkinsonism$clinically$and$OPCAXpredominant$cases$
more$ severe$ cerebellar$ signs$ (Ozawa,$ Paviour$ et$ al.$ 2004).$ However,$ neuroradiological$
studies$suggest$evidence$for$OPCA$radiologically$in$MSAXP$which$is$ in$agreement$with$our$
ﬁndings$–$in$one$study$50%$of$MSAXC$had$putaminal$atrophy$(Schrag,$Good$et$al.$2000)$and$
conversely$ in$MSAXP$ cerebellar$ﬁndings$ on$cMRI$can$ be$highly$ speciﬁc$ for$a$ diagnosis$ of$
MSAXP$when$compared$to$PD$ (90X100%)$ if$ less$ sensitive$ (14X71%)$ (Osaki,$Wenning$et$al.$
2002).$Our$cohort$has$ a$ bias$ towards$ parkinsonian$conditions$ and$ further$studies$ of$more$
purely$ cerebellar$MSA$ phenotypes$ are$ important$ to$ study$ the$ relationship$ between$ the$
relative$ distribution$ of$ pathology$ (which$ is$ not$ evident$ from$ clinical$ studies),$ MRI$ and$
clinical$ﬁndings.
We$ also$ found$putaminal$atrophy$and$ the$HPR$in$PSP$ in$our$study,$as$ reported$elsewhere$
(Yekhlef,$Ballan$et$al.$2003)$and$putaminal$atrophy$was$seen$in$one$PD$case$with$a$disease$
duration$ of$ 6.8$ yrs$ X$ although$ previous$ reports$ suggest$ that$ this$ is$ either$ absent$ in$ PD$




The$ pontine$ and$cerebellar$ features$ were$more$ robust$MRI$ﬁndings$ in$MSA$ –$ with$ MCP$
hyperintensity$ in$6/12$(50.0%)$ and$the$HCB$sign$in$7/12$(58.3%):$only$pontine$base$atrophy$
in$7/10$(70.0%)$and$discolouration$of$the$deep$cerebellar$white$matter$in$9/13$(69.2%)$were$
more$common$at$macroscopic$post$mortem$examination.$These$ ﬁgures$ are$ in$accordance$
with$published$studies$(Schrag,$Kingsley$et$al.$1998;$Schrag,$Good$et$al.$2000;$Bhattacharya,$
Saadia$et$al.$2002;$Seppi$and$Schocke$2005).'However,$the$MCP$sign$has$been$described$in$
Wilson’s$ disease,$ hepatic$ encephalopathy,$ extrapontine$ myelinolysis,$ acute$ disseminated$
encephalomyelitis,$ wallerian$ degeneration$ of$ the$ pontocerebellar$ tracts$ after$ pontine$
insult,$ leukodystrophy$ and$ toluene$ abuse$ (Uchino,$ Sawada$ et$ al.$ 2004)$ and$ is$ a$
characteristic$of$Fragile$X$ tremor$ataxia$syndrome$ (Brunberg,$Jacquemont$et$al.$2002).$The$
HCB$ sign$ is$ also$ seen$ in$ parkinsonism$ secondary$ to$ vasculitis$ (Muqit,$Mort$ et$ al.$ 2001),$
spinocerebellar$ ataxias$ (including$ SCAX2$ (Burk,$ Skalej$ et$ al.$ 2001),$ SCAX3$ (Murata,$




at$macroscopic$ post$mortem$examination$and$ the$ frequency$ of$ﬁndings$ such$as$ pontine$
and$cerebellar$atrophy$were$very$similar$to$that$seen$using$cMRI.
& 4.&cMRI&in&pathologically&conﬁrmed&PD
Very$ few$abnormalities$were$ seen$on$cMRI$in$the$PD$group$[table$4.5],$despite$ the$atypical$
clinical$ features$ in$our$study.$This$ is$ in$accordance$with$ the$ literature,$which$suggests$that$
MRI$changes$ in$PD$are$too$subtle$to$be$ reliably$detected$by$cMRI$(Savoiardo$2003;$Yekhlef,$
Ballan$ et$al.$ 2003;$Seppi$and$Schocke$ 2005;$Sitburana$ and$Ondo$2009).$Macroscopic$post$
mortem$ﬁndings$ are$ restricted$to$ the$ SN$and$ locus$ coeruleus$ (LC)$ both$ of$which$are$ not$
reliably$assessed$on$cMRI.$Our$very$atypical$group$of$PD$likely$ represents$ a$referral$bias$ to$
the$QSBB.$ In$addition$ to$ this$ it$has$not$been$routine$ in$ the$UK$for$patients$with$a$ clinical$





There$were$no$cMRI$speciﬁc$ﬁndings$ in$CBD$ and$in$no$case$was$cortical$atrophy$ felt$to$be$
asymmetric$ in$ CBD.$ Some$ of$ the$ literature$ suggests$ that$ frontoparietal$ hemispheric$
asymmetry$ is$ characteristic$ (Savoiardo$2003;$Tokumaru,$Saito$et$ al.$ 2009)$ however$ in$one$
study$of$pathologically$conﬁrmed$cases$this$was$not$evident$(Schrag,$Good$et$al.$2000).$The$
presence$of$midbrain$atrophy,$although$not$suﬃcient$to$be$classiﬁed$as$the$MGF$or$HB$sign,$
is$ counter$ to$ some$ published$ work$ (Savoiardo$ 2003)$ although$ CBD$ is$ known$ to$ aﬀect$
subcortical$structures$ such$ as$ the$ SN$and$STN$ so$midbrain$atrophy$ and$dilatation$ of$the$
third$ ventricle$ are$ not$unexpected$ﬁndings.$The$ HB$and$MGF$ signs$ indicate$ more$ severe$
midbrain$atrophy$ and$ are$ found$only$ in$ the$ PSP$ group.$This$ is$ in$keeping$with$ published$
series$ with$ pathological$ conﬁrmation$ where$ no$ distinguishing$ features$ were$ seen$ using$
cMRI$in$CBD$ (Schrag,$Good$et$al.$2000;$Josephs,$TangXWai$et$al.$2004).$The$most$common$
ﬁndings$ at$ macroscopic$ post$ mortem$ examination$ were$ cortical $ atrophy$ (particularly$
frontal)$ associated$with$deep$white$matter$ atrophy$ and$ dilatation$of$ the$ lateral$ ventricle$
[Table$ 4.8].$ CBD$ is$ particularly$ diﬃcult$ to$ diagnose$ during$ life$ and$ studies$ using$ clinical$
diagnoses$ of$ CBD$ –$ the$ soXcalled$ corticobasal$ syndromes$ (CBS)$ –$ will$ be$ particularly$
susceptible$to$errors$ in$predicting$the$underlying$pathological$diagnosis$(Ling,$O'Sullivan$et$




macroscopic$ brain$ assessment.$ $ Smaller$ nuclei$ where$ pathological$ changes$ occur$ are$
reliably$assessed$at$macroscopic$brain$examination$but$not$on$cMRI.$ $Although$some,$e.g.$
the$STN$may$be$more$clearly$ identiﬁed$at$3$Tesla$(Slavin,$Thulborn$et$al.$2006)$there$is$ very$
little$ published$ data$ on$ the$ diagnostic$ accuracy$ with$ pathological$ conﬁrmation.$
Microstructural$ abnormalities$ in$ the$ substantia$ nigra$ such$ as$ those$ found$ using$ DTI$
(Vaillancourt,$Spraker$et$al.$2009)$or$diﬀerences$ in$the$deposition$of $iron$ in$nuclei$such$as$
the$SN$(Martin,$Wieler$et$al.$2008)$are$interesting$new$MR$imaging$techniques$that$have$not$
been$ studied$ systematically$ in$ PSP$ and$ MSA.$Objective$ measurements$ of$ conventional$
images$ have$ been$ shown$ to$ improve$ accuracy$ in$ predicting$ the$ clinical$ diagnosis$
(Quattrone,$Nicoletti$et$al.$2008),$and$voxelXbased$morphometry$ (Josephs,$Whitwell$et$al.$




There$ are$ limitations$ of$this$study.$We$ included$a$ few$CBD$and$clinically$ atypical$PD$cases$





where$ some$ of$the$ signs$ could$not$ be$ assessed;$ the$ eﬀect$of$ including$ a$ few$ cases$ with$
lower$ﬁeld$strength$may$ have$ led$ to$underXreporting$of$ signal$change$ abnormalities.$The$
results$ obtained$ provide,$ therefore,$ a$ ‘realXworld’$ assessment$ of$ the$ diagnostic$ value$ of$
routine$ radiological$practice.$The$use$of$working$clinical$diagnoses$and$inclusion$of$clinically$
atypical$cases$ is$ important$in$studies$of$MRI$as$many$cases$are$often$excluded$from$clinical$




In$a$ cohort$ of$pathologically$ proven$parkinsonian$ illnesses$ some$ cMRI$ﬁndings$ are$ highly$
speciﬁc$ in$MSA$and$PSP$ but$lower$sensitivity$means$a$ signiﬁcant$proportion$of$cases$will$
not$ have$ diagnostic$ abnormalities.$ However,$ a$ consensus$ radiological$ diagnosis$ did$ not$
misclassify$PSP$as$MSA$or$vice$ versa.$Using$ subjective$ assessment$most$regional$atrophy$
found$ at$ macrocopic$ examination$ is$ detected$ using$ cMRI$ although$ it$ may$ not$ enable$
accurate$ diagnosis$ of$these$ conditions$ in$all$ cases$ even$ in$experienced$hands;$ the$ use$ of$
more$ advanced$ and$ novel$ MRI$ techniques$ will$ be$ needed$ to$ improve$ accurate$









et$ al.$ 2002).$ Characteristic$midbrain$atrophy$ in$ PSP$ and$ pontine$ atrophy$ in$MSA$ can$be$
assessed$ on$MRI$ (Massey,$Micallef$et$al.$ 2012);$ however$many$ MRXbased$measurements$
proposed$as$diagnostic$for$PSP$or$MSA$lack$pathological$veriﬁcation$and$are$often$not$easy$




























































































Table& 5.1:$ Published$ studies$ of$ measurements$ on$ conventional$MRI$ in$ PSP$ and$ related$
conditions.
Three$factors$determined$the$development$of$the$ratio:
1. The$ need$ for$a$ simple$ measurement$ that$ is$ easy$ to$perform$ even$ by$ nonXspecialists,$
easy$to$explain,$not$timeXconsuming$or$needing$special$software$and$reproducible.
2. The$ pattern$of$pathology$ and$ atrophy$ in$PSP$ and$MSA:$ involvement$of$ the$ midbrain$




3. Midsagittal$ images$ were$ felt$ to$ be$ more$ reliable$ than$ axial$ images$ for$ assessing$








the$Queen$Square$ Brain$Bank$ (QSBB)$at$UCL$Institute$of$Neurology;$brains$ were$ donated$
following$ethically$ approved$protocols$ under$ licence$ from$ the$ Human$Tissue$ Authority.$A$
cohort$of$PSP,$PD,$MSA$and$healthy$ subjects$was$ prospectively$ recruited$ at$ the$ National$
Hospital$ for$ Neurology$ and$ Neurosurgery,$ as$ part$ of$ an$ ethically$ approved$ study$ with$
written$informed$consent.
In$ the$ pathologically$ conﬁrmed$ group$ the$ diagnosis$ was$ determined$ using$ standard$
neuropathological$ criteria$ (Ince,$ Clarke$ et$ al.$ 2008).$ In$ the$ clinically$ diagnosed$ group$
participants$ fulﬁlled$ operational$ criteria$ (Gibb$ and$ Lees$ 1988;$ Litvan,$ Agid$ et$ al.$ 1996;$
Gilman,$Low$et$al.$1999)$and$were$ assessed$with$clinimetric$scales$ including$Hoehn$&$Yahr,
(Hoehn$and$Yahr$1967)$the$ uniﬁed$Parkinson’s$disease$rating$scale$ (UPDRS)$(Fahn,$Elton$et$
al.$1987),$Folstein’s$ MiniXmental$State$Examination$(MMSE)$(Folstein,$ Folstein$et$al.$ 1975),$
the$ frontal$assessment$battery$ (FAB)$ (Dubois,$Slachevsky$ et$ al.$2000),$Golbe’s$ PSP$ rating$
scale$ (PSPRS)$ (Golbe$ and$ OhmanXStrickland$ 2007)$ or$ the$ uniﬁed$ MSA$ rating$ scale$
(UMSARS)$ (Wenning,$ Tison$et$ al.$ 2004).$ Healthy$ controls$ had$ no$ history$ of$ neurological$
illness$at$time$of$imaging$[Figure$1].
In$ the$ pathologically$ conﬁrmed$ group$ cases$ were$ selected$ where$ conventional$ 1.5T$









to$ oblique$ superiorXinferior$ axes$ (thin$ white$ lines).$ The$ maximal$ measurement$








measured$ by$ another$ rater$(NF$X$ neurologist)$ for$ interXrater$assessment.$ In$ the$ clinicallyX
diagnosed$group$(n=62)$a$third$rater$(LM$X$neurology$trainee)$performed$all$measurements.
& 3.&Statistical&Analysis
Group$characteristics$were$ compared$using$multivariate$ analysis$ with$postXhoc$Bonferroni$
correction.$ An$ intraclass$ correlation$ coeﬃcient$was$ used$ to$ assess$ interXrater$ agreement$
and$ROC$ curve$analysis$to$deﬁne$cut$oﬀ$values$(maximal$sum$of$sensitivity$and$speciﬁcity)$
in$the$pathologicallyXconﬁrmed$group$that$were$subsequently$applied$to$the$clinical$group.$
Pearson’s$ correlation$ coeﬃcient$ was$ used$ to$ assess$ correlation$ of$ the$ midbrain$
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Table) 5.2:$ Demographic$ and$ clinimetric$ features$ of$ the$ pathologically$ conﬁrmed$ and$ clinically$
diagnosed$groups.$Statistically$signiﬁcant$ diﬀerences$ (ANOVA)$ in$ bold.$ In$ the$clinical$ cohort$ 17/21$












































































Table&5.& 3:$ Mean$ (SD)$measurements$ (mm)$ in$ the$ pathologically$ conﬁrmed$and$clinically$
diagnosed$ groups.$ Statistically$ signiﬁcant$ diﬀerences$ (ANOVA)$ in$ bold.$ Deﬁned$ by$ the$
maximum$sum$of$sensitivity$and$speciﬁcity$from$the$ROC$curve$in$pathologically$conﬁrmed$
cases,$a$midbrain$measurement$of$less$ than$9.35mm$had$83%$sensitivity,$100%$speciﬁcity$




Figure& 5.3:$ Scatterplots$ of$ the$ midbrain$ and$ pons$ measurements$ showing$ both$
pathologically$ conﬁrmed$ and$ clinically$ diagnosed$ groups$ and$ Receiver$ Operating$Curve$
analysis$in$the$pathologically$conﬁrmed$group$comparing$PSP$and$MSA.
E.&Discussion
In$pathologically$ conﬁrmed$ disease$ there$ was$ support$ for$ our$ hypothesis$ that$ there$ is$ a$
signiﬁcantly$ smaller$ midbrain$ tegmental$ measurement$ and$ a$ reduced$ midbrain$
tegmentum:pontine$base$ ratio$in$PSP$ compared$to$controls$and$MSA.$Conversely,$in$MSA$
there$was$a$trend$towards$an$increased$midbrain:pontine$base$measurement.$Put$simply,$in$
normal$ controls$ the$ midbrain$ tegmentum$ was$ approximately$ 2/3$ of$ the$ pontine$ base,$
whereas$in$PSP$ it$is$ less$ than$50%$and$in$MSA$it$is$greater$than$2/3$[Table$ 5.2;$Figure$5.3]$ X$




speciﬁcity$ and$ 83%$ sensitivity$ for$ a$ pathological$ diagnosis$ of$ PSP$ and$ a$ midbrain$
124
tegmentum:$pontine$base$ratio$of$0.52$or$less$had$a$67%$sensitivity$and$100%$speciﬁcity$for$
PSP$ when$ compared$ to$MSA.$When$applied$ to$the$ clinically$diagnosed$group$ the$ cutXoﬀ$
values$were$still$100%$speciﬁc$for$PSP,$with$sensitivities$of$90.5%$and$87.5%,$respectively.
& 1.&Comparison&with&visual&assessment&and&other&published&measurements
The$ maximal$ midsagittal$ midbrain$ tegmentum$ measurement$ and$ ratio$ of$ midbrain$
tegmentum$to$pontine$base$are$ approximately$equivalent$in$terms$of$area$under$the$curve$
in$ predicting$ the$ diagnosis:$ while$ the$ midbrain$ tegmentum$ measurement$ has$ higher$
sensitivity$for$the$diagnosis,$the$ratio$controls$for$head$size$which$is$a$confounding$factor$of$
simpler$ measurements.$ Visual$ assessment$ of$ conventional$ MRI$ indicates$ that$ the$ most$
useful$subjective$ feature$ of $the$ routine$ radiological$assessment$of$midbrain$atrophy$ is$ the$
hummingbird$ sign$ (Kato,$ Arai$ et$ al.$ 2003;$ Massey,$ Micallef$ et$ al.$ 2012).$ Axial $ plane$
measurements$ often$ show$overlap$of$ PSP$ with$ other$ groups$ (Schrag,$Good$ et$ al.$ 2000;$
WarmuthXMetz,$Naumann$et$al.$ 2001;$ Righini,$Antonini$ et$ al.$2004)$ and$ the$ variability$ in$
axial$plane$ taken$during$routine$MRI$makes$comparison$diﬃcult.$It$ is$more$ straightforward$
to$obtain$‘standard’$mid$sagittal$images$and$both$linear$measurements$ (Asato,$Akiguchi$et$




(Massey,$Micallef$et$al.$ 2012).$This$ is$ promising$ as$ a$measurement$which$ can$ be$ derived$
rapidly$ with$ little$ training.$ Furthermore$ our$ results$ compare$ favourably$ with$ previous$
reports$ of $linear$measurements$showing$overlap$between$PSP$and$MSA$but$not$control$or$
PD$ groups$ (WarmuthXMetz,$ Naumann$ et$ al.$ 2001)$ and$ even$ more$ complex$ area$
measurements$ where$ overlapping$values$ of $midbrain$and$pons$ area$ are$ still$ found$ (Oba,$
Yagishita$ et$ al.$ 2005;$ Groschel,$ Kastrup$ et$ al.$ 2006)$ as$ have$ more$ detailed$ analysis$ of$
midsagital$area$of$the$rostral$and$caudal$midbrain$tegmentum$(Kato,$Arai$et$al.$2003).
Our$ results$ support$ the$ hypothesis$ that$ because$ of$diﬀerential$ patterns$ of$atrophy$ (PSP$
with$greater$midbrain$loss$and$MSA$with$greater$pontine$ loss)$a$simple$ ratio$measurement$
of$midbrain:pons$ helps$ in$ diﬀerentiating$ PSP$ and$MSA.$ [Figure$ 5.3$ –$ the$ spread$ of$MSA$





We$ did$ not,$ however,$ ﬁnd$ a$ correlation$ between$ disease$ duration$ or$ severity$ measured$
using$clinimetric$scales.$A$previous$study$has$been$reported$a$correlation$of$disease$severity$
with$ the$ area$of$ the$midbrain$ in$sagittal$ section,$ and$a$midbrain$to$pons$ area$ ratio$(Oba,$
Yagishita$ et$ al.$2005)$ but$ other$studies$ using$ linear$measurements$ and$ the$ MRPI$ do$not$
report$on$this$(Schrag,$Good$et$al.$2000;$Kato,$Arai$et$al.$2003;$Righini,$Antonini$et$al.$2004;$
Quattrone,$ Nicoletti $ et$ al.$ 2008).$ A$ clear$ problem$ with$ these$ studies$ is$ the$ reliance$ on$
clinical$criteria$which$by$deﬁnition$restrict$the$spectrum$of$cases$ studied,$particularly$ early$
in$the$disease$ course$when$the$ clinical$diagnosis$is$most$uncertain.$In$order$to$address$ this$
issue,$ prospective$ studies$ of$ subsequently$ pathologically$ conﬁrmed$ disease$ will$ be$
necessary.$ In$ the$ case$ of$ a$ simple$ linear$ measurement$ it$ may$ be$ too$ much$ to$ expect$
correlation$ with$ measurements$ of$ disease$ severity.$ Indeed,$ area$ measurements$ of$ the$
midbrain$in$the$midXsagittal$plane$in$two$dimensions$although$useful$for$making$a$diagnosis$




The$ strengths$ of$ our$ study$ lie$ in$ the$ pathological$ validation$ of$ the$ diagnosis$ and$ the$
rationalised$ approach$ to$ developing$ simple$ measurement$ based$ on$ knowledge$ of$ the$
pathological$ topography.$ However,$ there$ was$ a$ relatively$ small $ sample$ size$ of$ the$
pathologically$ conﬁrmed$group$ although$our$ﬁndings$ were$ conﬁrmed$in$a$ larger$clinically$
diagnosed$cohort.
A$ strength$of$ our$ study$ is$ that$ the$ clinically$ diagnosed$group$of$MSA$ (8/10$MSAXP,$ 2/10$
MSAXC)$were$clinically$relevant$in$that$we$selected$those$with$largely$Parkinsonian$features$
who$ are$ more$ likely$ to$ cause$ diagnostic$ diﬃculty.$ Those$ with$ cerebellar$ predominant$
disease$might$be$expected$to$have$greater$pontine$atrophy$X$in$eﬀect$our$inclusion$of$a$high$
proportion$ of$MSAXP$ patients$ is$ a$ sterner$ test$ for$ our$ proposed$ measure.$ Post$Mortem$
studies$ conﬁrm$ a$ relationship$ between$ the$ relative$ distribution$ of$ pathology$ in$ the$




Many$ methods$ are$ described$ in$ the$ literature$ for$distinguishing$ between$PSP$ and$ other$
conditions$based$on$measurements$of$conventional$imaging.$However,$often$the$method$is$





specialist$training,$time$ consuming$procedures$or$ software$ that$is$not$already$ available$ in$
most$ basic$ imaging$ systems.$ It$ aﬀords$ a$ histopathologically$ supported$ and$ clinically$






The$ subthalamic$ nucleus$ (STN)$ was$ ﬁrst$ described$ by$ Jules$ Bernard$ Luys$ (1828X1897)$ in$
1865$(Parent$2002).$ $In$the$early$20th$ century$Purdon$Martin$identiﬁed$vascular$lesions$ in$the$
subthalamic$ region$ in$ cases$ of$ hemiballism$ (Purdon$ Martin$ 1927).$ More$ recent$ studies$
demonstrate$ that$ improvement$ in$ Parkinsonian$ symptoms$ in$ the$ 1XmethylX4X
phenylX1,2,3,6Xtetrahydropyridine$ (MPTP)$ monkey$ model$ of$ Parkinsonism$ is$ found$ after$




The$ oblique$ orientation$and$small$ size$ of$ this$ structure$ contribute$ to$the$ diﬃculties$ in$ its$
identiﬁcation$ using$ conventional $MRI.$ In$ planning$ placement$ of$ deep$ brain$ electrodes,$
standard$brain$atlases$are$ commonly$used$to$derive$the$coordinates$ of $the$STN$in$relation$
to$the$patient’s$ ventricular$landmarks$obtained$by$ ventriculography$ (Benabid,$Krack$ et$al.$
2000)$or$T1Xweighted$MR$(Starr$2002).$Clinical$and$electrophysiological$surrogates$are$used$
to$ conﬁrm$ electrode$ placement$ (Gross,$ Krack$ et$ al.$ 2006).$ However,$ the$ anatomical$
accuracy$ of$ this$ approach$has$ been$challenged$ by$ pathological $reports$ of$ inaccuracies$ in$
electrode$placement$(Counelis,$Simuni$et$al.$2003;$Hariz,$Blomstedt$et$al.$2004;$McClelland,$
Vonsattel$et$al.$2007)$ and$by$demonstration$of$the$ interXindividual$variability$ in$the$shape,$
size$and$position$of$the$STN$(den$Dunnen$and$Staal$2005;$Ashkan,$Blomstedt$et$al.$2007).$
Direct$visualisation$ of$the$ STN$is$ reported$using$reproducible$ MRI$methods$ (Zonenshayn,$
Rezai$et$al.$2000;$Hariz,$Krack$et$al.$2003;$Hariz,$Blomstedt$et$al.$2004;$Foltynie,$Zrinzo$et$al.$


































3 M Right 38 56 1.$No$diagnosis$made Metastatic$disease




























nucleus.$ The$ MR$axis$ was$ aligned$ perpendicular$ to$ the$ axis$ of$ the$ brainstem$ and,$ after$









2. Superior$ inXplane$ resolution$was$obtained$ in$one$case:$ 1024x1024$matrix$(in$plane$
resolution$44$μm),$132$averages;$other$parameters$as$above,$imaging$time$72$hours.




These$ parameters$ were$ chosen$on$ the$ basis$ of$ pilot$ acquisitions$ to$ yield$optimal$ image$
contrast$for$the$ structures$of $interest;$due$to$the$reduced$T2$relaxation$times$in$ﬁxed$tissue$













2006)$ with$ reference$ to$ neuroanatomical$ atlases$ (Schaltenbrand$ and$ Wahren$ 1977;$
Carpenter$and$Sutin$1983;$Nieuwenhuys,$Voogd$et$al.$1988).$After$manual$segmentation$the$
STN$volume$ was$calculated$using$the$ volume$and$statistics$ function.$SegmentationXmask$
measurements$ of$ the$ STN$width$ (maximum$ distance$ in$ the$ axial$ plane$ from$ medial$ to$
lateral$ tip)$ and$ depth$ (maximum$ distance$ in$ the$ axial$ plane$ between$ the$ anterior$ and$
posterior$ borders$ perpendicular$ to$ the$ width$ measurement)$ in$ the$ axial$ plane$ were$
obtained$with$ImageJ;$the$ height$was$ calculated$with$reference$to$the$number$of$1X1.5mm$
axial$ slices$ in$ which$ the$ STN$ appeared.$ The$ higherXcontrast$ SE$ images$ were$ used$ for$




The$position$of$the$STN$was$determined$ in$relationship$to$three$arbitrary$ lines$ in$the$axial$
plane$[See$ﬁgure$7.1]:$
1. The$midline
2. A$line$connecting$the$ anterior$border$of$the$ fornix$with$the$posterior$border$of$the$
mamillothalamic$tract$(the$FMT$line)




the$ anteromedial$ tip$of$the$ STN$(the$ STN$ line).$The$ FMT$ line$ and$STN$line$ were$ used$as$
reference$ at$ all $ levels.$The$ RN$ line$ was$ not$ used$ at$ levels$ above$ the$ RN,$ the$ transverse$











Excellent$ contrast$ between$ white$ and$ grey$ matter$ allowed$ clear$ deﬁnition$ of$ the$ STN$
boundaries$on$SE$images$in$all$cases.$In$the$axial$plane,$the$STN$was$almondXshaped$and$lay$
at$ an$ oblique$ angle$ to$ the$ anteroposterior$(AP)$ axis$ of$the$ brainstem$ [Figure$ 7.2].$ In$ 5/8$
cases$studied$(6/9$nuclei)$the$STN$was$of$intermediate$signal$intensity,$similar$to$that$of$the$
internal $ capsule$ and$ between$ that$ of $ grey$ matter$ structures$ such$ as$ the$ pulvinar$ and$
hypothalamus$ which$ appeared$ hyperintense,$ and$ that$ of$ the$ pallidum,$ ansa$ lenticularis$
(AL),$RN$and$SN$which$were$hypointense$[Figure$7.2].$In$2$cases$(long$duration$ﬁxation)$the$








the$ hypothalamus.$ Short$ white$ arrow:$ medial$ hypointensity$ of$ the$ STN$ (seen$ in$ 6/9$
subthalamic$nuclei$studied).$Arrow$head$in$2E$identifying$the$hypointense$band$forming$the$
anterior$border$of$the$STN$and$enabling$discrimination$from$the$SN$at$more$inferior$levels.$
Acquired$with$ an$ inXplane$ resolution$of$88μm.$Orientation:$A$X$anterior,$P$ X$posterior,$M$X$
medial,$L$X$lateral.
& 2.&Position&of&the&STN
Axial$SE$ images$were$available$ in$all$cases;$additional$coronal$and$sagittal $SE$images$were$
available$ in$ one$ [Figures$ 7.3$&$ 7.4].$The$STN$lay$ obliquely$ in$all$ three$ planes.$ In$ the$ axial$
plane,$the$STN$was$ approximately$40$degrees$ oblique$ to$the$midline:$at$the$more$ superior$
level $studied$the$mean$angle$was$42.8$degrees$(SD$7.3)$and$at$the$inferior$level$studied$38.1$




G].$Acquired$with$an$inXplane$resolution$of$88μm.$Orientation:$S$–$ superior,$ I$–$ inferior,$P$ –$
posterior,$A$–$anterior.
Figure&7.4:$Coronal$Plane:$The$ STN$ in$serial$1mm$coronal$sections$ in$a$ control$case$ from$









the$optic$ tract$ [Figure$ 7.3$AXG],$with$the$zona$ incerta$(ZI)$running$along$the$posterior$and$
superior$surface$ [Figure$ 7.3$CXE]$ and$ the$ lenticular$fasciculus$ (LF,$H2$ﬁeld$of$Forel)$ at$the$
most$ superior$aspect$ of $the$ STN$[Figure$ 7.3$DXF].$ In$more$medial$ sagittal$slices,$ the$ ansa$
lenticularis$ (AL)$ was$ seen$ sweeping$ around$ the$ medial$ internal$capsule$ [Figure$ 7.3$ F&G]$
forming$part$of$the$medial$and$anterior$border$of$the$STN.$The$AL$was$also$seen$joining$H2$
to$form$the$H$Field$of$Forel$[Figure$7.3$FXG]$and$the$thalamic$fasciculus$(H1)$[Figure$7.3$BXF].$
The$ anterior$and$medial$border$was$ clearly$ deﬁned,$bounded$by$ the$ZI,$and$the$ posterior$
aspect$ of$ the$ hypothalamus.$ [Figure$ 7.2C$ long$ arrow](Hamani$et$ al.,$ 2004).$ The$ LF$ also$
formed$the$most$medial$1/3$of$the$anterior$border$of$the$STN$at$the$most$superior$level.
The$superior$border$of$the$STN$was$formed$by$ the$ LF,$seen$as$ a$region$of$hypointensity$ in$
all$cases$ in$axial$ sections$ but$best$appreciated$in$the$ sagittal$and$ coronal$planes$ [Figures$
7.3DXF,$ 7.4DXE].$The$ LF$was$seen$as$ a$ slightly$ lower$intensity$ structure$ in$MR$slices$above$
the$STN$in$the$axial,$coronal$and$sagittal$planes.$
The$ posterior$ border$ was$ formed$ by$ a$ hyperintense$ band$ that$ corresponds$ to$ the$ grey$
matter$of $the$ zona$ incerta$ above$ the$ level$of$the$RN$[Figure$ 7.2A&B].$At$ lower$levels$ the$
hyperintense$ signal$arose$ from$tissue$between$the$STN$and$more$ caudally$ the$SN$and$the$
RN:$ this$ is$ the$ site$ of$myelinated$ ﬁbres$ orientated$ in$the$ axial$plane$ in$a$ posterolateralX
anteromedial$axis$ (Adachi$et$al.,$1999)$ of$the$nigrostriatal$tract(Adachi$et$al.,$1999;$Moore$
et$al.,$1971)$or$the$pallidoreticular$bundle$(bundle$Q)$(Schaltenbrand$and$Wahren,$1977).
The$ inferior$border$ of $the$ STN$ is$ formed$by$ the$ SN,$ which$ is$ wrapped$around$ the$ most$
inferolateral$ aspect$ [Figure$ 7.3$ AXF,$ Figure$ 7.4$ AXE$ white$ arrow].$ It$ is$ more$ diﬃcult$ to$
accurately$ deﬁne$this$boundary$in$the$axial$plane$ [Figure$7.2E$where$the$most$inferior$part$




In$the$ cases$where$higher$resolution$images$ acquired$with$an$ inXplane$resolution$of$44μm)$








MR$ images$ with$ corresponding$ LFB/CV$ stained$ sections$ were$ available$ in$ 4$ cases.$




Figure& 7.6& (previous& page):$ Comparison$ of$ 9.4T$ SE$ MRI$ images$ [AXD]$ and$ histological$
sections$stained$using$the$LFB/CV$method$[EXG].$MRI$in$plane$resolution$88$μm.$Images$are$
unlabelled$ to$ make$ comparison$ easier.$ For$ anatomical$ labels$ see$ ﬁgure$ 3.$ The$ STN$ is$
identiﬁed$ clearly$ as$ an$almond$ shaped$structure$ surrounded$ by$white$matter$ tracts$ (blue$
stain$on$LFB/CV$images).$LFB/CV$staining$within$the$STN$was$ uniform$in$4/4$cases$with$no$
particular$ anteromedial/posterolateral$ gradient$ evident.$ Structures$ corresponding$ to$ the$
borders$ of$the$STN$can$be$clearly$identiﬁed:$at$superior$levels$the$LF$can$be$seen$as$a$dark$
blue$myelinated$structure$corresponding$to$a$region$of$hypointensity$on$T2w$images$[A&E].$
One$step$inferiorly$[B&F]$the$STN$is$ clearly$ demarcated$by$ a$rim$of$dark$blue$ staining$and$
the$ ﬁbres$ of$the$ subthalamic$ fasciculus$ are$ seen$ radiating$through$the$ internal$capsule$ –$
corresponding$to$ the$ hypointensity$ seen$on$ the$ anterolateral$border$of$the$STN$on$T2w/
PDw$images.$The$ posteromedial$border$ is$ clearly$ deﬁned$on$the$LFB/CV$images$ as$white$
matter$tracts$but$on$the$MR$images$there$is$a$relatively$hyperintense$signal$arising$from$the$
region$of$the$zona$Incerta$[B&F].$A$region$densely$staining$for$myelin$is$seen$separating$the$
STN$ anteromedially$ from$ the$ superior$ SN$ posterolaterally$ on$ the$ LFB/CV$ image$ X$ this$
corresponds$ to$a$relatively$hypointense$ region$on$the$MR$image$[D&H].$It$can$be$seen$that$
the$medial$border$of$the$STN$is$ less$clearly$ deﬁned$on$the$ LFB/CV$image$at$this$ level$near$
the$ posterior$aspect$ of$ the$ anteromedial$ tip$on$ the$ LFB/CV$ image$ but$ this$ remains$ well$
deﬁned$on$the$9.4T$SE$MR$image$[H].
Perls$ stain$for$ iron$was$ performed$in$ 3$cases.$At$superior$ levels$ the$ most$intense$ staining$
was$ seen$ in$the$ globus$ pallidus$ and$the$AL$as$ it$ courses$ around$ the$ internal$capsule$ and$
comes$ to$ lie$ adjacent$to$the$anteromedial$tip$of$the$STN$[Figure$7.7AXC].$The$SN$was$ seen$
at$ lower$ levels$ with$ intense$ PerlXpositive$ staining$ particularly$ in$ the$ most$ anterior$ and$
medial$ portion$ [Figure$ 7.7DXF].$The$ STN$itself$stained$ less$ intensely$ and$ the$ more$ lateral$
and$ posterior$ portions$ were$ least$ heavily$ stained$ in$ 2/3$ cases,$ particularly$ in$ the$ more$
inferior$sections$[Figure$ 7.7BXE].$By$comparison$the$most$hypointense$signal,$correlating$to$
the$distribution$of$most$intense$Perl$staining,$was$seen$in$the$superior,$anterior$and$medial$









We$ have$ reconstructed$ the$ anatomy$ of$ the$ STN$and$surrounding$ structures$ by$ manually$
segmenting$ the$ ge3d$ images.$This$ allowed$ us$ to$ display$ the$ relationship$ of$ the$ STN$ to$
surrounding$structures$in$three$dimensions$(Figure$7.8).
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Figure& 7.8:& ThreeXdimensional$ reconstruction$ viewed$ from$ the$ midline$ showing$ the$
relationship$of$the$STN$(green)$to$the$internal$capsule$(purple),$RN$(red),$SN$(dark$blue),$MB$











1 (R) 12.0 3.3 6 120
1 (L) 11.4 3.2 6 103
2 ^ 12.6 3.3 4.5 83
3 15.5 3.5 7.5 113
4 12.6 3.2 6 100
5 11.5 3.3 7.5 126
6 11 2.9 6 103
7 11.2 2.9 7 95








Table&7.2:&Dimensions$ and$ volume$ of$ the$ STN.$ For$mean$ values$ those$ quoted$ are$ mean$





‘FMT Line’ Drawn between the Fornix and Mammillothalamic tract (FMT)
‘STN line’ Drawn across the medial and lateral tips of the STN in the axial plane
‘Midline’ Placed in the midline
‘RN line’ Parallel to the high signal line running between the STN and RN at inferior levels
Table&7.3:&Deﬁnition$of$axes$used$in$studying$the$STN$variability
The$STN$lies$at$a$mean$angle$of$approximately$40$degrees$to$the$midline$ [Table$7.4;$Figure$
7.1].$ The$ medial$ tip$ is$ 6mm,$ the$ lateral$ tip$ 13.5mm,$ the$ midpoint$ 10mm,$ the$ posterior$
boundary$9mm$and$the$anterior$boundary$11mm$to$the$midline.$The$posterior$boundary$lies$
4.3mm$(range$3.3X5.2)$and$the$anterior$boundary$7.5mm$(range$6.1X8.2)$from$the$ centre$ of$
the$ RN$ [Table$ 7.5].$The$ angle$ of$ the$ FMT$ line$ varies$ as$ the$ axial$position$ becomes$more$
inferior$ as$ it$ rotates$ to$ increase$ the$ angle$ between$ itself$and$ the$ STN$and$ midline.$The$
midpoint$of$the$ FMT$ lies$ 3.3X3.5mm$ lateral$to$the$midline.$The$ medial$tip$of$ the$STN$lies$
approximately$3mm$lateral$to$ the$FMT$and$within$1$mm$of$it$ in$the$AP$axis.$The$lateral$tip$



































X X X X X
Sup 42.8$(7.3) 5.8$(1.9) 13.5$(2.0) 9.9$(1.8) 8.9$(1.6) 10.7$(2.0)
Inf 38.1$(3.8) 5.7$(1.3) 13.4$(1.4) 9.7$(1.0) 8.9$(1.2) 11.2$(1.1)
Table&7.4b:&Measurements$relative$to$the$midline
Table& 7.4:&Measurements:$ angles$ (SD)$ in$ degrees,$ otherwise$ linear$measurements$ mean$
(SD)$in$mm.$x$is$distance$medialXlateral;$y$is$distance$anteriorXposterior.
Distance from mid 













STN$and$age$ at$ death.$However,$ with$ duration$of$ ﬁxation$ there$was$ a$ trend$ towards$ an$
increase$ in$ distance$ for$ the$ lateral,$ anterior$ and$ posterior$ borders$ and$ a$ statistically$
signiﬁcant$ increase$ in$ distance$ of$ the$ midpoint$ of$ the$ STN$ from$ the$ midline$ (Pearson$
correlation$coeﬃcient$X0.769,$$p$$=$0.043$for$the$STN$midpoint).$However,$this$relationship$is$
no$ longer$ signiﬁcant$ when$ the$ outlier$ with$ very$ long$ ﬁxation$ time$ is$ excluded$ from$ the$
analysis.
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Figure& 7.9:$ Variability$ of$ the$ position$ of$ the$ STN.$ Scatter$ plots$ on$ the$ left$ include$ the$
measured$locations$of$points$for$all$available$cases$for$superior$and$inferior$levels$examined.$
Scatter$ plots$ on$ the$ right$ show$the$ mean$ position$ relative$ to$ the$midpoint$between$ the$
fornix$ and$mamillothalamic$ tract$ in$ the$ axial $plane.$The$ upper$and$ lower$95%$conﬁdence$
intervals$ are$ also$plotted$using$coordinates$ in$the$xX$and$yXaxis.$Points$plotted$to$give$ the$






We$ have$ described$the$anatomy$of$the$STN,$its$ internal$structure$and$anatomic$variability$
seen$using$high$ﬁeld$MRI,$with$histological$validation.$On$ 9.4T$MRI,$a$ variable$ signal$was$
distinguished$within$ the$STN$in$75%,$reﬂecting$diﬀerences$ in$iron$deposition$as$ conﬁrmed$
by$ Perls$ stain.$ This$ anatomical$ variability$ conﬁrms$ the$ importance$ of$ direct$ STN$
visualisation$when$targeting$it$for$stereotactic$surgical$procedures.
High$ﬁeld$MRI$of$post$mortem$ tissue$ has$ been$used$to$deﬁne$ the$ anatomy$of$ structures$
diﬃcult$ to$ visualise$ on$ clinical$ MRI$ (Silver,$Djalilian$ et$ al.$ 2002;$ Lane,$Witte$ et$ al.$ 2005)$
including$the$STN$(Rijkers,$Temel$et$al.$2007).$The$main$advantages$ of$MR$microscopy$are$
increased$signalXtoXnoise$ ratio$ (SNR),$minimisation$of$movement$artefacts$ and$ the$ ability$
to$image$ in$orthogonal$planes$with$multiple$averages.$This$ enables$a$ signiﬁcant$increase$ in$
spatial$ resolution$ and$ reduced$ partial$ volume$ eﬀects.$ We$ obtained$ inXplane$ resolution$
comparable$ to$ macroscopic$ postXmortem$ examination$ X$ with$ clear$ demarcation$ of$ the$
boundaries$ of$ the$ STN$ and$ visualisation$ of$ small$ structures$ such$ as$ the$ subthalamic$
fasciculus,$the$lenticular$fasciculus$and$the$zona$incerta.
& 1.&STN&borders&and&internal&signal&on&high&ﬁeld&MRI
The$ borders$ of$the$ STN$were$ clearly$ visualised$ in$all$ specimens$ allowing$ straightforward$
diﬀerentiation$ from$ the$ SN.$ At$ 1.5T,$ the$ STN$ returns$ an$ apparently$ homogeneously$
distributed$ hypointense$ signal$ on$T2Xweighted$MRI$ (Bejjani,$ Dormont$ et$ al.$ 2000;$ Hariz,$
Krack$et$al.$2003;$Coenen,$Prescher$et$al.$2008).$This$hypointense$area$may$only$ represent$
one$component$of$the$STN;$another$smaller$component$may$not$be$ visible$on$MRI$or$with$
Perls$ stain$on$histology$ (Dormont,$Ricciardi$et$al.$2004).$In$our$study$at$9.4T,$we$ identiﬁed$
areas$of$signal$variability$within$the$STN$in$75%$of$cases:$a$relatively$hypointense$ area$was$
located$ anteromedially$ and$ a$ relatively$ hyperintense$ area$ was$ located$ posterolaterally$
[Figure$7.2].$The$anatomic$location$of$the$latter$suggests$that$it$corresponds$to$the$area$not$
consistently$ visualised$ at$ 1.5T.$ Perls$ stain$ conﬁrmed$ the$ diﬀerence$ in$ iron$ deposition$




functional$subdivision$of$the$STN$into$three$separate$ territories$–$ the$ limbic$anteromedial$
part,$ the$ associative$midXpart$ and$ the$ sensorimotor$ posterolateral$part.$These$ functional$
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of$our$cases,$with$ histological$ validation,$highlights$ the$ degree$ of$variability$ that$ can$be$
encountered.$ It$ is,$ however,$ important$ to$ note$ that$ it$ is$ not$ clear$ whether$ the$ STN$ as$
visualized$clinically$at$1.5T$represents$a$component$of$the$STN$or$the$complete$nucleus$and$
this$ will $have$ a$ bearing$ on$ targeting$ strategies$ in$ functional$ neurosurgery.$However,$we$




were$able$ to$validate$ a$method$of$targeting$the$PPN$by$ comparing$its$position$as$seen$on$
both$ conventional$ 1.5T$ MRI$ and$ high$ ﬁeld$ 9.4T$ post$ mortem$ MRI,$ with$ macroscopic$




In$our$study,$ the$STN$mean$volume$ of$106$mm3$ (range$ 83X126)$ is$ comparable$ to$previous$
measurements$ of$around$127$mm3$ post$mortem$in$controls$ (the$ quoted$measurement$ of$
254mm3$ is$for$both$sides$together)$(Hardman,$Halliday$et$al.$1997),$120$mm3$ (assuming$that$




into$ paraﬃn$ wax$ there$ is$ marked$ potentially$ nonXuniform$ tissue$ shrinkage$ (Quester$ and$









(Bejjani,$ Dormont$ et$ al.$ 2000).$ This$ is$ the$ region$ of$ the$ STN$ not$ so$ clearly$ seen$ on$





midline$ at$ superior$ levels$ and$ 9.7mm$ lateral$ to$ the$ midline$ more$ inferiorly.$ This$ is$
comparable$ to$ other$ post$ mortem$ data$ (den$ Dunnen$ and$ Staal$ 2005).$ Although$ it$ is$
important$to$note$ that$our$samples$were$not$studied$in$a$ plane$ parallel$to$the$ACXPC$ line,$
this$ variability$ again$ highlights$ the$ importance$ of$ direct$ visualisation$ of$ the$ STN$ for$




in$three$ dimensions$ (Rijkers,$Temel$ et$ al.$ 2007)$ –$ a$ feat$which$ cannot$ be$ performed$with$




improving$our$ability$to$accurately$ identify$the$STN$during$life$ (for$review$see$ (Massey$and$
Yousry$ 2010))$ including$added$susceptibility$ (T2*)$contrast$using$multiple$gradient$echoes$
(Elolf,$Bockermann$et$al.$ 2007),$susceptibility$weighted$imaging$ (Vertinsky,$Coenen$et$al.$
2009)$and$fast$grey$matter$acquisition$T1$inversion$recovery$(Suhyadhom,$Haq$et$al.$2009).$
However$none$ of$these$methodologies$ have$ thus$ far$ been$validated$ by$ comparison$ with$
histological $material.$The$ability$to$image$the$STN$during$life$at$spatial$resolutions$similar$to$
those$ reported$post$mortem$herein$would$provide$ signiﬁcant$progress$ in$both$ localisation$






Many$ studies$ have$ tried$ to$ deﬁne$ the$ substantia$ nigra$ (SN)$using$ conventional$MRI.$This$





Rutledge,$ Hilal$ et$ al.$ 1987;$Drayer$ 1988;$ Drayer$1988).$An$ anterior$and$ medial$ region$of$
signal$hypointensity$was$attributed$to$the$SNr,$and$the$lateral$posterior$region$with$higher$
signal$intensity$to$the$SNc$(Drayer,$Olanow$et$al.$1986).$Only$a$few$studies$performed$direct$
comparison$of$ early$ MR$and$ histological$ images$ (Flannigan,$ Bradley$ et$ al.$ 1985;$ Hirsch,$
Kemp$ et$ al.$ 1989;$ Solsberg,$ Fournier$ et$ al.$ 1990)$ and$ there$ are$ none$ using$more$ recent$
techniques.$The$basis$ for$the$ study$of$the$ anatomy$of$the$ SN$comes$ from$a$paper$in$1986$

















Disorders$ (QSBB),$ UCL$ Institute$ of$ Neurology,$ where$ tissue$ is$ donated$ according$ to$
ethically$approved$protocols$and$is$stored$under$a$licence$from$the$Human$Tissue$Authority.$




FormalinXﬁxed$tissue$was$ dissected$to$produce$a$tissue$ block$ that$included$ the$ substantia$
nigra.$ The$ MR$ axis$ was$ aligned$ perpendicular$ to$ the$ axis$ of$ the$ brainstem$ and,$ after$










2. Superior$ inXplane$ resolution$was$obtained$ in$one$case:$ 1024x1024$matrix$(in$plane$
resolution$44$μm),$132$averages;$other$parameters$as$above,$imaging$time$72$hours.
These$ parameters$ were$ chosen$on$ the$ basis$ of$ pilot$ acquisitions$ to$ yield$optimal$ image$




After$ imaging$ the$ tissue$ blocks$ were$ embedded$ in$ paraﬃn$ and$ serially$ sectioned$ at$ 20$
microns.$ Every$ 20th$ section$was$ stained$with$ Luxol$Fast$ Blue$ and$Cresyl$Violet$ (LFB).$MR$
images$and$LFB$slides$were$visually$compared$and$once$ the$best$match$between$histology$
and$ MRI$ was$ chosen,$ further$ sections$ were$ stained$ with$ Perls$ stain$ for$ iron$ and$
immunohistochemistry$for$substance$P$(SP)$and$calbindin$(CB).$Sections$were$dewaxed$and$
taken$ to$ absolute$ alcohol,$ blocked$ in$ H2O2$ /$ methanol$ for$ 10$ minutes$ and$ washed$ in$
running$ tap$ water.$All $antibodies$ were$ pretreated$by$ pressure$ cooking$ for$10$minutes$ in$
citrate$buﬀer$PH$ 6$and$washed$well$ in$running$tap$water$before$ being$transferred$to$PBS.$
Substance$ P$was$ blocked$ in$ 10%$normal$swine$ serum$ for$10$minutes.$All$ antibodies$were$
incubated$ for$ 1$ hour$at$ room$ temperature$ and$ then$washed$3x$ 5mins$ in$ PBS.$Polyclonal$
antibodies$ were$ incubated$ in$ swine$ anti$rabbit$ $ 1:200$ for$30$mins.$Monoclonal$antibodies$
were$incubated$in$rabbit$anti$mouse$1:200$for$30$mins$and$then$washed$3x$5mins$ in$PBS.$All$
sections$were$ incubated$in$Vector$ABC$for$30$mins$ and$washed$3x$5mins$ in$PBS.$Next,$the$
colour$was$ developed$with$ glucose$ oxidase$ nickel$dab$ solution$ and$ then$washed$ well$ in$
running$ tap$ water.$ Sections$ were$ counterstained$ in$ Mayers$ Haematoxylin$ for$1$ min$ and$
washed$ in$ running$ tap$ water.$ Finally$ they$ were$ dehydrated$and$mounted.$The$ following$
antibodies$ were$ used:$ $ Substance$ P$ (Invitrogen$ Polyclonal;$ 1:50);$ Calbindin$ (Abcam$
Monoclonal;$ 1:400).$ Macroscopic$ images$ were$ obtained$ at$ 20X40x$ magniﬁcation$ using$




2006).$ Reconstructions$ were$ then$made$ using$ the$ mesh$ function,$ and$ measurement$ of$










Once$ the$ anatomy$ was$ demonstrated$ the$ volume,$dimensions$ and$ variability$ in$borders,$
landmarks$ and$internal$anatomy$was$ studied$in$control$and$disease$ cases$ (PD,$PSP)$ at$the$




Twenty$ three$ cases$were$ included$in$the$ study$including$10$controls,$8$PSP$and$5$PD.$$The$
key$ case$ features$ and$ pathological$ diagnoses$ are$ shown$ in$ table$ 1$ and$ group$ data$ and$
measurements$in$table$2.$
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No Gender Side fixed Age DOF (days) Category Pathological diagnosis
1 F Both 94 4149 Control n/a
2* M right 94 51 Control Small vessel disease (severe), Braak & Braak stage IV
3* M right 38 56 Control minimal abeta deposition
4* M left 78 78 Control CAA (moderate)
5 M both 79 1029 Control pathological ageing, mild cvd
6 F Left 82 366 Control pathological ageing, mild svd, mod caa
7 F Right 82 302 Control Pathological ageing, right parietal infarct
8 F Right 72 67 Control MND
9 F Right 99 26 Control B&B IV NFT pathology
10 M Left 89 18 Control n/a
11* M Left 68 54 PSP PSP, Lewy Body Pathology, Pathological Ageing
12* M Right 69 89 PSP PSP, Pathological Ageing
13 M RIght 66 315 PSP PSP 
14 M Right 86 165 PSP PSP, Pathological Ageing, Small haemorrhagic frontal focus
15 M Whole 68 88 PSP PSP, Pathological Ageing
16 M Right 71 51 PSP PSP
17 F Right 75 85 PSP PSP 
18 M Left 67 51 PSP PSP, Acute MCA infarct
19* M Left 79 260 PD PD
20* M Right 83 28 PD PD
21 M Right 70 31 PD PD, Limbic Lewy Body Pathology
22 F Left 62 45 PD PD, neocortical Lewy Body Pathology
23 M Left 71 31 PD
PD, Limbic Lewy Body Pathology, 
Neocortical Lewy Body Pathology, 




Control PSP PD ANOVA
n 10 8 5 R
Gender 5F;'5M 1F;'7M 1F;'4M NS




























































































SP$and$ CB$ immunohistochemistry.$ Case$ 2$ was$ a$ 36$ yr$ old$ male.$ Serial$ axial$ sections$ at$ 1.5$mm$
through$a$single$SN$A:$cartoon$showing$key$anatomical$structures$based$on$SP$and$LFB$for$borders,$
LFB$for$location$of$pigmented$neurons$on$SNc$and$CB$for$nigrosomes.$Pigmented$neurons$are$shown$







LFB:$The$ border$was$ clear$except$superior$and$medially$ [Fig$8.1B$levels$ 1&2]$ where$ there$
were$ ‘interdigitations’$ of$blueXstaining$myelinated$ﬁbres$ and$ regions$ of$ low$LFB$ staining$
[Fig$8.2A&B].$ In$ the$most$ medial $portion$there$ is$ white$ matter$ clustering$which$has$ the$




all$levels].$This$encroached$on$the$myelinated$ﬁbres$ of $the$ corticospinal$tracts$and$AM$[Fig$
8.2B&E]$(see$below).
Immunohistochemistry:$SP$ stain$ deﬁnes$ the$ anterior$ border$by$ staining$ the$ striatonigral$
innervating$ﬁbres$and$is$in$agreement$with$the$LFB$stain$with$ﬁbres$seen$radiating$into$the$
CC$[Fig$8.1E,$Fig$8.2C&F].$This$gives$rise$to$a$linear$appearance$which$interdigitates$with$the$
crus$ cerebri $[Fig$8.1E$levels$1X3].$CB$also$has$ a$serrated$appearance$ at$this$ level$but$gives$ a$
more$uniform$appearance$with$more$dense$staining$medially.
Spin$ echo$ MRI:$ The$ medial$ part$ of$ the$ anterior$ border$ is$ more$ diﬀuse$ but$ lacks$ the$
interdigitating/serrated$appearance$of$the$anatomical$and$immunocytochemistry$[Fig$8.1D$
levels$1X7].$There$ is$ a$hypointense$ rim$(HR)$which$corresponds$ to$the$anterior$border$but$is$
more$prominent$superomedially.$
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Figure) 8.2:$The$ anteromedial$ border$ of$ the$ SN$ at$ superior$ levels.$AXC$ 10x$magniﬁcation;$ DXF$ 2x$
magniﬁcation.$ A$ &$ D$ LFB,$ B$ &$ E$ Perl$ stain,$ C$ &$ F$ SP.$ G$ high$ ﬁeld$ SE$ MRI$ image$ show$ region$
represented$by$histological$ sections.$Lower$and$ higher$ﬁeld$histological$ sections$using$ LFB$and$SP$




The$ posterior$ border$ of$ the$ SN$ is$ somewhat$ controversial$ in$ the$ literature.$ Using$ SP$
immunohistochemistry$ the$ parabrachial$ nucleus$ (Halliday$ 2004)$ or$ gamma$ group$ of$
Olzewski$(Olzewski$1954)$are$excluded$and$this$deﬁnition$has$been$used$for$this$study.$




more$ heavily$ myelinated$ [Fig$ 8.1B$ level$ 6X7].$ At$ midXlevels$ there$ is$ a$ small $ group$ of$
myelinated$ ﬁbres$which$we$have$ termed$posterolateral$white$matter$ (PL)$ [Fig$8.1B$levels$
2X5].$The$ medial$ posterior$ border$ is$ less$ clearly$ deﬁned$but$ at$ its$most$ medial$aspect$ is$
bounded$by$ﬁbres$of$the$third$nerve$in$the$midXlevel$section$[Fig$8.1B$level$5].
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Immunohistochemistry:$SP$ deﬁnes$ the$ border$ in$ correspondance$ with$ LFB$except$ in$ the$
midXlevels$ lateral$portion$where$ there$ is$ a$ small$posterior$protrusion$not$seen$on$LFB$[Fig$





high$ intensity$ band$ adjacent$ to$ the$ RN$and$ a$ region$ of$hypointensity$ bordering$ on$ the$
relative$ hyperintensity$ of$ the$ SN$ itself.$ At$ lower$ levels$ the$ hypointense$ band$ is$ more$
prominent$ corresponding$ to$ the$ increased$ Perl$ staining,$ and$ the$ border$ is$ formed$ by$ a$
hyperintense$band$separating$the$SN$from$the$ML$laterally$[Fig$8.1C&D$levels$6X7].$
& & c)&Lateral&Border
LFB:$The$ lateral$border$of$the$ SN$is$ bounded$by$the$ crus$ cerebri$wrapping$around$the$SN$
[Fig$8.1B$level$1X4]$and$the$abutting$of$the$CC$and$ML$at$lower$levels$[Fig$8.1B$level$5X7].$$


















1. Anterior$Medial$White$Matter$(AM):$ in$the$ anterior$and$medial$SN$there$are$myelinated$
ﬁbres$appearing$in$the$shape$of$a$ ‘hook’$ (H)$[Fig$8.1A&B$levels$1X6].$Clusters$ of$fascicles$
of$WM$staining$blue$ on$LFB$and$with$Perl$stain$are$ seen$within$ the$ SN,$ indicating$that$
they$ are$ a$ site$ of$ iron$ deposition.$ [Fig$ 8.1C$ levels$ 1X6].$ On$ spin$ echo$ MRI$ there$ is$
corresponding$ signal$ hypointensity$ [Fig$ 8.1D$ levels$ 1X6].$ Higher$ ﬁeld$ images$
demonstrate$Perl$staining$as$both$pigment$in$the$neuropil $and$in$clusters$of$white$matter$
[Figure$8.2B&E].
2. Anterior$ Lateral$White$ Matter$ (AL):$ in$ the$ anterolateral$ portion$ of$ the$ SN$ there$ is$ a$
triangular$ region$ containing$ myelinated$ ﬁbres$ [Fig$ 1B$ levels$ 2X5].$ These$ ﬁbres$ have$
higher$Perl$staining$ [Fig$8.1C$ levels$ 2X5]$ and$ are$ seen$as$ hypointense$ on$MRI$ [Fig$8.1D$
levels$2X5].
3. Posterior$Lateral$White$Matter$(PL):$in$the$posterolateral$SN$there$are$myelinated$ﬁbres$









ﬁeld$ SE$ MRI$ it$ appears$ heterogeneously$ with$ a$ hypointense$ rim$ (HR)$ and$ relatively$





&$ Fig$ 8.3].$These$ are$ visible$ on$ the$ LFB$and$Perl$ stained$ sections$ and$ can$be$ deﬁned$ by$
location$ (Hassler$ 1937;$ Gibb,$ Fearnley$ et$ al.$ 1990)$ or$ by$ using$ calbindin$
immunohistochemistry$to$delineate$soXcalled$‘nigrosomes’$where$there$is$relatively$reduced$
calbindin$staining$of$the$neuropil$(Damier,$Hirsch$et$al.$1999)[Fig$8.1A&E$levels$2X7;$Fig$8.3].$
Not$all$ pigmented$ cells$ are$ found$ in$ nigrosomes$ (Damier,$Hirsch$et$ al.$ 1999)$ and$ this$ is$
demonstrated$in$the$cartoon$[Fig$8.1A$levels$2X7].$On$Perl$stain$there$is$less$intense$staining$
within$ the$ nigrosomes,$ particularly$ seen$ at$ lower$ levels$ [Figure$ 8.1C$ levels$ 4X7]$ and$Perl$
staining$is$less$intense$in$nigrosomes$[Fig$8.1C$level$6$&$7].
Nigrosome$ 1$(N1$X$the$ ‘ventrolateral$tier’)$was$seen$in$levels$ 3X7.$It$was$closely$apposed$to$
the$posterior$border$of$AL$[Fig$8.1A&E$levels$3X5]$and$formed$a$solitary$band$in$lower$levels$
[Fig$8.1$A&E$levels$6X7].$On$spin$echo$MRI$it$appears$as$a$hyperintense$band$radiating$across$
from$the$ posterolateral$border$towards$ the$ anteromedial$border$deﬁned$by$ hypointensity$
of$the$AL$on$the$anterior$border$and$a$hypointense$band$on$the$posterior$border$particularly$
medially$where$the$‘hook’$formed$by$the$AM$was$seen$[Fig$8.1A&D$levels$3X7].$
Nigrosome$ 2$ (N2$ X$ the$ pars$ medialis)$ was$ seen$ at$ all$ levels$ where$ pigmented$ cells$ were$
found$[Fig$8.1A&E$levels$2X7]$at$the$most$posterior$and$medial$tip$of$the$SN.$This$was$not$so$
clearly$seen$on$spin$echo$MRI.$There$is$relative$signal$hyperintensity$at$the$most$medial$and$
posterior$ tip$ but$ this$ does$ not$ directly$ correspond$ to$ the$ size$ and$ shape$ of$ the$ region$






Nigrosome$4$(N4$X$the$ ‘dorsolateral$tier’)$was$ seen$in$ levels$ 3$&$4.$It$abutted$the$ posterior$
border$ of$ the$ SN$ and$ the$ PL$ [Fig$ 8.1$ levels$ 3&4].$On$ spin$ echo$ MRI$ it$ appeared$ as$ a$
hyperintense$ band$ posterior$ to$ N1$ and$ bounded$ by$ the$ signal$ hypointensity$ of$ the$
parabrachial$nucleus$immediately$adjacent.
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Figure) 8.3:$The$ internal$anatomy$of$ the$SN$using$LFB$and$ CB$ immunohistochemistry.$LFB$and$CB$
stains$delineating$the$anatomy$of$the$nigrosomes$within$ the$SN$at$axial$ levels$as$per$ ﬁgure$1.$At$ the$
`superior$ level$ (2)$ anterior$ and$ medial$ SN$ represents$ a$ regions$ without$ neuromelanin$ containing$
neurons$and$is$the$SNr.$At$the$lower$levels$represented$(3,$5,$6)$clusters$of$neurons$are$seen$both$on$
LFB$ and$ CB$ immunohistochemistry. $On$CB$ stain$ regions$ of$ relative$ CBXpoor$ stain$ are$ designated$
nigrosomes$(Damier,$Hirsch$et$al.$1999).
Nigrosome$5$(N5)$was$found$at$the$most$superior$level$where$pigmented$cells$were$found$
only$ [Fig$ 8.1A&E$ level$ 2].$ This$ was$ seen$ on$ conventional$ MRI$ as$ a$ region$ of$ signal$
hyperintensity$between$the$AL$and$PL.
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On$spin$echo$MRI$N1$and$N4$in$ the$ lateral$SNc$give$ the$appearance$ of$a$ spin$echo$signal$
hyperintense$ ‘pincer’$grasping$a$ spin$echo$signal$hypointense$ ‘hook’$ corresponding$to$the$
Perl$staining$AM.$
& 7.&Sagittal&and&coronal&plane&images





In$ the$ coronal$ plane$ the$ superomedial$ border$ is$ deﬁned$ by$ a$ hypointense$ rim$ (HR)$
separating$ it$from$the$STN$in$ the$ superior$half;$ in$the$ inferior$half$it$ is$separated$from$the$




the$anterior$portion$of$the$ midbrain$ posterior$to$ the$CC$ and$anterior$to$the$STN,$RN$and$
DSCP.$ It$ lay$ at$ an$ oblique$ angle$ in$ all$ three$ planes:$ in$ the$ axial$ plane$ the$ SN$ was$
approximately$40$degrees$ from$the$midline$at$the$ level$of$the$STN$and$RN,$and$30$degrees$






was$ no$ signiﬁcant$diﬀerence$ between$PD$ and$controls$ [Table$ 8.2].$The$SN$is$ most$broad$
and$deep$at$ the$ level$of$the$ RN$(mean$width$11.72mm;$mean$depth$2.99mm),$tapering$at$






The$ anterior$border$was$more$ clearly$deﬁned$laterally$with$haziness$ in$the$medial$section$
with$heavy$deposition$of$iron$and$WM,$SP+$ﬁbres$ invaginating$into$the$CC$ in$controls,$PD$
and$PSP$[Figs$ 8.2,$8.5X8.7,$table$ 8.3].$This$was$also$ true$on$SE$MRI$ in$controls$ and$PD$ [Fig$










































































































































































































































































The$ pigmented$ neurons$ of$ N1$ are$ clearly$ seen$ within$ a$ region$ of$ reduced$ Perl$ staining$ and$ as$ a$






associated$with$ increased$Perl$stain$in$controls.$ In$the$disease$ group$the$nigrosomes$were$
192
much$less$densely$populated$with$pigmented$neurons$in$PD$[Fig$8.6$A$&$E]$[Tabl3$8.3].$In$PD$
the$nigrosomes$ looked$thick$and$pale$ [Fig$8.66$C$&$G];$in$PSP$ thin$and$streaky$with$dense$
Perl$ staining$ [Fig$ 8.7$ B$ &$ F].$ On$ SE$ MRI,$ nigrosomes$ were$ paler$ in$ PD$ but$ still$mostly$




and$white$matter$landmarks$are$present$and$ subjectively$and$objectively$do$ not$appear$ to$have$lost$





69$ yr$ old$male$ [EXH].$A$&$E:$LFB.$B$&$F:$Perl$stain.$C$&$G:$high$ﬁeld$SE$MRI.$D$&$H:$SP.$The$whole$
structure$is$markedly$atrophic$as$exempliﬁed$by$the$reduced$volume$measurements$and$the$reduced$


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































this$ with$ post$mortem$ histological$ tissue$ in$ the$ same$ specimens.$The$ anterior$border$ is$
more$clearly$delineated$ laterally$and$inferiorly$and$there$ is$an$intermingling$of$the$SN$and$
CC$ particularly$ anteriorly$ and$medially$at$the$most$superior$levels$ characterised$by$ higher$
iron$ deposition$ on$Perl$ staining$ and$ a$ serrated$ edge$ on$ SP$ immunohistochemistry.$ The$
posterior$border$ is$ formed$ by$ white$ matter$ lying$between$the$ SN$and$RN$ in$ the$medial$
aspect$and$the$SL$and$ML$in$the$lateral$aspect$and$is$mostly$hypointense.$The$hyperintense$
band$described$in$the$ literature$ is$more$ posterior,$ abutting$ the$ RN$and$ forms$ part$of$the$
PBN$[Fig$8.1$B$&$D$levels$3X5].$We$describe$three$bundles$of$white$matter$on$histopathology$





posterior$ border$ from$ the$ STN.$ $ The$ SNc$ is$ deﬁned$ by$ the$ position$ of$ the$ pigmented$
neuromelanin$ positive$ neurons.$ By$ using$ immunohistochemistry$ for$ CB$we$ are$ able$ to$
describe$ the$ accurate$position$of$Damier’s$ nigrosomes$ (Damier,$Hirsch$et$al.$ 1999).$These$
are$ seen$on$high$ ﬁeld$SE$MRI$as$ hyperintense$ regions$ whose$ position$ can$be$ clariﬁed$ by$
reference$ to$ the$white$matter$landmarks$AM,$AL$and$PL.$ In$controls$the$AM$white$matter$
landmark$forms$ a$hypointense$ hook$ appearance,$and$the$combination$of$high$signal$from$













based$on$histopathological$ﬁndings$in$the$ same$tissue$ rather$than$the$ presumed$anatomy$
based$ upon$atlas$ comparisons.$By$using$post$mortem$ tissue$we$ were$not$ constrained$ by$
movement$artifacts$or$problems$with$time$such$as$heating$and$patient$tolerability$meaning$
that$we$ could$ acquire$ multiple$ averages$ to$ increase$ signalXtoXnoise$ ratio$ and$ at$ high$ inX
plane$resolution.$At$the$same$time$this$is$also$a$limitation$in$that$the$times$we$have$used$are$
not$practical.$Furthermore,$there$are$ signiﬁcant$diﬀerences$between$imaging$post$mortem$
tissue$ at$ room$ temperature$ when$ compared$ to$ imaging$ the$ brain$ in$ vivo$ at$ 37$ degrees$
including$diﬀerences$ in$physical$properties$ such$as$the$ relaxation$times,$and$diﬀerences$ in$
measurements$ due$ to$ asymmetric$ tissue$ shrinkage$ during$ the$ ﬁxation$ process.$ The$
histopathological$ protocol$ at$ the$QSBB$ﬁxes$ half$ of$ the$ brain$ with$ the$ other$ frozen$ for$
biochemical$ studies$ so$ asymmetries$ and$ study$ of$ the$ side$ contralateral$ to$ the$ clinically$
worst$ aﬀected$ side$ could$ not$be$ undertaken.$Additionally,$ our$ sample$ size$ is$ necessarily$
small $due$to$the$contraints$of$working$with$post$mortem$tissue$and$practical$considerations$
in$ terms$ of$ time$ both$ in$ terms$ of$ imaging$ time$ available$ and$ the$ burden$ imposed$ for$
technical$support$for$tissue$processing,$cutting$and$staining$serial$slides$for$analysis.
& 5.&The&intricate&anatomy&of&the&SN
The$anatomy$of$the$SN$is$ highy$complex:$ it$is$ comprised$not$only$ of$the$SNr$and$SNc$but$
the$SNc$ is$ comprised$ of$an$ intricate$network$ of$neurons$ segregated$ into$functionally$ and$
anatomically$distinct$groups.$Not$only$ does$ it$lie$ in$a$busy$environment$but$as$ can$be$ seen$
from$ the$ serial$ axial$ sections$ [Fig$ 8.1]$ it$ varies$ in$ its$ dimensions$ and$ the$ internal$
organisation$ throughout$ its$ course.$ The$ internal$ organisation$ has$ been$ the$ subject$ of$
debate$ in$the$ literature$ for$some$ time$(Hassler$1937;$Olzewski$1954;$German,$Manaye$et$al.$
1989;$ Fearnley$ and$Lees$ 1991;$Gibb$ and$Lees$ 1991;$Gibb$1992;$McRitchie,$Halliday$ et$al.$
1995;$McRitchie,$Hardman$ et$ al.$ 1996;$Damier,$Hirsch$ et$ al.$ 1999)$ and$ diﬀerences$ in$ the$
angle$ of$ cut$ can$ have$ eﬀects$ on$ the$ results,$ such$ is$ the$ variability.$At$ the$ current$ time$
conventional$imaging$of$the$ brainstem$ is$ too$ insensitive$ to$pick$up$some$ of$the$ subtleties$
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and$ this$ likely$ explains$ the$ heterogeneity$of$ the$ results$ of$clinical$ studies,$along$with$ the$
fact$the$the$anatomy$on$MRI$has$not$yet$been$clearly$validated.
Inconsistencies$ in$ the$ description$of$ the$ SN$on$ conventional$MRI$has$ been$noted$ before$
using$ conventional$MRI$(Savoiardo,$Girotti$et$al.$1994;$Gorell,$Ordidge$ et$al.$1995;$Adachi,$
Hosoya$ et$ al.$ 1999;$Martin,$Wieler$et$al.$ 2008;$ Massey$ and$Yousry$ 2010).$Apart$ from$ the$
seminal$ paper$ of$Oikawa$ et$ al$ there$ have$ been$ few$ studies$ looking$ at$ the$ pathological$
conﬁrmation$ of$ the$ representation$ of$ the$ SN$on$ MRI$ (Oikawa,$ Sasaki$et$ al.$ 2002).$ As$ a$
consequence$ of$this,$may$early$ studies$have$been$based$on$a$presumed$understanding$of$
the$anatomy$on$conventional$MRI$(Duguid,$De$La$Paz$et$al.$1986;$Rutledge,$Hilal $et$al.$1987;$




but$ without$ pathological $ conﬁrmation.$ HighXresolution$ 3T$ imaging$ sensitive$ to$ the$
paramagnetic$ eﬀects$ of$ neuromelanin$ shows$ signal$ hyperintensity$ in$ the$ SN$ (Sasaki,$
Shibata$et$al.$2006).$ $Mulitshot$diﬀusionXweighted$MR$imaging$with$a$left$to$right$diﬀusion$
direction$ gradient$ may$ deﬁne$ the$ borders$ of$ the$ SN$ better$ than$T2$ weighted$ imaging$
(Adachi,$ Hosoya$ et$ al.$ 1999).$ Other$ published$ techniques$ to$ delineate$ the$ SN$ include$
DESPOT1$ (Menke,$ Jbabdi$ et$ al.$ 2010),$ relaxometry$ (Ordidge,$ Gorell$ et$ al.$ 1994;$Gorell,$
Ordidge$ et$al.$ 1995;$Martin,$Wieler$et$al.$ 2008;$ Peran,$Cherubini$et$al.$ 2010),$ segmented$
inversion$ recovery$ imaging$ (SIRRIM)$ (Hutchinson,$ Raﬀ$et$ al.$2003;$Raﬀ,$Hutchinson$et$al.$






in$ high$ signal$ intensity$ in$ PD$ are$ encouraging$ signs$ of $ detecting$ diﬀerences$ but$ the$
pathological$correlate$ of$this$ is$ not$ clear.$While$ we$did$not$study$ this$ particular$ feature$ in$
our$work,$using$SE$MRI$we$did$not$see$dramatic$diﬀerences$between$control$and$PD$groups$
X$in$accordance$with$much$of$the$ literature.$However,$when$compared$to$PSP$ there$was$ a$
clear$ subjective$ diﬀerence$ in$ appearance$ of$ the$ SN$ which$ is$ not$ reliably$ evident$ on$
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conventional$MRI,$although$diﬀerences$have$ been$reported.$The$undulation$of$the$anterior$




CB$ immunohistochemistry$ has$ enabled$ us$ to$ deﬁne$ nigrosomes$ on$ our$ histological$




absent$ in$ PD$ the$ SE$ MRI$ high$ signal$ remains$ [Figure$ 8.6].$ This$ is$ in$ keeping$ with$
pathological$work$where$ the$ nigrosome$ structure$ is$ maintained$even$in$the$ face$ of$loss$ of$
pigmented$SNc$cells$(Damier,$Hirsch$et$al.$1999).$ $This$ is$interesting$the$context$of$much$of$
the$published$literature$on$ the$ SN$in$PD.$Many$ studies$have$ tried$ to$detect$diﬀerences$ in$
the$traditionally$deﬁned$SNc$(Duguid,$De$La$Paz$et$al.$1986)$using$conventional$MRI.$There$
are$ reports$ of$ reduced$width$ (Duguid,$De$ La$ Paz$ et$ al.$ 1986;$ Braﬀman,$ Grossman$ et$ al.$
1989;$ Stern,$Braﬀman$ et$al.$ 1989;$ Pujol,$ Junque$ et$ al.$ 1992;$Yagishita$ and$Oda$ 1996)$ or$
smudging$of$the$SNr$hypointensity$ (Drayer$1988;$Savoiardo,$Strada$ et$al.$1989;$Savoiardo,$




Using$ multishot$ diﬀusionXweighted$ MR$ imaging$ to$ deﬁne$ the$ borders$ of$ the$ SN$more$
clearly$ also$did$not$ show$a$ reduced$SN$width$ in$PD$ (Adachi,$Hosoya$ et$ al.$ 1999),$or$ PDX
weighted$ or$ fast$ SITR$ images$ (Oikawa,$ Sasaki$et$ al.$ 2002).$However,$ this$ is$ not$ greatly$
surprising$as$although$there$is$clearly$huge$loss$of$neuromelanin$containing$pigmented$cells$
in$the$SNc$in$PD$(Fearnley$and$Lees$ 1991;$Hardman,$Halliday$ et$al.$1997;$Ma,$Roytta$ et$al.$
1997)$ the$ pathological$ literature$ points$ to$ the$ fact$ that$ the$ volume$ of$ the$ SN$does$ not$
reduce$in$PD$ (Ma,$Roytta$ et$al.$1997).$In$fact,$pathological$data$ in$aging$(Cabello,$Thune$ et$
al.$ 2002)$ and$ a$ recent$ imaging$ study$ in$ PD$ (Kwon,$ Kim$et$ al.$ 2012)$ suggest$ that$ it$ may$
paradoxically$ increase$ in$size.$The$explanation$for$this$ is$ unclear$but$it$seems$ fairly$ certain$
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that$SN$atrophy$should$not$be$expected$in$PD.$Our$data$supports$this$idea$X$both$in$terms$of$
the$absolute$measured$volume$ not$being$signiﬁcantly$diﬀerent$ from$ controls$ in$PD$ [Table$
8.2],$and$in$the$appearance$of$the$SN$in$the$ axial$plane$having$preserved$width$and$depth$
both$ subjectively$ [Figure$ 8.6]$ and$ on$ formally$measuring$ it$ [Table$ 8.2].$Therefore,$ other$
methods$ of$determining$ongoing$ Lewy$ body$ pathology$ are$ needed$ if$ we$ are$ to$ expect$
positive$results$in$the$SN.$More$recently,$studies$have$shown$a$regional$predilection$of$PD$in$
the$SN$using$DTI$region$of$interest$studies$ (Chan,$Rumpel$et$al.$2007;$Vaillancourt,$Spraker$
et$ al.$ 2009;$ Peran,$Cherubini $et$ al.$2010)$ in$agreement$ with$ the$ pathological$ topography$
(Fearnley$ and$ Lees$ 1991).$However,$ subsequent$studies$ have$ not$conﬁrmed$ this$ (Menke,$
Scholz$et$al.$2009).$
In$ PSP$ the$ story$ is$ diﬀerent$ in$ that$ far$ greater$ destruction$ of$ the$ borders$ and$ internal$
architecture$of$the$SN$is$ found$with$ loss$ of$the$nigrosomal$SE$MRI$hyperintensity$ [Figure$
8.7,$Table$8.3$&$8.4].$This$is$manifest$as$a$ reduced$volume$which$is$consistent$with$both$the$
pathological$literature$where$PSP$aﬀects$both$SNr$and$SNc$(Hardman,$Halliday$et$al.$1997),$
and$ imaging$ literature$ where$ a$ smaller$SN$ has$ been$described$using$multishot$ diﬀusionX




There$ are$ many$ unanswered$ questions.$ There$ is$ very$ little$ information$ about$ the$
heterogeneity$of$iron$deposition$in$the$SN$and$the$anterior$border$of$the$SN$and$the$precise$
location$ of$ the$ iron,$ or$ its$ role$ in$ the$ pathogenesis.$The$ precise$ anatomical$ correlate$ of$
signal$hyperintensity$on$SE$MRI$ in$the$ region$of$the$nigrosomes$ is$ not$clear$but$it$appears$
not$ to$ be$ the$ pigmented$ neurons$ of$the$ SNc,$ as$ already$ discussed.$The$ best$method$ to$
study$the$anatomy$of$the$SN$is$also$unclear$X$iron$is$ clearly$ important$in$the$pathogenesis$
and$ so$ ironXsensitive$ techniques$ such$ as$T2*$and$SWI$should$be$ employed;$ but$ we$ have$
shown$ that$iron$ strays$ outside$ the$ SN$proper$ and$may$ be$misleading$ in$determining$ the$
boundary$of$the$SN.$Further$studies$are$needed$to$answer$some$of$these$ questions$ and$in$







tissue.$The$ nigrosomes$ are$ seen$using$this$ technique$ and$preserved$in$PD$but$not$PSP,$ in$







Accurate$ clinical$ diagnosis$ of$ neurodegenerative$ diseases$ presenting$ with$ parkinsonism$
progressive$supranuclear$palsy$(PSP)$or$multiple$system$atrophy$(MSA)$can$be$diﬃcult.$Post$
Mortem$series$show$that$only$84.2%$of$PSP$cases$and$88.2%$of$MSA$cases$may$be$correctly$




Nevertheless,$ there$ is$ distinct$neuropathological$topography$X$the$ key$ features$of$PSP$are$
atrophy$and$deposition$of$tau$in$the$midbrain,$subthalamic$nucleus$(STN),$substantia$nigra$
(SN),$globus$ pallidus$ (GP),$ superior$cerebellar$peduncles$ (SCPs)$ and$dentate$nucleus$ (DN)$
which$are$most$severely$aﬀected$(Tsuboi,$Slowinski $et$al.$2003;$Williams,$Holton$et$al.$2007);$
in$ MSA$ alpha$ synuclein$ containing$ glial $ cytoplasmic$ inclusions$ are$ found$ in$ the$ SN,$
dorsolateral$ putamen$ and$ pontine$ base,$ middle$ cerebellar$ peduncles$ (MCPs)$ and$
cerebellum$(Ozawa,$Paviour$et$al.$2004).$
Conventional$MRI$ ﬁndings$ in$ PSP$ and$MSA$ are$ speciﬁc,$ but$ sensitivity$ is$ low$ (50X67%$ )$
(Massey,$Micallef$et$al.$ 2012).$RegionXof$interest$ (ROI)X$ based$ studies$ of$ quantitative$ MR$
techniques$such$as$diﬀusion$tensor$imaging$(DTI)$have$clinical $utility$(Stamelou,$Knake$et$al.$
2011)$and$may$reveal$ $abnormalities$ in$the$absence$of$changes$on$conventional$MR$images$
in$MSA$ (Seppi,$Scherﬂer$et$ al.$2006;$Seppi,$Schocke$ et$al.$2006).$However,$this$ approach$




Focal$ grey$ (GM)$ and$ white$ matter$ (WM)$ loss$ can$ be$ assessed$ with$ voxelXbased$
morphometry$ (VBM)$ (Ashburner$and$Friston$2000)$ and$microstructural$disruption$ of$WM$

















This$ study$ was$ approved$ by$ the$ local$ ethics$ committee$ and$ research$ and$ development$
department$ at$ UCL/UCLH$ Biomedical$ Research$ Centre.$ Written$ informed$ consent$ was$
obtained$ in$ 48$ participants$ who$ had$ 3T$ MRI$ $ (Siemens$ Tim$ Trio;$ Siemens,$ Erlangen,$
Germany):$ 20$ healthy$ controls,$ and$ 18$ PSP$ and$ 10$ MSA$ patients$ fulﬁlling$ research$
diagnostic$ criteria$ (Litvan,$ Agid$ et$ al.$ 1996;$ Gilman,$ Low$ et$ al.$ 1999).$ Twenty$ healthy$








Volumetric$T1Xweighted$images$ (3DXMPRAGE;$time$ to$repetition$(TR)$ /$ time$ to$echo$(TE)$/$




resolution$ 2mm)$ were$ acquired.$ Prior$ to$ analysis$ data$ were$ screened$ for$ movement$
artefact.$
3.&MRI&Analysis
DARTELIVBM% analysis:$T1$ MPRAGE$ data$ were$ processed$ in$SPM8.$ Firstly,$ they$ were$
manually$ reorientated$ and$ then$ underwent$ ‘uniﬁed’$ segmentation$ which$ combines$
segmentation,$bias$ correction$and$template$normalisation$ in$one$step$(Ashburner$and$
Friston$ 2005).$ The$ resulting$ WM$ and$ GM$ tissue$ segments$ from$ all$ subjects$ were$
processed$with$DARTEL$(Diﬀeomorphic$Anatomical$Registration$Through$Exponential$




model$ in$SPM8$using$age$and$total$intracranial $volume$ (computed$as$ the$ sum$of$GM,$




TBSS:$Voxelwise$ analysis$ of$DTI$data$ was$ carried$out$using$TBSS$ (TractXBased$spatial$
statistics$ (Smith,$ Jenkinson$ et$ al.$ 2006),$ part$ of$ FSL$ (Functional$ MRI$ of$ the$ brain$
(FMRIB)$ Software$ Library)$ (Smith,$ Jenkinson$ et$ al.$ 2004).$ DWI$ data$ were$ processed$
using$ the$ FDT$(FMRIB’s$Diﬀusion$Toolbox)$ in$FSL$ (Smith,$Jenkinson$et$al.$2006).$First,$
fractional$anisotropy$ (FA)$ and$mean$diﬀusivity$ (MD)$ images$were$ created$by$ﬁtting$ a$
single$ tensor$model$to$the$ raw$diﬀusion$data$using$FSLXFDT,$and$then$brainXextracted$
using$ the$ brain$ extraction$ tool$ (FSLXBET).$ Radial$diﬀusivity$ (RD)$ and$ axial$diﬀusivity$
(AD)$were$ calculated$and$then$FA,$MD,$RD$ and$AD$ data$were$aligned$ into$ a$common$




al.$ 1999).$ Next,$ the$ mean$ FA$ image$ was$ created$ and$ thinned$ to$ create$ a$ mean$ FA$
skeleton$which$ represents$ the$ centres$ of$ all $ tracts$ common$ to$ the$ group.$ Data$ was$






When$a$ statistically$ signiﬁcant$relationship$was$ found$ between$disease$ group$and$WM$or$
GM$ loss,$ or$FA$or$MD,$ it$was$ tested$ for$ correlation$with$disease$ severity$ as$ measured$ by$
disease$ duration$or$ clinimetric$ score.$Age$ was$ used$ as$ a$ covariate$ in$ the$ analysis.$ Using$
SPM8$ for$DARTELXVBM$ data$ the$ whole$ brain$ result$ was$ adjusted$ using$ a$ smallXvolume$















































































*UPDRS$ II$ signiﬁcantly$ greater$ in$ MSA$ than$ PSP$ (p$ <$ 0.05);$ **UPDRS$ III$ signiﬁcantly$
greater$in$MSA$ than$PSP$ (p$<$0.05);$ ***FAB$signiﬁcantly$ lower$ in$PSP$ than$ in$MSA$ (p$<$
0.05).
FortyXeight$cases$ were$ included$ in$the$ analysis$ in$ 44$ of$which$both$VBM$ and$TBSS$were$
performed;$ in$ 2$artefactXfree$ DTI$ data$ were$ unavailable$ for$TBSS,$ and$ in$a$ further$2$T1X
volumetric$ data$ exhibited$ an$ unacceptable$ level$ of$motion$ artefact$ leaving$ 46$ in$ each$
group.$ Of$ the$ 18$ PSP$ participants$ 15$ were$ clinically$ classiﬁed$ as$ probable$ PSP,$ and$ 3$
possible$PSP.$Of$the$10$MSA$participants$8$were$of$the$MSAXP$phenotype$(1$possible$MSA,$7$
probable$MSA),$2$of$the$MSAXC$phenotype$ (1$possible$MSA,$1$probable$MSA).$There$were$





(p$<$0.001)$[table$9.2;$ﬁgure$9.1C,$G,$I,$K].$There$was$extensive$volume$ loss$ in$the$ following$
regions$ classiﬁed$ as$WM:$ the$ dentate$ nucleus,$SCPs,$ pontine$ and$midbrain$ tegmentum,$
region$of$the$SN$and$STN,$crus$cerebri,$thalamus,$and$GP$(p$<$0.001)[table$9.2;$ﬁgure$9.1AX
C,$F,$IXK].$
TBSS:%extensive$ symmetrical$WM$ FA$ reduction$was$ found$near$ the$ dentate$ nuclei,$SCPs,$
decussation$of$ the$SCPs,$the$ corpus$ callosum$(sparing$ the$ splenium),$the$anterior$ limb$of$
the$ internal$capsule,$and$WM$throughout$the$ frontal,$parietal $and$occipital$lobes$ including$
the$olfactory$tracts,$superior$longitudinal$fasciculi$and$forceps$major$and$minor.$There$was$
relative$ sparing$ of$ the$ posterior$ limb$ of$ the$ internal$ capsule,$ the$ external$ capsule,$ the$
corticospinal$ tracts,$ the$ MCPs$ and$ the$ WM$ of$ the$ temporal$ lobes$ [Table$ 2;$ ﬁgure$ 1].$
























































































































































































































































































DARTELIVBM:%GM$loss$was$ seen$in$the$ right$caudate$ nucleus,$anterior$ right$putamen$and$
inferior$ cerebellar$ hemispheres$ (p$ <$0.001)$ and$ there$ was$ a$ trend$ to$GM$ loss$ in$ the$ left$
anterior$putamen$ and$ caudate$ head$ (p=0.052)$ [table$ 2];$ there$ was$ patchy$ cerebellar$GM$
loss$ [table$ 2;$ ﬁgure$ 2A,$ B,$ E,$ I].$ There$ was$ extensive$ symmetrical$ volume$ loss$ in$ the$
following$regions$classiﬁed$as$WM:$the$cerebellar$WM,$MCPs,$pontine$base$(relative$sparing$
of$the$tegmentum)$[Figure$2A,$B,$E,$F,$IXK],$and$in$the$region$of$the$posterolateral$putamen$
and$surrounding$WM$including$the$ external$capsule$ and$the$ posterior$ limb$ of$the$ internal$
capsule$(p$<$0.001)$[Table$2;$ﬁgure$2C,$G].$
TBSS:%Reduced$FA$was$ found$symmetrically$in$ the$ deep$cerebellar$WM,$inferior$cerebellar$
peduncles,$MCPs,$ pontocerebellar$ crossing$ ﬁbres,$ corticospinal$ tracts$ (at$ the$ level$ of $the$
pons),$ right$ SCP,$ body$ of$ the$ corpus$ callosum$ (midXportion$ and$ forceps$ minor)$ and$
corticospinal$ tract$ in$ the$ precentral$ gyrus$ [Table$ 2;$ Figure$ 2].$ There$ was$ no$ statistically$
signiﬁcant$MD$increase$in$MSA,$but$there$were$trends$suggestive$of$changes$in$the$left$MCP$
and$deep$cerebellar$WM,$the$midXportion$of$the$corpus$callosum,$the$external$capsule,$both$




























































































































































































































































































Disease$ severity$ in$ PSP$ as$ measured$ by$ the$ PSPRS$ correlated$ $ with$ midbrain$ atrophy$
[Figure$ 9.3A]$ and$disease$ duration$with$FA$ reduction$ in$the$ parietal$WM$ [Figure$ 3B].$The$
PSPRS$ score$ also$ correlated$ with$MD$ increase$ in$ the$ frontal$ white$ matter$ and$ anterior$
corpus$callosum$[Figure$9.3C].
Figure&9.3:$Correlation$of$quantitative$MRI$with$clinimetric$scores$and$disease$duration.$A:$
WM$ loss$ correlating$ with$ PSPRS$ in$ PSP$ (uncorrected$ p$ value$ <0.001$ with$ clusterXlevel$
nonstationary$ correction$p$ value$ <$ 0.05);$ B:$ signiﬁcant$ reduction$ in$ FA$ in$PSP$correlating$
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TBSS$showed$ involvement$of$frontal$white$matter$tracts$ and$more$extensive$ involvement$
of$WM$ in$ the$ parietoXoccipital$ lobes$ (in$ PSP)$ in$ areas$ where$ VBM$ did$ not$ show$ any$
diﬀerences$ compared$ to$ controls.$DTI$ is$ sensitive$ to$microstructural$damage$ which$ may$
become$ evident$ before$ atrophy$ is$ signiﬁcant$ enough$ to$ be$ detected$ either$ by$ standard$









Focke,$ Helms$ et$ al.$ 2011).$ Other$ regions$ such$ as$ the$ cerebral$ peduncles$ are$ frequently$
atrophic$ (Brenneis,$Seppi$et$ al.$ 2004;$ Price,$Paviour$ et$ al.$ 2004;$ Josephs,$Whitwell$ et$ al.$
2008;$Agosta,$Kostic$et$al.$ 2010;$Focke,$Helms$et$al.$2011)$ and$WM$ loss$ in$the$ SCP$ (Price,$
Paviour$et$al.$ 2004;$Agosta,$ Kostic$et$al.$ 2010),$external$capsule$ (Josephs,$Whitwell$et$al.$




at$ post$mortem$and$during$life$on$MRI$ (Tsuboi,$Slowinski$et$ al.$2003;$ Paviour,$Price$et$al.$
2005;$Slowinski,$Imamura$et$al.$2008).$GM$loss$ in$the$ head$of$the$ caudate$nucleus$ and$the$
anterior$putamen$has$also$been$reported$(Brenneis,$Seppi$et$al.$2004;$Price,$Paviour$et$al.$
2004;$Cordato,$Duggins$et$al.$2005;$Josephs,$Whitwell$et$al.$2008;$Agosta,$Kostic$et$al.$2010;$
Josephs,$Whitwell$et$al.$ 2011).$We$ did$not$ﬁnd$ cortical$GM$ loss$ in$concordance$ with$ $ an$
earlier$VBM$ study$ in$ PSP$ (Price,$ Paviour$et$al.$ 2004),$although$ other$ investigators$ $ have$
variably$found$cortical$volume$loss$in$speciﬁc$regions,$including$the$insular$cortex$(Brenneis,$
Seppi$et$al.$2004;$Agosta,$Kostic$ et$al.$2010),$orbitofrontal$cortex$ (Cordato,$Duggins$ et$al.$
2005;$ Agosta,$ Kostic$ et$ al.$ 2010),$ hippocampus$ (Agosta,$ Kostic$ et$ al.$ 2010)$ and$
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parahippocampal$gyrus,(Padovani,$Borroni$et$al.$2006)$premotor$cortex,(Padovani,$Borroni$
et$ al.$ 2006;$ Josephs,$Whitwell $ et$ al.$ 2008;$ Focke,$ Helms$ et$ al.$ 2011)$ frontal$ operculum$
(Brenneis,$Seppi$et$ al.$2004;$Cordato,$Duggins$ et$ al.$ 2005;$ Boxer,$Geschwind$ et$al.$ 2006;$
Padovani,$Borroni$et$al.$2006)$and$supplementary$motor$area$(Brenneis,$Seppi$et$al.$2004;$
Josephs,$Whitwell$et$al.$2008;$Whitwell,$Avula$et$al.$2011).
Post$mortem$ studies$ indicate$ that$ cortical$ involvement$ in$ PSP$ is$ commonly$milder$ than$
subcortical$ frontal$ atrophy$ (Dickson$ 1999;$ Dickson,$ Rademakers$ et$ al.$ 2007;$ Williams,$
Holton$ et$ al.$ 2007).$ However,$ $ biochemical$ mapping$ using$ Western$ blot$ analysis$ of$
pathological$ tau$ has$ demonstrated$ widespread$ deposition$ in$ neocortical$ areas$ with$ a$
frontal$predilection$(Vermersch,$Robitaille$ et$ al.$1994).$Precentral $gyrus$ involvement$may$
lead$ to$ a$ primary$ lateral$ sclerosis$ phenotype,$ frontal$ and$ parietal$ association$ cortex$
involvement$ to$ a$ corticobasal$ syndrome$ and$ frontal$ tau$ deposition$ to$ the$ behavioural$
variant$ of$ frontoXtemporal$ dementia$ (Dickson,$ Ahmed$ et$ al.$ 2010).$This$ variability$ may$
explain$ diﬀerences$ in$ neuroradiological$ ﬁndings$ in$ the$ literature.$ Our$ study$ was$ not$
designed$ to$detect$the$ regional$variations$ in$ the$ subtypes$ of$PSP$ although$ others$ report$
diﬀerences$ between$Richardson’s$ syndrome$ and$ PSPXP$ (Agosta,$ Kostic$ et$ al.$ 2010)$ and$
cognitive$ and$ extrapyramidal$ predominant$ pathologically$ conﬁrmed$ PSP$ (Josephs,$
Whitwell$et$al.$2008).
& & b)&TBSS&in&PSP




frontal$ white$ matter$ tracts$ could$ provide$ an$ explanation$ for$ $ the$ ‘subcortical’$ frontalX
dysexecutive$syndrome$in$PSP.$A$white$matter$process$ is$supported$by$the$fact$that$the$tau$
protein$is$ involved$in$axonal$transport$and$abundant$tau$is$ found$in$WM$using$Western$blot$
(Zhukareva,$ Joyce$ et$ al.$ 2006).$ An$ alternative$ explanation$ for$ WM$ loss$ is$ secondary$
Wallerian$degeneration$from$areas$of$cortical$or$striatal$atrophy.$Either$way,$eﬀects$on$WM$
may$be$detected$only$by$measures$of$white$matter$integrity$such$as$FA$and$MD.
Previous$ reports$ using$ TBSS$ in$ PSP$ show$ less$ frontal$ WM$ involvement$ but$ conﬁrm$
involvement$of$posterior$frontal$white$matter,$anteriorcorpus$ callosum$ $and$ the$SCPs$ and$
connections$(Whitwell,$Avula$et$al.$2011),$changes$ in$FA,$and$also$RD$and$AD$ in$the$ corpus$
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callosum,$ olfactory$ cortex$ and$ SCP$ and$ connections$ but$ not$ the$ frontal$ subcortical$WM$
(Knake,$Belke$ et$al.$2010),$and$extensive$white$matter$disease$ consistent$with$our$ﬁndings$
(Agosta,$ Pievani$ et$ al.$ 2012;$ Saini,$ Bagepally$ et$ al.$ 2012).$ Changes$ in$ FA$ were$ more$
widespread$than$changes$ of$MD$ in$our$study$and$ in$contrast$to$others$(Knake,$Belke$ et$al.$
2010;$Agosta,$Pievani$et$al.$ 2012;$Saini,$Bagepally$ et$al.$2012)$we$ did$ not$ﬁnd$ statistically$
signiﬁcant$ diﬀerences$ in$ radial$ (RD)$ or$ axial$ (AD)$ diﬀusivities$ in$ any$ of$ the$ aﬀected$




Correlation$of$midbrain$WM$volume$ loss$and$increased$MD$ in$ frontal$WM$with$the$ PSPRS$




VBM$ ﬁndings$ in$MSA$ were$ centred$on$ the$ striatum$ and$pontocerebellar$connections,$ as$
expected$ [Table$ 9.2;$ Figure$ 9.2]$ (Schott,$Simon$ et$ al.$ 2003;$Ozawa,$ Paviour$et$ al.$ 2004;$
Hauser,$ Luft$ et$ al.$ 2006).$ In$MSA$WM$ loss$ has$ been$ reported$ in$WM$ deep$ to$ the$ insula$
(Brenneis,$Seppi$et$ al.$ 2003),$ the$ corpus$ callosum$ (Brenneis,$Seppi$et$ al.$2003;$Minnerop,$
Luders$ et$al.$2010),$the$corticospinal$tract$(Minnerop,$Luders$et$al.$2010)$and$the$brainstem$
including$ the$ pons,$ MCP$ and$ cerebellar$WM$ (Minnerop,$ Specht$ et$ al.$ 2007;$ Minnerop,$
Luders$ et$al.$ 2010).$We$ found$bilateral$patchy$cerebellar$GM$atrophy$and$bilateral$head$of$
caudate$and$putaminal$atrophy.$Our$cohort$is$ a$mixed$cohort$with$8/10$MSAXP$which$may$
explain$the$relative$mildness$of$GM$atrophy$ in$the$ cerebellum.$This$region$is$more$ severely$
aﬀected$in$MSA$with$a$ predominantly$cerebellar$phenotype$ (Ozawa,$Paviour$et$al.$2004),$
although$cerebellar$GM$ loss$ is$ found$ in$ both$MSAXP$ and$MSAXC$ (Specht,$Minnerop$et$al.$
2003;$Minnerop,$Specht$et$al.$2007;$Minnerop,$Luders$et$al.$2010)(Chang,$Chang$et$al.$2009),$
as$ is$atrophy$of$the$head$of $the$caudate$(Brenneis,$Seppi$et$al.$2003;$Specht,$Minnerop$et$al.$






We$ are$ not$aware$of$any$published$studies$of$voxelwise$analysis$of$DTI$data$ in$MSA.$ROIX
based$ MR$diﬀusion$ studies$ of$ the$ MCPs$ and$ Pons$ reveal$ selective$ reduction$ in$ FA$ and$
increased$MD$in$the$MCP$in$MSA.(Nilsson,$Markenroth$Bloch$et$al.$2007)$(Paviour,$Thornton$
et$al.$2007)$DTI$studies$of$the$pons$showed$a$decreased$FA$in$the$ transverse$ pontine$ﬁbers$
as$ the$ cross$ sign$ on$ conventional$ MR$ developed,$ preceding$ the$ FA$ reduction$ in$ the$
longitudinal$pontine$ﬁbers.(Makino,$Ito$et$al.$2011)$
Our$TBSS$data$conﬁrm$the$involvement$of$the$MCP$and$pontine$and$cerebellar$WM$tracts$in$
MSA$ and$ add$ important$ information$ including$ involvement$ of$ the$ corpus$ callosum$ and$
posterior$ frontal$ (motor$ and$ premotor)$ deep$ WM$ tracts.$ This$ ﬁts$ with$ emerging$
pathological$and$clinical$evidence$ that$MSA$patients$ have$ cognitive$ deﬁcits$ particularly$ in$
executive$ function$ and$ visuospatial$ skills$ (Kawai,$Suenaga$ et$ al.$ 2008;$ Kao,$Racine$ et$ al.$
2009),$ and$ that$ these$ are$ more$ pronounced$ in$ MSAXP.$ Pathological$ studies$ indicate$
involvement$with$pathognomonic$glial$cytoplasmic$inclusions$ found$ in$the$ supplementary$
motor$area,$ primary$ motor$ cortex,(Jellinger,$Seppi$et$al.$ 2005)$ cingulate$motor$area$ and$
premotor$cortex$(Papp$and$Lantos$1994;$Su,$Yoshida$et$al.$2001).
( 3.(Comparison&of&PSP&and&MSA&groups
Direct$comparison$of$the$ PSP$ and$MSA$group$ $did$not$reveal$ $any$ statistically$ $signiﬁcant$
diﬀerences$with$ $either$VBM$or$TBSS$.$This$may$ seem$at$ﬁrst$surprising$given$the$ $speciﬁc$
regional$diﬀerences$ between$ these$ two$ conditions$ $ and$ the$ control$group,$ as$ described$
above.$However,$ the$ lack$of$signiﬁcant$diﬀerences$ in$ the$ direct$ comparison$ is$ likely$ to$ be$
due$to$the$ fact$that$there$will $be$ greater$diﬀerences$ between$controls$ and$disease$ (either$
PSP$or$MSA)$than$between$PSP$and$MSA;$these$ diseases$ show$widespread$pathology$and$





Advantages$ of$ vowelXwise$ techniques$ are$ that$ they$ are$ operatorXindependent,$ enable$
wholeXbrain$exploration$and$do$not$require$regions$of$interest$to$be$placed$a%priori.$We$have$
used$high$ﬁeld$MRI$at$3T$with$associated$increase$ in$signalXtoXnoise$ ratio,$and$the$DARTEL$
addition$ to$ SPM8$ to$ improve$ grey$ matter$ segmentation$ although$ this$ is$ still$ limited$
particularly$ in$ posterior$ regions.$ Our$ statistical$ analysis$ was$ devised$ to$ give$ few$ false$
positives,$and$thus$ homogenized$our$clusters$ into$large$ regions$which$may$have$impacted$
on$our$correlative$analysis.$Others$have$taken$another$perspective$(Josephs,$Whitwell$et$al.$
2008;$Agosta,$Kostic$et$al.$2010)$making$them$more$ sensitive$to$the$detection$of$subgroup$
diﬀerences.$Although$we$ do$not$have$ pathological$conﬁrmation$of$ the$ clinical$diagnosis,$
our$cohort$comes$from$a$centre$experienced$in$assessing$parkinsonian$disorders.
F.&Conclusion
VBM$and$TBSS$give$ complementary$ information$about$pathological$processes$ in$PSP$ and$
MSA$ during$ life.$ Systematic$study$ of$quantitative$ techniques$ sensitive$ to$microstructural$
ﬁndings$before$ atrophy$ has$ occurred$is$ important$ not$only$ for$making$an$ early$diagnosis,$
but$ also$ in$ the$ context$ of$ our$ evolving$ understanding$ of$ clinical$ and$ pathological$
heterogeneity.$Future$studies$should$look$at$radiological$signatures$of$these$diseases$using$
multimodal$ MRI.$ The$ role$ of$ these$ parameters$ as$ potential$ biomarkers$ for$ disease$











3. Regular$ falls,$ unintelligible$ speech$ and$ cognitive$ impairment$ also$ occurred$ earlier$ in$
PSP$than$in$MSA.$
4. In$PSP$ an$ RS$ phenotype,$male$ gender,$ older$age$ of$onset$ and$a$ short$ interval$ from$
disease$onset$to$reaching$the$ﬁrst$clinical$milestone$were$all$independent$predictors$ of$
shorter$disease$duration$to$death.$
5. Patients$ with$RS$also$reached$clinical$milestones$ after$a$ shorter$interval$from$disease$
onset,$compared$to$patients$with$PSPXP.$
6. In$MSA$early$autonomic$failure,$female$gender,$older$age$of $onset,$a$short$interval$from$
disease$ onset$ to$ reaching$ the$ ﬁrst$ clinical$ milestone$ and$ not$ being$ admitted$ to$
residential$ care$ were$ independent$ factors$ predicting$ shorter$ disease$ duration$ until$
death.$
7. The$ time$ to$the$ ﬁrst$clinical$milestone$ is$ a$ useful $prognostic$predictor$for$survival.$We$
conﬁrm$ that$ RS$ had$ a$ less$ favourable$ course$ than$ PSPXP,$ and$ that$early$ autonomic$
failure$in$MSA$is$associated$with$shorter$survival.




2. We$ conﬁrmed$ the$ sequence$ eﬀect$ in$PD$ (progressive$ bradykinesia$ and$hypokinesia$ X$
‘true$bradykinesia’)$which$was$not$seen$in$PSP.
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3. ‘Hypokinesia’$with$‘absence$ of$decrement’$were$ identiﬁed$ in$87%$of$ﬁnger$tap$trials$ in$
the$PSP$group$and$only$12%$in$the$PD$OFF$levodopa$group.$











1. Radiological$ assessment$ of$MRI$ was$ correct$ in$ 16$ /22$ (72.7%)$ PSP$ cases$ $ and$ 10/13$
(76.9%)$ MSA$ cases$ with$ substantial$ interXrater$ agreement;$ no$ PSP$ case$ was$
misclassiﬁed$as$MSA$or$vice$versa.$
2. MRI$was$ less$ sensitive$ but$more$ speciﬁc$than$clinical$diagnosis$ in$PSP$ and$both$more$
sensitive$and$speciﬁc$than$clinical$diagnosis$in$MSA.$
3. The$ ‘hummingbird’$ and$ ‘morning$ glory’$ signs$ were$ highly$ speciﬁc$ for$ PSP,$ and$ ‘the$
middle$ cerebellar$peduncle$sign’$ and$‘hot$cross$bun’$for$MSA$but$sensitivity$was$ lower$
(up$to$68.4%)$and$characteristic$ﬁndings$may$not$be$present$even$at$autopsy.
4. No$speciﬁc$abnormalities$in$PD$or$CBD
Conventional$MRI,$ clinical$ diagnosis$ and$macroscopic$ examination$ at$ post$ mortem$ have$
similar$sensitivity$and$speciﬁcity$ in$predicting$a$neuropathological$diagnosis.$This$study$has$
validated$speciﬁc$radiological$signs$in$pathologically$conﬁrmed$PSP$and$MSA.$However,$the$
low$ sensitivity$of$ these$ and$macroscopic$ﬁndings$ at$autopsy$ suggest$ a$ need$ for$ imaging$
techniques$sensitive$to$microstructural$abnormalities$without$regional$atrophy.
Simple$ linear$measurements$ of$the$midbrain$and$pons$ and$the$midbrain$to$pons$ ratio$on$
midsagittal$MR$images$support$the$ diagnosis$of$PSP$in$the$ clinic.$This$method$was$devised$
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in$pathologically$conﬁrmed$disease$ and$corroborated$ in$a$ clinically$ diagnosed$cohort.$The$
key$ﬁndings$were:





PSP.$ In$ the$ clinically$ deﬁned$ group$ 19/21(90.5%)$ PSP$ cases$ had$ a$ midbrain$
measurement$of$less$than$9.35$mm.
This$is$a$simple$and$reliable$measurement$in$pathologically$conﬁrmed$disease$based$on$the$
topography$ of$atrophy$ in$PSP$ with$ high$ sensitivity$ and$ speciﬁcity$which$may$ be$ a$ useful$
tool$in$the$clinic.$
& 3.&The&Anatomy&of&the&STN&and&SN&using&high&ﬁeld&MRI
These$ two$ small $ nuclei $ in$ the$ midbrain$ are$ key$ structures$ in$ Parkinsonian$ conditions.$
Review$of$the$literature$reveals$that$the$STN$has$been$diﬃcult$to$identify$accurately$ using$
conventional$ MRI$ and$ the$ SN$ is$ also$ not$ well$ deﬁned.$ By$ using$ high$ ﬁeld$ MRI$ of$ post$
mortem$ tissue$ with$subsequently$ histologic$and$immunohistochemical$study$ of$the$ same$
tissue$it$was$possible$to$deﬁne$the$anatomy$of$these$structures$more$clearly.
Key$ﬁndings$in$the$STN$include:
1. The$ anatomy$ of$ the$ STN$ and$ surrounding$ structures$ was$ demonstrated$ in$ all$ three$
anatomical$ planes$ using$ 9.4T$ MR$ images$ in$ concordance$ with$ LFB/CV$ stained$
histological$sections.$
2. Signal$ hypointensity$ was$ seen$ in$ 6/8$ cases$ in$ the$ anterior$ and$ medial$ STN$ that$
corresponded$with$regions$of$more$intense$Perl$staining.$
3. There$was$ signiﬁcant$variability$ in$the$volume,$shape$and$location$of$the$borders$of$the$
STN.












4. The$ volume$and$dimensions$ of $the$SN$were$ similar$in$PD$and$controls,$but$reduced$in$
PSP
This$enabled$a$histologically$validated$anatomical$description$of$the$SN$on$high$ﬁeld$SE$MRI$



















increasing$PSP$ rating$scale$ score,$and$ frontal$WM$ reduced$ fractional $anisotropy$ with$
disease$duration.$
Marked$subcortical$WM$ changes,$ particularly$ in$PSP,$were$ not$evident$ on$VBM$ indicating$
that$more$ subtle$ ﬁndings$ may$ be$ detectable$ during$life$ using$TBSS$analysis.$ Frontal$WM$




There$ are$ signiﬁcant$diﬀerences$ in$the$ clincial$features$ and$natural$history$of$PSPXRS$and$
PSPXP$ and$ the$ underlying$ pathology$ is$ of$diﬀerent$ severity.$The$ natural$ history$ of$other$
presentations$(PSPXPAGF,$PSPXPNFA$etc)$ is$not$well$described.$$Retrospective$study$of$case$
notes$ has$ intrinsic$ limitations$ given$ the$ heterogeneity$ of$ physicians$ assessing$ patients$
under$diﬀerent$clinical$scenarios.$Ideally$ a$prospective$study$of $PSP$ should$be$ undertaken$
with$ subsequent$ pathological$ conﬁrmation.$ This$ would$ require$ the$ entry$ criteria$ to$ the$
study$to$be$very$ loose$ in$order$to$ increase$ the$ sensitivity$ and$to$ identify$early$and$atypical$
cases.
Now$ that$ it$ is$ clear$ in$ PSPXRS$ that$ true$ ﬁnger$ taps$ are$ manifestations$ of$ hypokinesia$
without$decrement$rather$than$true$bradykinesia$it$would$be$interesting$to$assess$whether$
PSPXP$ cases$ have$ true$ bradykinesia.$ This$ would$ again$ require$ prospective$ study$ with$
pathological$ conﬁrmation$ of$ the$ diagnosis.$ Furthermore,$ the$ diagnostic$ utility$ of$ this$
ﬁnding$ could$ be$ assessed$ with$ a$ blinded$ video$ analysis$ of$ ﬁnger$ taps$ by$ a$ panel$ of$
movement$disorders$experts$to$conﬁrm$the$clinical$validity$and$reproducibility$of$the$clinical$
ﬁnding.$ Given$ this$ ﬁnding$ other$ conditions$ including$ MSA,$ CBD$ and$ even$ pyramidal$
disorders$ may$ provide$ complementary$ ﬁndings$ given$ that$ one$ would$ expect$ pyramidal$




Most$ studies$ of$ conventional$ imaging$ are$ in$ clinically$ diagnosed$ cases.$ While$ clinical$
research$ criteria$ predict$ the$ pathological$ diagnosis$ with$ high$ positive$ predictive$ values,$
there$ are$ still $many$misidentiﬁed$and$ atypical$cases$ that$are$ excluded.$ It$ is$ this$ group$ in$
which$ imaging$ﬁndings$ would$ have$ the$ greatest$clinical$utility.$ In$ seeking$ to$ address$ the$
question$ of$ how$ good$ conventional$ MRI$ is$ at$ predicting$ the$ pathological$ diagnosis$ in$
conﬁrmed$ disease$ this$ work$ describes$ speciﬁc$ but$ subjective$ abnormalities.$ The$ second$
study$ in$ this$ section$ supports$ the$ use$ of$ simple$ linear$ measurements$ to$ increase$ the$
sensitivity$of$ conventional$MRI.$ However,$ it$ is$ still$not$clear$ at$what$stage$ these$ ﬁndings$
become$apparent,$although$one$anticipates$that$atrophy$would$take$some$ time$to$develop.$
Studies$of$MRI$techniques$which$may$be$present$before$atrophy$is$evident$hold$promise$(for$
example,$diﬀusionXweighted$ imaging$in$ the$ putamen$ in$MSA$ (Seppi,$Schocke$ et$al.$ 2006;$
Seppi,$ Schocke$ et$ al.$ 2006)$ but$ there$ are$ unresolved$ issues$ with$ quantitative$ MRI$
techniques$ including$ the$ use$ of$ diﬀerent$ MRI$ techniques$ at$ diﬀerent$ centres$
(standardisation).$
& 3.&Studying&anatomy&of&high&ﬁeld&MRI
High$ ﬁeld$MRI$ is$ becoming$more$ readily$ available$ and$ the$ anatomy$ of$ smaller$ nuclei$ is$
starting$to$be$more$accurately$deﬁned$as$the$ resolution$of$imaging$during$life$ is$improving.$
The$accuracy$of$anatomical$description$is$very$important.$In$the$STN$there$are$no$region$of$
interest$ studies$ of$ clinical$ utility$ due$ to$ anatomical/resolution$ constraints.$The$ ability$ to$
study$this$nucleus$in$disease$would$be$very$useful$as$ it$is$a$key$nucleus$pathologically$in$PSP$
and$it$is$also$very$important$in$PD,$where$pathophysiological$changes$make$it$a$key$nucleus$
for$ targeting$ at$ DBS.$ High$ ﬁeld$ MRI$ using$ post$ mortem$ tissue$ enables$ not$ only$ the$
identiﬁcation$ of$ not$ only$ the$ STN$ but$ also$ many$ small$ surrounding$ structures.$ The$
challenge$will$be$to$reproduce$ this$during$life.$Shorter$acquisition$times$will$be$needed$and$
these$may$be$achieved$using$fast$spin$echo$and$other$promisin$techniques$(MTR,$SWI$etc.).
The$exact$correlate$ of $signal$changes$on$MRI$will$need$to$be$determined$ (gliosis,$neuronal$
loss,$protein$deposition)$ if$true$markers$ of$pathological$progression$in$the$STN$and$SN$are$
to$be$determined$during$life.$Studies$correlating$the$pathological$changes$with$quantitative$




Increasing$ use$ of$ high$ ﬁeld$ 3T$ scanners$ and$ multiple$ MRI$ modalities$ may$ give$
complementary$ information$ during$ life$ not$ only$ about$ atrophy$ but$ also$ microstuctural$
integrity.$ Region$of$ interest$ studies$ are$ labourXintensive$ and$ require$ a$ priori$ assumptions$
about$the$ brain$regions$ to$be$assessed.$Volumetric$techniques$ have$advantages,$but$so$far$
have$been$used$to$study$disease$groups$rather$than$being$useful$for$predicting$disease$in$an$
individual$ case.$ Other$ techniques$ including$ automatic$ segmentation$ techniques$ may$ be$
useful$ in$this$ regard,$ but$use$ of$ such$methods$ will$ require$ the$ development$of$individual$
disease$ signatures$and$a$ recognition$of$the$heterogeneity$ of$these$within$a$ pathologically$
deﬁned$ disease$ and$ potential$ overlap$ with$ other$ diseases.$ Again,$ standardisation$ of$
techniques$ across$ sites$will $be$ important$for$reproducibiliy$ of$results$ and$in$order$to$be$ of$
clinical$utility$a$standard$postprocessing$protocol$will$be$needed:$many$studies$use$diﬀerent$
thresholds$ and$ smoothing,$ for$ example.$Many$ of$ these$ ideas$ could$ be$ addressed$with$ a$
single$large$prospective$study$of$these$techniques$in$carefully$selected$cases$presenting$to$a$
movement$ disorders$ clinic.$ The$ protocol$ would$ involve$ standardised$ detailed$ clinical$





instance,$ thanks$ are$ due$ to$Professor$Andrew$Lees,$ for$allowing$me$ to$ join$ the$hallowed$
members$of$the$Queen$Square$Brain$Bank.$Working$for$Professor$Lees$both$in$the$clinic$and$
in$research$has$ formed$the$ basis$ for$my$ clinical$career$in$neurology$and$I$can$ think$of$no$
better$ role$ model.$ Sean$O’Sullivan,$ Laura$Moriyama,$ Helen$ Ling,$Atbin$ Djamshidian$ and$
Karen$Doherty$were$constant$companions$ and$sources$ of $encouragement$and$inspiration.$
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of$them$ X$a$ task$ for$which$I$ shall $be$ eternally$ grateful$to$her.$Many$ physicists$ have$ been$
crucial$to$diﬀerent$aspects$of$the$studies$described$here$including$Harry$Parkes,$PoXWah$So,$
Mark$ White,$ Enrico$ de$ Vita,$ Laura$ Mancini,$ Chris$ Sinclair,$ John$ Thornton$ and$ Professor$
Xavier$Golay.$I$am$ indebted$ to$Caroline$Micallef$and$ Professor$Nick$Fox$who$ spent$many$
hours$ with$me$ looking$at$MRI$scans.$Dr$Mario$Miranda$and$Dr$Othman$AlXHelli$made$ the$
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